VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 17 (21-31 agosto / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

FDA approves the new COVID vaccine. Here's the best time to get it

Aug 21. The Food and Drug Administration approved the new COVID vaccines from Pfizer and Moderna.

It's the third time the vaccines have been updated to match circulating strains since the original series. The shots should be available within days. The agency hasn't yet approved a third vaccine, from drugmaker Novavax.

The timing of the new vaccines — last year's rollout was in mid-September — is significant, since most of the U.S. is still caught in the summer wave of COVID-19 illness. As of Monday, the Centers for Disease Control and Prevention reported, the number of people testing positive for Covid keeps rising and emergency room visits for Covid have been increasing since mid-May. Hospitalizations are rising, too.

Here's what to know about the updated vaccines.

How are the new COVID vaccines different?

The new shots from Pfizer and Moderna are designed to target the KP.2 strain, a descendant of the highly contagious JN.1 variant that began circulating widely in the U.S. last winter. The drugmakers started making the new doses in June after the FDA advised them to freshen the formulas to match the version of the virus that was gaining ground in the U.S.

A third vaccine, from drugmaker Novavax, has been updated to target the JN.1 strain. JN.1 and KP.2 have largely faded from circulation, according to the CDC.

As of Saturday, a sister strain called KP.3.1.1 accounted for about 36% of all new COVID-19 cases, while another sister strain, KP.3, accounted for about 17%.

It's unclear exactly how effective the vaccines will be against the newer strains, but experts expect that they will protect against severe illness.

A spokesperson from Pfizer told NBC News that data submitted to the FDA shows that its vaccine generates a "substantially improved" immune response against multiple currently circulating variants, including KP.3, compared to earlier versions of the vaccine.

There are "very minor sequence differences" between the variants, said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.

A paper published this month in the journal Infectious Diseases found that KP.3.1.1 shares similarities with JN.1 and KP.2, although it has a few additional mutations that may help it spread more easily.

"All these changes are incremental. They do not change the overall big picture," Moore said. "KP.3.1.1 is just another step in the road that the overall omicron lineage is taking towards greater transmissibility."

What are side effects of the new Covid vaccines?

Like other versions of the Covid vaccines and similar to flu shots, the most common reaction is some pain at the injection site. Other side effects include: tiredness, headache, muscle pain, chills, fever, nausea.

The CDC says the side effects typically resolve after a few days. Serious side effects, such as the life-threatening allergic reaction called anaphylaxis, are rare.

Pfizer and Moderna's vaccines have been associated with a small but increased risk of myocarditis, the inflammation of the heart muscle, mostly in young men. Most people make a full recovery.

How much will it cost?

Pfizer, Moderna and Novavax are charging up to $150 per dose for a Covid vaccine, according to data from the Centers for Medicare and Medicaid Services.

The vast majority of people with public and private health insurance should pay nothing out of pocket for the updated Covid vaccines —as long as they stick with an in-network provider, said Jennifer Kates, director of the Global Health & HIV Policy Program.

Medicare and Medicaid require that the vaccines are free for patients. The Affordable Care Act, also known as Obamacare, requires private insurers to cover all vaccines that are recommended by the CDC's vaccine committee and director.

However, Kates added that the ACA's requirement does not apply to grandfathered plans — plans that existed before the ACA was signed into law — and short-term health plans.

"People enrolled in these plans may face cost sharing for the Covid vaccine, or the vaccine may not be covered at all," she said.

Children without insurance can get free vaccines through the government-run Vaccines for Children Program.

For adults without health insurance, the situation is a bit different. The CDC's Bridge Access Program — which has been paying for shots for uninsured adults — is expected to shut down in August because of a lack of funding.

Once the funding runs out, uninsured individuals may be able to access free Covid vaccines through community health centers and other safety net providers that participate in the Section 317 vaccine program for adults, Kates said. Section 317 is a federal initiative that gives funding to states to provide vaccines for uninsured and underinsured adults.

"Some state and local health departments may also have a limited supply for people without insurance, but any supply will be very limited," Kates said.

Fuente: NBC News. Disponible en https://acortar.link/rgHYNo

Mpox vaccine coming soon, says Covishield manufacturer SII's CEO Adar Poonawalla

Aug 21. A day after state government guidelines were issued for responding to Mpox cases, Adar Poonawalla, CEO of Serum Institute of India (SII), announced the company is developing a vaccine against the disease with hopes for a "positive outcome" within a year, as reported by TOI. The new vaccine aims to address the risks posed by the Mpox outbreak.

Poonawalla stated, "In view of the global health emergency declared due to the Mpox outbreak, SII is working on developing a vaccine for this disease to cater to millions of lives that might be at risk. Hopefully, we will have more updates and positive news to share within a year's time."

Mpox virus: Government Guidelines and Testing Efforts

The government has released official guidelines for isolating suspected Mpox cases, with the National Institute of Virology (NIV) in Pune responsible for sample testing. In the TOI report, Dr. Pragya Yadav, a scientist at the NIV, shared insights on their ongoing efforts.

Dr. Yadav said, "We've been testing Mpox samples since 2022. But this time, due to the new lineage of Mpox, there are concerns. Samples have been coming in continuously but, so far, we haven't had a positive."

What are the Mpox virus strains

Experts have raised alarms over the new lineage, CLADE 1B, which has the added capacity to spread sexually. Despite this, they believe it will not necessitate lockdown-like measures.

Dr. Raman Gangakhedkar, former head of the division of epidemiology & communicable diseases and director-in-charge of the National AIDS Research Institute, expressed his concerns from an HIV-AIDS perspective.

Mpox Vaccine Effectiveness and Strategy

Dr. Gangakhedkar said, "Mpox usually spreads only through close contact with an infected person, via bodily fluids and sores. But this new lineage also spreads sexually so as an HIV-AIDS expert, that concerns me. People may hide their infection once these skin lesions develop."

He further elaborated on the effectiveness of the existing vaccines and potential strategies for vaccination.

"The vaccines currently available have shown an efficacy of about 80% so they are effective. But the live attenuated vaccine/s may turn out to be better for administering vulnerable persons. Mass vaccination will not be required as a strategy. If we do need to start vaccinating, we may have to prioritize those who have multiple sexual partners," he added.

The ongoing efforts by SII and NIV aim to mitigate the risks associated with the Mpox outbreak, with a focus on developing an effective vaccine and executing strategic isolation guidelines.

Fuente: The Economic Times. Disponible en https://acortar.link/bAmGz0

Vaccination with Pneumosil to begin in Camagüey



Aug 22. The application of the anti-pneumococcal vaccine Pneumosil-10, aimed at protecting children under one year of age against ten pneumococcal serotypes, will begin on September 9, with the objective of reducing and controlling invasive pneumococcal disease.

The Pneumosil vaccine will be introduced to the regular vaccination schedule, and on this occasion it will be received by all infants born between January 1st and June 30th, for a total of 2,022 infants in Camagüey in a three-dose schedule (at two months after birth, four months and a reactivation seven months later). At the same time, all infants arriving at two months of age will start the scheme.

There is no contraindication for vaccination on the same day, using different syringes and in different anatomical sites, with Pneumosil and other vaccines in the schedule, such as IPV and Heberpenta-L, for example. These drugs are administered simultaneously in many countries without an increase in the occurrence of adverse events, said Dr. Taimi Miranda Vergara, in charge of the vaccination program in the province.

All infants will be vaccinated at the polyclinic vaccinatories, after medical evaluation and indication as established by the National Immunization Program. In addition, primary care and other areas involved in the health system, as well as the faculties of Medical Sciences and social actors, will work in a coordinated manner.

Possible side effects include muscle discomfort, redness or inflammation at the puncture site; fever or feverishness may also occur after vaccination.

Fuente: Radio Cadena Agramonte. Disponible en https://acortar.link/0eyqTr

Ministerio de Salud de Vietnam lanza campaña de vacunación contra sarampión

22 ago. El Ministerio de Salud lanzó una campaña para proporcionar vacunas contra el sarampión a los niños de todo el país en una conferencia híbrida, para conmemorar la Semana Mundial de la Inmunización 2024.

Inyección de vacuna para niños en Vietnam (Fuente: VNA)

En su intervención en el evento, efectuado la víspera, la ministra de Salud, Dao Hong Lan, pidió a los padres y cuidadores que vacunen a los niños por completo y en el plazo previsto, por la salud de los niños a través de vacunaciones y campañas de vacunación periódicas.

"La vacunación es una de las medidas más importantes para prevenir enfermedades infecciosas peligrosas. Gracias a la

vacunación, se eliminan o controlan muchas enfermedades infecciosas peligrosas. Se estima que el Programa Ampliado de Inmunización (PAI) mundial previene de dos a tres millones de muertes cada año", dijo Hong Lan.

Con el riesgo de un brote de sarampión en el mundo, incluido Vietnam, el Ministerio de Salud se ha coordinado con la Organización Mundial de Salud (OMS) y la UNICEF para desarrollar y emitir una campaña para proporcionar una vacuna contra el sarampión en 2024 con un millón 134 mil 200 dosis de vacuna financiadas por el Gobierno australiano.

La campaña se llevará a cabo en las unidades educativas y centros médicos de los distritos con riesgo de brotes de sarampión. Las vacunas se proporcionarán de forma gratuita a los niños de uno a diez años, al personal médico en riesgo en los centros de examen y tratamiento médicos y a aquellos que no hayan recibido la cantidad necesaria de vacunas según lo prescrito.

Según Hong Lan, el programa de vacunación aún enfrentará muchas dificultades y desafíos debido a la situación impredecible de las enfermedades infecciosas y la baja tasa de vacunación tras la pandemia de COVID-19. La contaminación ambiental, el cambio climático, los desastres naturales, las inundaciones y la urbanización crearon condiciones favorables para que las enfermedades infecciosas reaparezcan, se propaguen y broten.

Sugirió que los Comités Populares de las provincias y ciudades promuevan la implementación de la vacunación regular para niños en el marco del EPI para garantizar la seguridad y la eficacia y alentar a las familias a vacunar a sus hijos de manera completa y en el calendario previsto.

La representante de la OMS en Vietnam, Angela Pratt, señaló que cientos de miles de niños en Vietnam no han sido vacunados desde 2021 debido a las interrupciones relacionadas con la pandemia y la reciente falta de existencias de vacunas, lo que ha provocado la mayor disminución sostenida de las tasas de inmunización infantil en Vietnam en más de 20 años.

"Como resultado, ya estamos viendo más casos y grupos de enfermedades prevenibles mediante vacunación, incluidas la difteria y la tos ferina, y nos preocupa que actualmente nos enfrentemos al riesgo muy real de un brote de sarampión a gran escala", dijo Pratt.

La representante de la OMS también elogió a la oficina del Primer Ministro, la Asamblea Nacional y la Ministra de Salud por el liderazgo y los inmensos esfuerzos del año pasado para desbloquear el suministro de vacunas.

"Sé que ahora podemos contar con el mismo liderazgo y compromiso para responder a los brotes de sarampión que estamos viendo actualmente en varias provincias, la amenaza de brotes en otros lugares y, al hacerlo, evitar la transmisión a gran escala".

Pratt también dijo que la OMS ha finalizado la adquisición de un suministro de emergencia de más de un millón de dosis de vacunas contra el sarampión y la rubéola, que se utilizarán para la respuesta a los brotes y las actividades de inmunización complementaria en las zonas de mayor riesgo.

En Vietnam, existen actualmente 11 tipos de vacunas para prevenir enfermedades infecciosas, entre ellas la tuberculosis, la difteria, la tos ferina, el tétanos, el sarampión, la polio, la hepatitis B, la encefalitis japonesa B, la rubéola y el rotavirus, todas ellas desplegadas en el marco del EPI.

En el futuro, el Ministerio de Salud implementará un plan para agregar nuevas vacunas al EPI, incluidas las vacunas para prevenir la diarrea causada por el rotavirus, una vacuna para prevenir la enfermedad neumocócica y la vacuna para prevenir el cáncer de cuello uterino causado por el virus del papiloma humano.

En los últimos 40 años, se han administrado cientos de millones de dosis de vacunas a niños y mujeres vietnamitas de forma gratuita. El EPI ha hecho una importante contribución para lograr la erradicación de la polio en 2000 y la eliminación del tétanos neonatal en 2005.

Fuente: VietnamPlus. Disponible en https://acortar.link/mrRwr1

Vacuna contra VPH: nuevo esquema protege a niñas y niños contra el cáncer en edad adulta

24 ago. La vacunación es una herramienta importante en la lucha contra el cáncer, producido por el Virus de Papiloma Humano (VPH), un grupo de más de 200 virus de los cuales algunos se transmiten por contacto sexual.

Pueden causar lesiones o verrugas papilomatosas que pueden llevar a distintos tipos de cáncer, entre ellos el cáncer de cuello uterino, uno de los más comunes y peligrosos para las mujeres y el cáncer de pene en los hombres.

Con el nuevo esquema de vacunación, que entró en vigencia el 1 de agosto de este año en Paraguay, se promueve la equidad de género en la protección contra este virus y con el aumento de la cobertura se apunta a reducir significativamente los casos de cáncer y mejorando así la calidad de vida de la población.

El Dr. Guillermo Legal, pediatra del departamento de docencia e investigación del Programa Ampliado de Inmunizaciones (PAI) instó a los padres, madres y tutores a llevar a sus hijos e hijas a vacunarse y recordó que las vacunas son efectivas y con estas se protege hoy a los niños y niñas contra enfermedades oncológicas en la edad adulta causadas por este virus.

"La implementación del nuevo esquema incluye dosis única para niñas de 9 a 18 años y niños nacidos en el año 2014, siguiendo las recomendaciones de la Organización Mundial de la Salud (OMS)."

El nuevo esquema implementado es el siguiente:

• Niñas de 9 a 18 años: dosis única para aquellas que no hayan sido vacunadas previamente.

• Niños nacidos en el año 2014: esquema de una dosis.

El esquema de dosis única proporciona una protección comparable a los regímenes de dos o tres dosis, de acuerdo a las pruebas de evaluación recientes del Grupo de Expertos en Asesoramiento Estratégico sobre Inmunización (SAGE) de la OMS.

Si bien la vacunación contra el VPH hasta ahora se centró en las niñas y mujeres, se destaca la importancia de que los varones también reciban la vacuna ya que los protege del cáncer de pene, ano, orofaringe y ayuda a prevenir contagios con sus futuras parejas puesto que son ellos portadores del virus que en las mujeres causa el cáncer de cuello uterino.

"La vacunación contra el VPH puede prevenir más del 90 % de los casos de cáncer de cuello uterino en las mujeres y también previene otro tipo de cánceres en varones como el de pene, ano y orofaringe. "

Fuente: Ministerio de Salud Pública y Bienestar Social Paraguay. Disponible en https://acortar.link/lsvR19

Moderna recibe la aprobación de la Comisión Europea para la vacuna contra el virus respiratorio sincitial

24 ago. Moderna ha anunciado este viernes que la Comisión Europea (CE) ha concedido la autorización de comercialización de mRESVIA (mRNA-1345), una vacuna de ARNm contra el virus respiratorio sincitial (VRS). Tal y como ha informado la farmacéutica, que se dio a conocer gracias a sus dosis contra la covid, este nuevo antídoto servirá para proteger a los adultos mayores de 60 años de la enfermedad del tracto respiratorio inferior causada por la infección por VRS.

La vacuna usa la tecnología del ARN mensajero, la misma utilizada para la de la COVID-19 / GTRES

La autorización de comercialización sigue a la Opinión Positiva del Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA). Así, según el criterio, la luz verde de este fármaco es válida en los 27 Estados miembros de la UE, así como en Islandia, Liechtenstein y Noruega.

Se trata de la primera vacuna con tecnología de ARN mensajero –igual que la del coronavirus– autorizada en la UE para una enfermedad distinta de la covid. Su llegada no ha sido sencilla, ya que ha tenido que pasar por las numerosas evaluaciones de la EMA, la última el pasado mes de junio. Bruselas también ha autorizado otras vacunas contra el virus respiratorio sincitial el pasado año para proteger a grupos vulnerables, entre ellos los lactantes.

«La vacunación salva vidas. En una Unión Europea de la Salud fuerte, estamos decididos a garantizar que todo el mundo tenga acceso a la protección que necesita contra las enfermedades graves», ha asegurado Stella Kyriakides, comisaria de Salud, que ha valorado la aprobación de la primera vacuna a base de ARN mensajero como ejemplo de «la importancia de innovar cuando se trata de proteger la salud de la ciudadanía».

Por su parte, Stéphane Bancel, director ejecutivo de Moderna, ha afirmado que la aprobación de 'mRESVIA' es «un hito importante para la salud pública» y pone de relieve «el liderazgo de Moderna en el campo del ARNm». Además, ha continuado, esta aprobación supone «la primera autorización de una vacuna de ARNm para una enfermedad más allá de la COVID-19 en Europa».

Por otro lado, ha apuntado que este antídoto protege a los adultos mayores contra los efectos graves causados por el VRS. Además, se administra mediante una jeringa precargada para mejorar la facilidad de administración, lo que puede reducir el tiempo de preparación de la vacuna y los errores administrativos», ha explicado.

Superó todas las fases de análisis

La autorización comercial de 'mRESVIA' se basa en los datos positivos del ensayo clínico de fase 3 ConquerRSV, un estudio mundial realizado en aproximadamente 37.000 adultos de 60 años o más en 22 países. El análisis primario con 3,7 meses de seguimiento medio halló una eficacia de la vacuna (EV) frente a la enfermedad del tracto respiratorio inferior (ETRI) por VRS del 83,7 % (IC del 95,88 %: 66,0 %, 92,2 %), resultados publicados 'The New England Journal of Medicine'.

En un análisis suplementario con una mediana de seguimiento de 8,6 meses, mRNA-1345 mostró una eficacia duradera, con una efectividad del 63,3 % (IC del 95 %: 48,7 %, 73,7 %) frente a ETRI por VRS, incluyendo dos o más síntomas. La eficacia fue del 74,6 % (IC del 95 %: 50,7 a 86,9) frente a ETRI por VRS con dos o más síntomas, incluida la disnea, y del 63 % (IC del 95 %: 37,3 % a 78,2 %) frente a ETRI por VRS con tres o más síntomas.

Síntomas comunes tras la inoculación

- Dolor en el lugar de la inyección
- Fatiga
- Cefalea
- Mialgia
- Artralgia

El criterio estadístico del estudio se mantuvo estricto, con un límite inferior del IC del 95 % a 20 %, cumpliéndose para ambos criterios de valoración.

Fuente: EL DEBATE. Disponible en https://acortar.link/wNswcT

KPJ Damansara Launches Malaysia's First Dengue Vaccine

Aug 26. KPJ Damansara Specialist Hospital in Petaling Jaya, Selangor, has launched Malaysia's first dengue vaccine, the Qdenga live-attenuated dengue tetravalent vaccine by Japanese pharmaceutical company Takeda.

The dengue vaccination package by the private hospital costs RM400 for two doses that are given three months apart.

"All eligible persons beyond four years old should consider taking the dengue vaccine, which has been shown to reduce the risk of getting dengue and decreases the risk of hospitalisation by 84 per cent.

"There have been no major adverse effects with the dengue vaccine," said consultant paediatrician Dr Musa Mohd Nordin at the August 24 "Merdeka from Dengue Deaths" launch event.

According to the Ministry of Health's (MOH) latest dengue report for the 33rd epidemiological week of the year (August 11-17), a cumulative total of 92,827 cases were reported until the 33rd epid week, marking a 22 per cent increase from 75,928 cases reported in the same period in 2023.

A total of 83 deaths from dengue fever complications were reported for this year until the 33rd epid week, marking a 54 per cent increase from 54 deaths reported in the same period last year.

"Dengue imposes an economic burden in Malaysia," Dr Musa said.

"Vector control has achieved only limited success in reducing dengue transmission. A dengue vaccine should be considered as part of an integrated approach to dengue prevention and control."

According to the KPJ Damansara Specialist Hospital paediatrician, the cost of dengue illness was RM196 million annually in 2019, whereas the cost of dengue prevention and control in 2018 was RM260 million. The total cost of dengue is RM456 million every year.

Citing 2018 research, Dr Musa noted that half of hospitalised patients for dengue stayed for a prolonged period of more than three days.

There is currently no definitive curative treatment for dengue and no antiviral is available. Clinical management of dengue is mainly supportive. In addition, individuals who are infected for the second time are at greater risk of severe dengue that can be deadly.

Social & Economic Research Initiative (SERI) chairwoman Nurul Izzah Anwar, who is also a former Lembah Pantai MP, highlighted the longstanding challenge of dengue in the country.

“Despite intensive efforts by the government, such as widespread mosquito control programmes and community engagement in eliminating breeding sites, Malaysia continues to grapple with a high burden of dengue fever cases.”

A woman named Sherin Tan, whose two children received the dengue vaccine, said at the KPJ Damansara Specialist Hospital launch event that she knew of many people who suffered severely from dengue fever.

“With this vaccine, I hope no more children will have to endure the pain of dengue.”

Launch of Malaysia's first dengue vaccine at KPJ Damansara Specialist Hospital in Petaling Jaya, Selangor, on August 24, 2024. Pictured are consultant paediatrician Dr Musa Mohd Nordin at the podium, and Social & Economic Research Initiative (SERI) chairwoman Nurul Izzah Anwar (fifth from left). Photo from Dr Musa Mohd Nordin.

Fuente: Code Blue. Disponible en https://acortar.link/bIpwRo

Decesos por dengue reactivan solicitud de vacunas

26 ago. Los tres costarricenses fallecidos el jueves en medio del peor brote nacional de esa enfermedad reactivan hoy el debate sobre la introducción en el país de vacunas contra la enfermedad, empleadas en seis estados de la región.

La reactualización del tema siguió a revelaciones de la vicepresidenta y ministra de Salud, Mary Munive, respecto a que el gobierno está a la espera de los resultados en Honduras de un plan piloto de inmunización contra ese padecimiento arboviral (transmitido por mosquitos), según el canal Teletica.

Los decesos –explica la televisora- fueron posteriores al momento de las declaraciones de la titular el 18 de agosto, pero los contagios oscilaban entonces y se mantienen ahora en unos 15 mil, para un incremento del 329 por ciento respecto a los diagnosticados en similar etapa de 2023.

La propia titular comunicó a la nación el deceso de los primeros fallecimientos este año de dos pacientes comprobados de padecer dengue y de un tercero sospechoso de contraer la enfermedad, junto al reporte de mil nuevos casos, que ratifican el peor brote de dengue en la historia local.

Especialistas locales estudian aún –según la ministra- los análisis sobre los tres fallecimientos, a fin de determinar si el virus transmitido por el mosquito Aedes aegypti fue el responsable o no de esas muertes, que no ocurrían por esa causa desde 2006.

Según esas fuentes, los dos inmunizantes que se abren paso en el mundo contra esta enfermedad, entre otras naciones en la referida Honduras, uno, el TAK003, es desarrollado por la farmacéutica japonesa Takeda, y el otro, el CYD-TDV, por el grupo francés Sanofi Pasteur.

La primera –detalla Teletica- es una vacuna viva atenuada, que contiene versiones debilitadas de los cuatro serotipos del virus y se emplea en personas de 6 a 16 años y en entornos con alta carga de dengue y alta intensidad de transmisión.

El segundo inmunizador es un preparado tetravalente recombinante viva para personas de 9 a 60 años, en zonas donde el dengue es endémico, administrada mediante una serie de tres dosis con un intervalo de seis meses entre cada una de ellas, explica la televisora.

Los pacientes comprendidos en los ensayos sobre ambos compuestos, que incluyen también a ciudadanos de Argentina, Perú, Chile, Brasil y Colombia, deben someterse a un cribado o examen para detectar otras patologías y solo recibirán los inmunizadores quienes den negativo a ellas.

El canal Teletica recibió opiniones favorables a la introducción de las vacunas por parte de dos expertos locales consultados por el canal, el infectólogo Álvaro Avilés y el epidemiólogo Juan José Romero.

Avilés opinó que la incidencia y prevalencia del dengue exige la instauración de medidas de impacto, además de las ya conocidas, aunque estimó que deben aplicarse en las zonas de más riesgo y enfocadas en los cuatro serotipos del dengue.

Fuente: Prensa Latina. Disponible en https://acortar.link/sMnbNu

Comenzará campaña de vacunación en Cuba

27 ago. Como parte del Programa Nacional de Inmunización , comenzará el próximo 9 de septiembre la aplicación de la vacuna antineumocócica Pneumosil-10 dirigida la protección de los niños menores de un año , nacidos en 2024, contra 10 tipos de neumococos.

Según informó a la ACN el doctor Francisco Durán, director nacional de Higiene y Epidemiología, este proceso continuará para los infantes de dos años de edad cuando se disponga de la vacuna

antineumocócica Quimio-Vio, desarrollada por el Instituto Finlay de Vacunas y actualmente en producción en el Centro Nacional de Biopreparados.

También se efectuará la inyección de la vacuna anti gripal para adultos, con énfasis en los grupos de riesgo mayores de 60 años de edad, personas con enfermedades pulmonares, asmáticos y diabéticos, para prevenir el virus influenza, causante de cuadros respiratorios, dijo la fuente.

Durán detalló que en la actualidad se aplica la antigripal a la población infantil de dos años y en el caso de las vacunas contra la COVID-19 se ponen a grupos vulnerables una dosis de refuerzo.

Precisó que a inicios del año 2025 empezará una campaña de vacunación contra el virus del papiloma humano, infección de trasmisión sexual la cual puede provocar cáncer cérvicouterino en las mujeres y neoplasia anorrectal.

Apuntó que por primera vez se aplicará en Cuba a las niñas de nueve años de edad y luego se extenderá a la población femenina hasta los 14 años para repercutir en la disminución de enfermedades malignas.

Fuente: Radio Bayamo. Disponible en https://acortar.link/EufyPW

EMA approves expanded age indication for GSK's RSV vaccine, Arexvy

Aug 29. GSK plc has announced that the European Commission has authorised Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at increased risk. Since June 2023, GSK's RSV vaccine has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD4.

- An estimated 20 million adults aged 50-59 in 30 European countries* have a medical condition that increases their risk for RSV disease.
- Authorisation helps protect this population for the first time ahead of this RSV season.
- This follows approval in US, with other countries anticipated, including Japan later this year.

Adults with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes are at increased risk for severe consequences from an RSV infection compared to those without these conditions5,6. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation or death.

It is estimated that there are about 65 million adults aged between 50 and 59 in the European Union/ European Economic Area1, with an estimated 20 million of these people (one-third) having at least one underlying medical condition that puts them at increased risk for RSV disease.

Tony Wood, Chief Scientific Officer, GSK, said: "Today's approval reflects the importance of broadening the benefits of RSV immunisation to adults aged 50-59 who are at increased risk. RSV infection can have a significant impact on the health of older adults and particularly those with certain existing medical conditions, which can add pressure onto healthcare systems. As we enter the RSV season, we are pleased to be the first to deliver a vaccine to help protect more people in Europe from RSV-LRTD."

*****_estimated from the % of individuals aged 50-59 in France, Italy and Spain with at least one chronic condition3 extrapolated to the EU/EEA population of 50-59 years in 2024.1 The European Commission has the authority to approve medicines for the European Union member states, as well as in the European Economic Area (EEA) countries Iceland, Norway and Liechtenstein._

The regulatory application was supported by positive results from a phase III trial evaluating the immune response and safety of GSK's RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions.

Prof. Dr. Tino F. Schwarz, Klinikum Würzburg Mitte, Würzburg, Germany said: "There are a great number of patients in the age-group 50-59 years living with certain underlying medical conditions with an increased risk for severe RSV infection. These patients are likely to benefit from the extension of the age indication of the RSV vaccine, helping to reduce the burden of disease of RSV associated LRTDs. I hope that the NITAGs in Europe will rapidly adapt the indication of RSV vaccination to include these patients".

In addition to the US and European approvals, GSK has also filed regulatory submissions to extend the use of this vaccine to adults aged 50-59 at increased risk, including in Japan and other geographies with regulatory decisions undergoing review. Trials evaluating the immunogenicity and safety of the vaccine in adults aged 18-49 at increased risk and immunocompromised adults aged 18 and over are expected to read out in later in 2024.

Fuente: Directors Talk Interviews. Disponible en https://acortar.link/RUOMe0

New HPV vaccine from Zerun Bio receives WHO prequalification

Aug 29. This important milestone will provide countries with an additional option for affordable HPV vaccination and will contribute to sustainable supply of HPV vaccine—ensuring more girls are reached by this lifesaving vaccine.

Walrinvax™, a bivalent human papillomavirus (HPV) vaccine, has been prequalified by the World Health Organization (WHO). Walrinvax is manufactured by Yuxi Zerun Biotechnology Co., Ltd. in Yuxi City, Yunnan Province, China, a fully owned subsidiary of Shanghai Zerun Biotechnology under Walvax Biotechnology Co., Ltd. Walrinvax is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Countries facing barriers to national introduction or struggling to expand their HPV vaccine program due to price or supply constraints will now have another option for affordable, sustainable access.

"There is currently a significant gap in the existing HPV vaccine supply worldwide," says Mr. Yunchun Li, Board Chairman of Walvax. "With the achievement of WHO prequalification, and our commitment to supplying more than half our HPV production capacity to the global market, Walrinvax can be a great help in the global effort to fill that supply gap."

HPV is extremely common worldwide. Of the more than 100 types of the virus, at least 14 are cancer causing—including types 16 and 18, which cause about 70 percent of cervical cancers globally. Cervical cancer is a leading cause of cancer death among women in countries with low- and middle-income economies.

HPV vaccines are highly effective. Since their introduction, they have significantly reduced vaccine-type HPV infections and precancerous cervical lesions. WHO's global strategy to accelerate the elimination of cervical cancer calls on countries to, by the year 2030, fully vaccinate 90 percent of girls against HPV by age 15. WHO recommends one or two doses of HPV vaccine in girls and women between 9 and 20 years of age.

WHO prequalification—which ensures a vaccine meets strict international quality, safety, and efficacy standards—allows Walrinvax to be procured by United Nations agencies and Gavi, the Vaccine Alliance.

Walrinvax was licensed for use in China on March 22, 2022, and has been widely administered to girls and women locally, but prequalification allows it to enter the global public vaccine market—a critical step in expanding vaccine access.

PATH has been providing technical assistance to Zerun Bio to support the product development and prequalification process since 2017. Activities included improving the quality management and pharmacovigilance systems and providing chemistry, manufacturing, and controls; quality; and clinical advice for the prequalification dossier.

"The prequalification of Walrinvax will help move the world closer to its HPV vaccination goals, and we are encouraged by Zerun and Walvax's commitment to serving the global market," says Yuan Yuan, PATH China country representative. "The addition of another HPV vaccine to the global toolkit will help ensure equitable vaccination for girls in low- and middle-income countries."

Only four other HPV vaccines are currently prequalified by WHO. Merck International manufactures GARDASIL®, a quadrivalent vaccine that covers HPV types 6, 11, 16, and 18, first licensed in the United States in 2006; and GARDASIL 9, a nonavalent vaccine that covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, first licensed in the United States in 2014. GlaxoSmithKline manufactures a bivalent HPV vaccine, Cervarix®, that protects against HPV types 16 and 18, first licensed in Europe in 2007. Xiamen Innovax Biotech Co., Ltd. manufactures Cecolin®, a bivalent vaccine that covers HPV types 16 and 18, first licensed in China in 2019, and to which PATH also provided technical assistance prior to prequalification. GARDASIL 9 is not currently available for Gavi-eligible markets.

Fuente: Path. Disponible en https://acortar.link/JotjxK

Third-Generation Dengue Vaccines May Become Available Soon

Aug 29. As the global Dengue fever outbreak continues into the fall of 2024, health leaders say this year may be the worst for dengue cases.

The majority of reported cases in the United States (4,100) are related to international travel, and many people are searching for a Dengue vaccine before their next trip.

Unfortunately, access to effective and safe vaccines remains challenging in the U.S.

As of August 29, 2024, neither of the two Dengue vaccines in use is actually available in the U.S., except for Dengue-endemic Puerto Rico.

Based on recent announcements from India, third-generation Dengue vaccines could become available soon.

In Dengue-endemic India, the Indian Council of Medical Research and Panacea Biotec announced on August 14, 2024, that they had started a Phase 3 clinical trial for DengiAll, their anti-dengue vaccine candidate.

This news is essential since India currently does not have an approved vaccine for the illness.

Other Dengue vaccine candidates include, but are not limited to, the following:

Indian Immunologicals Limited (IIL) expects to launch its dengue fever vaccine commercially by 2026. IIL's managing director, K. Anand Kumar, said on August 20, 2024, that the vaccine's early-stage trials of about 90 individuals aged 18-50 did not demonstrate any adverse effects.

According to a phase 3 clinical study, which continues through 2024, Butantan Institute's Butantan-DV tetravalent dengue vaccine candidate showed an efficacy of 79.6% in preventing the disease in Brazil.

Serum Institute of India's tetravalent dengue vaccine live candidate Dengusiil is conducting phase 2 clinical research. A study published in August 2023 reported that the vaccine was highly immunogenic.

To warn people of their health risks after a Dengue infection, the U.S. Centers for Disease Control and Prevention reissued a Global Travel Health Notice on August 14, 2024, highlighting dengue outbreaks in 26 countries, including the Americas, Africa/Middle East, Costa Rica, and Asia/Pacific Islands.

Without access to second-generation Dengue vaccines, the CDC suggests that travelers to at-risk areas prevent mosquito bites by wearing long-sleeved shirts and long pants outdoors and sleeping in an air-conditioned room or room with window screens.



US CDC Dengue Travel Alert August 2024

Fuente: Precision Vaccinations. Disponible en https://acortar.link/IZUIgP

FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

Aug 30. Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of age and older. It includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2.

“The COVID-19 vaccines have had a tremendous positive impact on public health and vaccination continues to be the most effective method for COVID-19 prevention,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “COVID-19 continues to be a very real risk for many people, and we encourage individuals to consider getting an updated COVID-19 vaccine when eligible.

Today's authorization provides an additional COVID-19 vaccine option that meets the FDA's standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization."

This authorization follows the FDA's recent approvals and authorizations of updated mRNA COVID-19 vaccines for 2024-2025 manufactured by ModernaTX Inc. and Pfizer Inc.

What You Need to Know

Individuals 12 years of age and older who have never been vaccinated with any COVID-19 vaccine are eligible to receive two doses of this updated vaccine, 3 weeks apart.

Individuals who have been vaccinated only with one dose of any Novavax COVID-19 vaccine are eligible to receive one dose of the updated Novavax COVID-19 vaccine at least 3 weeks after the previous dose.

Those who have been vaccinated with a prior formula of a COVID-19 vaccine from another manufacturer or with two or more doses of a prior formula of the Novavax COVID-19 vaccine are eligible to receive a single dose of the updated Novavax COVID-19 vaccine at least 2 months after the last dose of a COVID-19 vaccine.

The FDA assessed manufacturing and nonclinical data to support the change to the 2024-2025 formula. The updated vaccine is manufactured using a similar process as previous formulas of this vaccine. Individuals who receive this vaccine may experience similar side effects as those reported by individuals who received previous formulas of this COVID-19 vaccine and as described in the fact sheets.

The FDA has determined that the updated Novavax COVID-19 vaccine has met the statutory criteria for issuance of an EUA, including that the known and potential benefits of the vaccine outweigh its known and potential risks in individuals 12 years of age and older.

As part of today's action, the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is no longer authorized for use.

The FDA granted the emergency use authorization of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) to Novavax Inc. of Gaithersburg, Maryland.

Fuente: U.S. Food & Drug Administration. Disponible en https://acortar.link/UikCRp

Cofepris autoriza vacuna contra enfermedades neumocócicas; podrá aplicarse desde la sexta semana de vida

31 ago. La Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) autorizó una vacuna antineumocócica conjugada que podrá aplicarse desde la sexta semana de vida.

Imagen Ilustrativa Infobae

El biológico está indicado para la prevención de enfermedades invasivas, neumonía y otitis media aguda en pacientes desde seis semanas hasta 17 años de edad.

Mientras que para personas de 18 años en adelante, la vacuna tiene como objetivo prevenir enfermedades neumocócicas; es decir aquellas causadas por el neumococo, una bacteria que provoca infecciones como la neumonía.

Así lo informó este viernes la autoridad sanitaria mediante un comunicado en el que también dio a conocer la autorización de 191 insumos para la salud entre los que destacan medicamentos dirigidos a diferentes especialidades.

¿Qué otros insumos para la salud aprobó Cofepris?

La Cofepris destacó la autorización de ocho medicamentos dirigidos a las especialidades de psiquiatría, cardiología, ginecología, endocrinología, hematología, neumología y reumatología.

También autorizó 174 registros sanitarios a dispositivos médicos, de los cuales 59 están destinados para atención médica, incluyendo sistemas de válvula aórtica, fijación lumbar y sistema intersomático, entre otros.

Asimismo, aprobó 55 equipos como la unidad de rayos X panorámica, el sistema de ultrasonido y el electrocardiógrafo, por citar algunos.

Los 60 restantes son reactivos o kits de diagnóstico, tales como la prueba rápida inmunocromática para la detección de VIH 1 y VIH 2, la PCR en tiempo real para identificar 14 tipos de VPH y la prueba de detección de grupos sanguíneo.

A estos insumos se suman ocho ensayos clínicos, entre los que destaca el estudio de fase IIA para revertir la hipertensión arterial pulmonar (HAP) en pacientes incidentes con formas idiopáticas o hereditarias graves de hipertensión pulmonar.

Los ensayos clínicos son investigaciones que se realizan en humanos con el propósito de identificar insumos de salud efectivos, seguros y eficaces en materia de diagnóstico, tratamiento y prevención de enfermedades.

“Estas autorizaciones reflejan el compromiso de la autoridad sanitaria federal con la salud pública, puesto que los medicamentos, ensayos y dispositivos aprobados demostraron, tras exhaustivos procesos de evaluación, que cumplen los más altos estándares de seguridad, calidad y eficacia”, mencionó.

Cofepris evaluará vacuna contra Mpox

Durante este día la autoridad sanitaria también informó que mantiene una estrecha comunicación con la empresa danesa Bavarian Nordic, fabricante de la vacuna Jynneos, contra la viruela y Mpox.

“La empresa ha notificado que el dossier actualizado para solicitar registro sanitario será presentado ante esta autoridad sanitaria el próximo martes 3 de septiembre”.

Señaló además que realizará la evaluación de seguridad, calidad y eficacia de manera inmediata y ágil, por lo que se espera una aprobación en los próximos 10 días.

“Comprometida con el acceso, Cofepris realizará la evaluación de seguridad, calidad y eficacia de manera inmediata y ágil, por lo que se espera una aprobación en los próximos 10 días”, dijo.

Al respecto el subsecretario de Prevención y Promoción de la Salud, Ruy López Ridaura, informó que la Secretaría de Salud (Ssa) está en espera del proceso de autorización de uso de emergencia de la vacuna contra la Mpox, por parte de la Cofepris.

El funcionario detalló que desde la Seretaría de Salud se está impulsando la posibilidad de la vacunación “con un enfoque de salud pública, de salud colectiva”.

Fuente: infobae. Disponible en https://acortar.link/YLfXyR

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2024/08/21"[Date - Publication] : "2024/0831"[Date - Publication])) 680 records.

[Zoster vaccination].

Krasselt M, Trawinski H, Lübbert C.Inn Med (Heidelb). 2024 Aug 28. doi: 10.1007/s00108-024-01764-6. Online ahead of print.PMID: 39196355

Vaccine process technology-A decade of progress.

Buckland B, Sanyal G, Ranheim T, Pollard D, Searles JA, Behrens S, Pluschkell S, Josefsberg J, Roberts CJ.Biotechnol Bioeng. 2024 Sep;121(9):2604-2635. doi: 10.1002/bit.28703. Epub 2024 May 6.PMID: 38711222

Discovering vaccines: the trial tale.

Vinusha V, Girish C.Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug 23. doi: 10.1007/s00210-024-03368-1. Online ahead of print.PMID: 39177789

Oral manifestations after vaccinations: A systematic review of observational studies.

Messina S, Natale P, Graziano G, Galleggiante S, Strippoli GFM, Petruzzi M.Oral Dis. 2024 Sep;30(6):3671-3678. doi: 10.1111/odi.14883. Epub 2024 Feb 6.PMID: 38321527

Human Immunodeficiency Virus **Vaccine**: Promise and Challenges.

Graciaa DS, Walsh SR, Rouphael N.Infect Dis Clin North Am. 2024 Sep;38(3):475-485. doi: 10.1016/j.idc.2024.04.004. Epub 2024 Jun 13.PMID: 38876903

Forssman and the staphylococcal hemolysins.

Ingmer H, Leisner JJ, Fulaz S.APMIS. 2024 Aug 27. doi: 10.1111/apm.13459. Online ahead of print.PMID: 39188243

Influenza **Vaccine** Effectiveness and Progress Towards a Universal Influenza **Vaccine**.

Cowling BJ, Okoli GN.Drugs. 2024 Aug 21. doi: 10.1007/s40265-024-02083-8. Online ahead of print.PMID: 39167316

Viral vector-based therapeutic HPV vaccines.

Ji T, Liu Y, Li Y, Li C, Han Y.Clin Exp Med. 2024 Aug 28;24(1):199. doi: 10.1007/s10238-024-01470-5.PMID: 39196444 **Free PMC article.**

Editorial: ML-driven **vaccine** against COVID-19: Developmental challenges and foresight.

Singh D, Damaševičius R, Kumar V, Bagnoli F, Pecetta S, Rappuoli R.Vaccine. 2024 Aug 26;42(23):126267. doi: 10.1016/j.vaccine.2024.126267. Online ahead of print.PMID: 39191180

Strategies of rational and structure-driven **vaccine** design for Arenaviruses.

Peter AS, Hoffmann DS, Klier J, Lange CM, Moeller J, Most V, Wüst CK, Beining M, Gülesen S, Junker H, Brumme B, Schiffner T, Meiler J, Schoeder CT.Infect Genet Evol. 2024 Sep;123:105626. doi: 10.1016/j.meegid.2024.105626. Epub 2024 Jun 20.PMID: 38908736

Asymptomatic parasitemia and RTS,S **vaccine** efficacy.

Arisue N, Palacpac NMQ.Lancet Infect Dis. 2024 Sep;24(9):942-944. doi: 10.1016/S1473-3099(24)00214-7. Epub 2024 May 6.PMID: 38723649

COVID-19 **Vaccine**: Predicting **Vaccine** Types and Assessing Mortality Risk Through Ensemble Learning Algorithms.

Monadhel H, Abbas AR, Mohammed AJ.F1000Res. 2024 Aug 23;12:1200. doi: 10.12688/f1000research.140395.1. eCollection 2023.PMID: 38799245

Combinative workflow for mRNA **vaccine** development.

Khanzode R, Soni G, Srivastava S, Pawar S, Wadapurkar R, Singh A.Biochem Biophys Rep. 2024 Jun 28;39:101766. doi: 10.1016/j.bbrep.2024.101766. eCollection 2024 Sep.PMID: 39040540

Vaccines and **Vaccine** Response in the Small Bowel Transplant Patient.

Lacaille F.Gastroenterol Clin North Am. 2024 Sep;53(3):431-439. doi: 10.1016/j.gtc.2023.12.004. Epub 2024 Jan 23.PMID: 39068004

The partnership for international **vaccine** initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.

Bresee JS, Lafond KE.Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255. Online ahead of print.PMID: 39214784

Leveraging artificial intelligence in **vaccine** development: A narrative review.

Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, Clement David-Olawade A.J Microbiol Methods. 2024 Sep;224:106998. doi: 10.1016/j.mimet.2024.106998. Epub 2024 Jul 15.PMID: 39019262

Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.

Wang B, Mohammed H, Andraweera P, McMillan M, Marshall H.J Infect. 2024 Sep;89(3):106225. doi: 10.1016/j.jinf.2024.106225. Epub 2024 Jul 8.PMID: 38986746

Spirocerca lupi draft genome, **vaccine** and anthelmintic targets.

Rothmann-Meyer W, Naidoo K, de Waal PJ.Mol Biochem Parasitol. 2024 Sep;259:111632. doi: 10.1016/j.molbiopara.2024.111632. Epub 2024 Jun 2.PMID: 38834134

COVID-19 severity, breakthrough infections and **vaccine** safety in young individuals with autoimmune diseases: insights from the COVAD study.

Alunno A, Carubbi F, Tan AL, Sen P, Cavagna L, Joshi M, Day J, Saha S, Gutiérrez CET, Caballero-Uribe CV, Distler O, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD Study Group.Rheumatol Int. 2024 Sep;44(9):1725-1731. doi: 10.1007/s00296-024-05654-w. Epub 2024 Jul 13.PMID: 39003346

Determinants of parental demand of human papillomavirus vaccination for adolescent daughters in China: Contingent valuation survey.

Chang J, Zhu S, Zhang Y, Carvalho N, Xu S, Lu Y, Liu X, Fang Y, Meng Q.Int J Health Plann Manage. 2024 Sep;39(5):1456-1481. doi: 10.1002/hpm.3818. Epub 2024 Jul 16.PMID: 39014911

A novel and cost-effective real-time RT-PCR targeting 24 nucleotides deletion to differentiate PEDV wild-type and classical attenuated **vaccine** strains.

Wang Z, Li X, Shang Y, Wu J, Lan X.J Virol Methods. 2024 Sep;329:114986. doi: 10.1016/j.jviromet.2024.114986. Epub 2024 Jun 22.PMID: 38914314

Comorbidities and confusion: addressing COVID-19 **vaccine** access and information challenges.

Attwell K, Roberts L, Blyth CC.Commun Dis Intell (2018). 2024 Aug 21;48. doi: 10.33321/cdi.2024.48.33.PMID: 39165022

Immunotherapeutic advances in glioma management: The rise of **vaccine**-based approaches.

Andrew Awuah W, Shah MH, Tan JK, Ranganathan S, Sanker V, Darko K, Tenkorang PO, Adageba BB, Ahluwalia A, Shet V, Aderinto N, Kundu M, Abdul-Rahman T, Atallah O.CNS Neurosci Ther. 2024 Sep;30(9):e70013. doi: 10.1111/cns.70013.PMID: 39215399

Untangling the role of the microbiome across the stages of HIV disease.

Ortiz AM, Brenchley JM.Curr Opin HIV AIDS. 2024 Sep 1;19(5):221-227. doi: 10.1097/COH.0000000000000870. Epub 2024 Jul 24.PMID: 38935047

From **vaccine** hesitancy to **vaccine** motivation: A motivational interviewing based approach to **vaccine** counselling.

Gagneur A, Gutnick D, Berthiaume P, Diana A, Rollnick S, Saha P.Hum Vaccin Immunother. 2024 Dec 31;20(1):2391625. doi: 10.1080/21645515.2024.2391625. Epub 2024 Aug 26.PMID: 39187772

Prevalence and Correlates of SARS-CoV-2 **Vaccine** Uptake and Hesitancy Among People With HIV Across the United States.

Spinelli MA, Johnson MO, Lisha NE, Jain JP, Moreira CV, Glidden DV, Burkholder GA, Crane HM, Jacobson JM, Cachay ER, Mayer KH, Napravnik S, Moore RD, Gandhi M, Christopoulos KA.J Acquir Immune Defic Syndr. 2024 Sep 1;97(1):13-18. doi: 10.1097/QAI.0000000000003466.PMID: 39116328

A Hepatitis E Virus Infection Model in the Mongolian Gerbil: Ready for Antiviral and **Vaccine** Studies.

Gouttenoire J, Neyts J.Gastroenterology. 2024 Sep;167(4):652-653. doi: 10.1053/j.gastro.2024.05.016. Epub 2024 May 23.PMID: 38795734

Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology.

Jacob EM, Huang J, Chen M.Precis Clin Med. 2024 Aug 1;7(3):pbae017. doi: 10.1093/pcmedi/pbae017. eCollection 2024 Sep.PMID: 39171210

Clinical trials and recent progress in HIV **vaccine** development.

Zubair A, Bibi B, Habib F, Sujan A, Ali M.Funct Integr Genomics. 2024 Aug 28;24(5):143. doi: 10.1007/s10142-024-01425-9.PMID: 39192058

Modulation of gut-microbiota through probiotics and dietary interventions to improve host health.

Dasriya VL, Samtiya M, Ranveer S, Dhillon HS, Devi N, Sharma V, Nikam P, Puniya M, Chaudhary P, Chaudhary V, Behare PV, Dhewa T, Vemuri R, Raposo A, Puniya DV, Khedkar GD, Vishweswaraiah RH, Vij S, Alarifi SN, Han H, Puniya AK.J Sci Food Agric. 2024 Aug 30;104(11):6359-6375. doi: 10.1002/jsfa.13370. Epub 2024 Feb 19.PMID: 38334314

How could our genetics impact COVID-19 **vaccine** response?

Zheng K, Chong AY, Mentzer AJ.Expert Rev Clin Immunol. 2024 Sep;20(9):1027-1039. doi: 10.1080/1744666X.2024.2346584. Epub 2024 Apr 27.PMID: 38676712

Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein **vaccine** (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.

Falsey AR, Hosman T, Bastian AR, Vandenberghe S, Chan EKH, Douoguih M, Heijnen E, Comeaux CA, Callendret B; CYPRESS investigators.Lancet Infect Dis. 2024 Sep;24(9):1015-1024. doi: 10.1016/S1473-3099(24)00226-3. Epub 2024 May 24.PMID: 38801826

Influenza **vaccine** during pregnancy, recommendations from healthcare providers, and race/ethnicity in the United States.

Xie S, Monteiro K, Gjelsvik A.Arch Gynecol Obstet. 2024 Sep;310(3):1441-1450. doi: 10.1007/s00404-023-07366-1. Epub 2024 Feb 1.PMID: 38300355

Preferences for a Clostridioides difficile **vaccine** among adults in the United States.

Vietri J, Maculaitis MC, Cappelleri JC, Yu H, Kopenhafer L, Beusterien K.Vaccine. 2024 Aug 31;42(24):126261. doi: 10.1016/j.vaccine.2024.126261. Online ahead of print.PMID: 39217776

Self-Reported COVID-19 **Vaccine** and Booster Acceptance and Hesitancy Among Autistic Adults in Pennsylvania: Cross-Sectional Analysis of Survey Data.

Shea L, Cooper D, Ventimiglia J, Frisbie S, Carlton C, Song W, Salzer M, Lee B, Hotez E, Vanness DJ.JMIR Public Health Surveill. 2024 Aug 28;10:e51054. doi: 10.2196/51054.PMID: 39196609

Development of an engineered extracellular vesicles-based **vaccine** platform for combined delivery of mRNA and protein to induce functional immunity.

Luo X, McAndrews KM, Arian KA, Morse SJ, Boeker V, Kumbhar SV, Hu Y, Mahadevan KK, Church KA, Chitta S, Ryujin NT, Hensel J, Dai J, Dowlatshahi DP, Sugimoto H, Kirtley ML, LeBleu VS, Shalapour S, Simmons JH, Kalluri R.J Control Release. 2024 Aug 30;374:550-562. doi: 10.1016/j.jconrel.2024.08.017. Online ahead of print.PMID: 39146981

A nanoparticle **vaccine** based on the VP1(21-26) and VP2 structural proteins of Senecavirus A induces robust protective immune responses.

Cao N, Li Y, Zhang H, Liu X, Liu S, Lu M, Hu Z, Tian L, Li X, Qian P.Vet Microbiol. 2024 Sep;296:110198. doi: 10.1016/j.vetmic.2024.110198. Epub 2024 Jul 25.PMID: 39067145

Clostridium perfringens antigens and challenges for development of vaccines against necrotic enteritis in poultry.

Waller SB, Galvão CC, Rodrigues RR, Aguirres CL, Quatrin PHDN, Alves MLF, Ferreira MRA, Conceição FR.Anaerobe. 2024 Aug 24;89:102902. doi: 10.1016/j.anaerobe.2024.102902. Online ahead of print.PMID: 39187174

The systemic capillary leak syndrome following COVID-19 **vaccine**.

Zhao C, Xue R, Zhao K, Lei R, Zhao M, Liu L.Hum Vaccin Immunother. 2024 Dec 31;20(1):2372149. doi: 10.1080/21645515.2024.2372149. Epub 2024 Aug 22.PMID: 39171563

Recent approaches in computational modelling for controlling pathogen threats.

Lees JA, Russell TW, Shaw LP, Hellewell J.Life Sci Alliance. 2024 Jun 21;7(9):e202402666. doi: 10.26508/lsa.202402666. Print 2024 Sep.PMID: 38906676

Vaccine hesitancy in South Tyrol: a narrative review of insights and strategies for public health improvement.

Wiedermann CJ, Barbieri V, Plagg B, Piccoliori G, Engl A.Ann Ig. 2024 Sep-Oct;36(5):569-579. doi: 10.7416/ai.2024.2625. Epub 2024 Mar 28.PMID: 38545675

Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis.

Zeng B, Liu X, Yang Q, Wang J, Ren Q, Sun F.Int J Infect Dis. 2024 Sep;146:107118. doi: 10.1016/j.ijid.2024.107118. Epub 2024 Jun 13.PMID: 38878994

COVID-19 vaccination in low and middle-income countries: Creating a sustainable roadmap for promoting public health intervention.

Oladapo RK, Obidiro OP, Oyetola AB, Olajide A, Oladapo MO, Lawrence US, Hasan MM, Islam Z, Mustapha AA, Osuagwu-Nwogu E, Ghazanfar S, Olaleye MA, Monisola I, Ibraheem B, Afolayan AA, Barakat A, Adewole MO.Int J Health Plann Manage. 2024 Sep;39(5):1612-1625. doi: 10.1002/hpm.3834. Epub 2024 Aug 1.PMID: 39090524

'We're at war.' Healthcare workers' experience with organisational change, uncertainty and **vaccine** hesitancy in 2021 and 2022 during the COVID-19 vaccination programe in Poland.

Wróblewski M, Stankowska J, Kawiak-Jawor E.Int J Health Plann Manage. 2024 Sep;39(5):1298-1312. doi: 10.1002/hpm.3801. Epub 2024 Mar 28.PMID: 38549154

Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox **vaccine**.

Greenberg RN, Schmidt D, Reichhardt D, Roesch S, Vidojkovic S, Maclennan J, Chen LM, Gruenert R, Kreusel C, Weidenthaler H, Meyer TPH, Chaplin PJ.Hum Vaccin Immunother. 2024 Dec 31;20(1):2384189. doi: 10.1080/21645515.2024.2384189. Epub 2024 Aug 22.PMID: 39171509

Dendritic cell **vaccine** for glioblastoma: an updated meta-analysis and trial sequential analysis.

Wong CE, Chang Y, Chen PW, Huang YT, Chang YC, Chiang CH, Wang LC, Lee PH, Huang CC, Hsu HJ, Lee JS.J Neurooncol. 2024 Aug 21. doi: 10.1007/s11060-024-04798-w. Online ahead of print.PMID: 39167243

Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.

Bai Z, Wan D, Lan T, Hong W, Dong H, Wei Y, Wei X.ACS Nano. 2024 Aug 26. doi: 10.1021/acsnano.3c10797. Online ahead of print.PMID: 39185745

An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria.

Chen L, Kang Z, Shen J, Zhao R, Miao Y, Zhang L, Zheng Z, Zhang Z, Liu N, Wang C, Fang H, Zhou J, Wang Y, Liu Z, Yang Y, Chen Q.Sci Bull (Beijing). 2024 Aug 30;69(16):2565-2579. doi: 10.1016/j.scib.2024.06.016. Epub 2024 Jun 14.PMID: 38918142

Vaccine practices, literacy, and hesitancy among parents in the United Arab Emirates.

Barqawi HJ, Samara KA, Kannas SM, Habbal O, AlSarraf NA, Dreezi MA, Abu-Gharbieh E.PLoS One. 2024 Aug 27;19(8):e0307020. doi: 10.1371/journal.pone.0307020. eCollection 2024.PMID: 39190761 COVID-19 and influenza **vaccine** uptake in women with criminal-legal system involvement.

Asupoto O, Li X, Hemberg JL, Emerson A, Black D, Geana MV, Wickliffe J, Glenn J, Ramaswamy M, Wurcel AG.Vaccine. 2024 Aug 30;42(21):126176. doi: 10.1016/j.vaccine.2024.126176. Epub 2024 Jul 30.PMID: 39079808

MIP **vaccine** in leprosy: A scoping review and future horizons.

Narang T, Jain S, Kaushal I, Dogra S.Indian J Dermatol Venereol Leprol. 2024 Sep-Oct;90(5):606-614. doi: 10.25259/IJDVL_1172_2023.PMID: 38899419

Three-dimensional cell culture: Future scope in cancer **vaccine** development.

Rahman M, Sahoo A, Almalki WH, Salman Almujri S, Aodah A, Alnofei AA, Alhamyani A.Drug Discov Today. 2024 Sep;29(9):104114. doi: 10.1016/j.drudis.2024.104114. Epub 2024 Jul 25.PMID: 39067612

Trabecular thickening on mammography post-COVID **vaccine** and RSV **vaccine**: Case report.

Siegel A, Adam R, Rubner R, Bains H, Ha R, Maldjian T.Radiol Case Rep. 2024 Jun 17;19(9):3729-3731. doi: 10.1016/j.radcr.2024.05.045. eCollection 2024 Sep.PMID: 38983306

Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Technical Report.

Committee on Infectious Diseases.Pediatrics. 2024 Aug 26:e2024068508. doi: 10.1542/peds.2024-068508. Online ahead of print.PMID: 39183667

Lessons Learnt on Infectious Bronchitis Virus Lineage GI-23.

Finger A, Ashash U, Goldenberg D, Raviv Z.Avian Pathol. 2024 Aug 27:1-50. doi: 10.1080/03079457.2024.2398030. Online ahead of print.PMID: 39190026

Qualitative real-time RT-PCR assay for nOPV2 poliovirus detection.

Dolgova AS, Kanaeva OI, Antonov SA, Shabalina AV, Klyuchnikova EO, Sbarzaglia VA, Gladkikh AS, Ivanova OE, Kozlovskaya LI, Dedkov VG.J Virol Methods. 2024 Sep;329:114984. doi: 10.1016/j.jviromet.2024.114984. Epub 2024 Jun 15.PMID: 38885908

Psychosocial dimensions of **vaccine** hesitancy: A systematic review.

Rizzo M, Gattino S, Trombetta T, Calandri E, De Piccoli N.J Community Psychol. 2024 Sep;52(7):857-876. doi: 10.1002/jcop.23133. Epub 2024 Jul 10.PMID: 38988066

Assessing real world **vaccine** effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) **vaccine** impact on HPV infection and cervical disease.

Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K.Vaccine. 2024 Aug 30;42(21):126177. doi: 10.1016/j.vaccine.2024.126177. Epub 2024 Aug 10.PMID: 39128198

COVID-19 **Vaccine** Hesitancy in Caregivers of Hospitalized Children From 2020 Through 2023.

Orbea M, Lopez MA, Huang X, Guffey D, Cunningham RM, Healy CM, Boom JA, Bocchini CE.Hosp Pediatr. 2024 Sep 1;14(9):701-713. doi: 10.1542/hpeds.2023-007660.PMID: 39099438

Information and **vaccine** hesitancy: The role of broadband Internet.

Amaral-Garcia S, Nardotto M, Propper C, Valletti T.Health Econ. 2024 Sep;33(9):1936-1948. doi: 10.1002/hec.4856. Epub 2024 May 27.PMID: 38801742

Vaccines for Respiratory Viruses-COVID and Beyond.

Rajanala K, Upadhyay AK.Vaccines (Basel). 2024 Aug 22;12(8):936. doi: 10.3390/vaccines12080936.PMID: 39204059

COVID-19 vaccination intention among internally displaced persons in complex humanitarian emergency context, Northeast Nigeria.

Gidado S, Musa M, Ba'aba AI, Okeke LA, Nguku PM, Hassan IA, Bande IM, Usman R, Ugbenyo G, Hadejia IS, Nuorti JP, Atkins S.PLoS One. 2024 Aug 30;19(8):e0308139. doi: 10.1371/journal.pone.0308139. eCollection 2024.PMID: 39213303

Characteristics Associated With Homebound Vaccination Against COVID-19.

Ren J, Kumar A, Zhao D, Ornstein KA, Gliatto PM.J Am Med Dir Assoc. 2024 Sep;25(9):105147. doi: 10.1016/j.jamda.2024.105147. Epub 2024 Jul 11.PMID: 39004101

Bioproduction and immunogenic evaluation of SARS-CoV-2 prototype **vaccine** in silkworm BmN cells.

Zheng H, Zhao H, Xiong H, Awais MM, Zeng S, Sun J.Int J Biol Macromol. 2024 Sep;276(Pt 2):134027. doi: 10.1016/j.ijbiomac.2024.134027. Epub 2024 Jul 20.PMID: 39033889

The progress of tumor vaccines clinical trials in non-small cell lung cancer.

Wang X, Niu Y, Bian F.Clin Transl Oncol. 2024 Aug 23. doi: 10.1007/s12094-024-03678-z. Online ahead of print.PMID: 39179939

Recent efforts in the development of glycoconjugate **vaccine** and available treatment for tuberculosis.

Banoo S, Yadav Y, Tyagi R, Manna A, Sagar R.Bioorg Chem. 2024 Sep;150:107610. doi: 10.1016/j.bioorg.2024.107610. Epub 2024 Jul 1.PMID: 38991488

Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation.

Zhang P, Gorman J, Tsybovsky Y, Lu M, Liu Q, Gopan V, Singh M, Lin Y, Miao H, Seo Y, Kwon A, Olia AS, Chuang GY, Geng H, Lai YT, Zhou T, Mascola JR, Mothes W, Kwong PD, Lusso P.Cell Rep. 2024 Aug 27;43(8):114518. doi: 10.1016/j.celrep.2024.114518. Epub 2024 Jul 18.PMID: 39028623

Factors associated with COVID-19 **vaccine** uptake among South African health care workers.

George G, Strauss M, Lansdell E, Nota P, Peters RPH, Brysiewicz P, Nadesan-Reddy N, Wassenaar D.Vaccine. 2024 Aug 30;42(21):126181. doi: 10.1016/j.vaccine.2024.126181. Epub 2024 Aug 6.PMID: 39111155

Integrating immunoinformatics and computational epitope prediction for a **vaccine** candidate against respiratory syncytial virus.

Nguyen TL, Kim H.Infect Dis Model. 2024 Apr 16;9(3):763-774. doi: 10.1016/j.idm.2024.04.005. eCollection 2024 Sep.PMID: 38708060

Construction of Toxoplasma gondii SRS29C nucleic acid **vaccine** and comparative immunoprotective study of an SRS29C and SAG1 combination.

Yan A, Tian J, Ye J, Gao C, Ye L, Zhang D, Song Q.Mol Biochem Parasitol. 2024 Sep;259:111630. doi: 10.1016/j.molbiopara.2024.111630. Epub 2024 May 23.PMID: 38795969

Respiratory diphtheria in the time of Omicron.

Simpson A, Douglas P, Draper J, Sintchenko V, Cutcher Z, Ashton D.Commun Dis Intell (2018). 2024 Aug 21;48. doi: 10.33321/cdi.2024.48.41.PMID: 39165018

Immune evasiveness of SARS-CoV-2 variants and **vaccine** selection.

Inghammar M, Kahn F.Lancet Infect Dis. 2024 Sep;24(9):937-938. doi: 10.1016/S1473-3099(24)00286-X. Epub 2024 May 15.PMID: 38761805

Advances in the study of LNPs for mRNA delivery and clinical applications.

Wang B, Shen B, Xiang W, Shen H.Virus Genes. 2024 Aug 22. doi: 10.1007/s11262-024-02102-6. Online ahead of print.PMID: 39172354

The mark of success: The role of **vaccine**-induced skin scar formation for BCG and smallpox **vaccine**-associated clinical benefits.

Bæk O, Schaltz-Buchholzer F, Campbell A, Amenyogbe N, Campbell J, Aaby P, Benn CS, Kollmann TR.Semin Immunopathol. 2024 Aug 26;46(5):13. doi: 10.1007/s00281-024-01022-9.PMID: 39186134

Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.

Bronstein MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S.Vaccine. 2024 Aug 30;42(21):126198. doi: 10.1016/j.vaccine.2024.126198. Epub 2024 Aug 5.PMID: 39106578

Deciphering immune responses: a comparative analysis of influenza vaccination platforms.

Jones CH, Hauguel T, Beitelshees M, Davitt M, Welch V, Lindert K, Allen P, True JM, Dolsten M.Drug Discov Today. 2024 Sep;29(9):104125. doi: 10.1016/j.drudis.2024.104125. Epub 2024 Aug 2.PMID: 39097221

Epitopes screening and **vaccine** molecular design of PEDV S protein based on immunoinformatics.

Li S, Bai X, Wang C.Sci Rep. 2024 Aug 22;14(1):19537. doi: 10.1038/s41598-024-70579-0.PMID: 39174674

HPV **Vaccine** Usage Among the U.S. Military Academy Corps of Cadets (2018-2025).

Brasko B, McClean J, Penick E, Mullaney S.Mil Med. 2024 Aug 30;189(9-10):2094-2099. doi: 10.1093/milmed/usad428.PMID: 37976181

Effectiveness and impact of monovalent rotavirus vaccination in Afghanistan: a test-negative case-control analysis.

Anwari P, Burnett E, Safi N, Samsor A, Safi H, Chavers TP, Parashar UD, Clark AD, Tate JE.Lancet Glob Health. 2024 Sep;12(9):e1517-e1525. doi: 10.1016/S2214-109X(24)00237-7.PMID: 39151986

COVID-19 vaccinations pre- and antepartum: a consideration of the evidence and discussion of issues.

Feinberg Isaacs T, Dahan MH.Arch Gynecol Obstet. 2024 Aug 28. doi: 10.1007/s00404-024-07701-0. Online ahead of print.PMID: 39196328

Predictors of the willingness to accept a free COVID-19 **vaccine** among households in Nigeria.

Eyawo O, Ugoji UC, Pan S, Oyibo P, Rehman A, Mahboob M, Esimai OA.Vaccine. 2024 Aug 30;42(23):126225. doi: 10.1016/j.vaccine.2024.126225. Online ahead of print.PMID: 39216208

Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.

Li P, Faraone JN, Hsu CC, Chamblee M, Zheng YM, Carlin C, Bednash JS, Horowitz JC, Mallampalli RK, Saif LJ, Oltz EM, Jones D, Li J, Gumina RJ, Xu K, Liu SL.Cell Rep. 2024 Aug 27;43(8):114520. doi: 10.1016/j.celrep.2024.114520. Epub 2024 Jul 17.PMID: 39024099

DNA-Engineered Degradable Invisibility Cloaking for Tumor-Targeting Nanoparticles.

Zhao Y, Hou J, Guo L, Zhu S, Hou X, Cao S, Zhou M, Shi J, Li J, Liu K, Zhang H, Wang L, Fan C, Zhu Y.J Am Chem Soc. 2024 Aug 28. doi: 10.1021/jacs.4c09479. Online ahead of print.PMID: 39196310

Mapping the functional B-cell epitopes of *Shigella* invasion plasmid antigen D (IpaD).

Li S, Zhang W.Appl Environ Microbiol. 2024 Aug 21;90(8):e0098824. doi: 10.1128/aem.00988-24. Epub 2024 Jul 31.PMID: 39082807

Sea water acclimation of rainbow trout (Oncorhynchus mykiss) modulates the mucosal transcript immune response induced by Vibrio anguillarum and Aeromonas salmonicida **vaccine**, and prevents further transcription of stress-immune genes in response to acute stress.

Khansari AR, Wallbom N, Sundh H, Sandblom E, Tort L, Jönsson E.Fish Shellfish Immunol. 2024 Sep;152:109733. doi: 10.1016/j.fsi.2024.109733. Epub 2024 Jun 27.PMID: 38944251

Computational strategies in Klebsiella pneumoniae **vaccine** design: navigating the landscape of in silico insights.

Douradinha B.Biotechnol Adv. 2024 Aug 30;76:108437. doi: 10.1016/j.biotechadv.2024.108437. Online ahead of print.PMID: 39216613

A systematic review of interventions to promote human papillomavirus (HPV) vaccination in Africa.

Olaoye O, Macdonald S.Public Health. 2024 Sep;234:47-57. doi: 10.1016/j.puhe.2024.05.015. Epub 2024 Jul 1.PMID: 38954882

Association of new onset seizure and COVID-19 vaccines and long-term follow-up: A systematic review and meta-analysis.

Rafati A, Jameie M, Amanollahi M, Pasebani Y, Salimi N, Kazemi MHF, Jameie M, Pasebani MY, Sakhaei D, Feizollahi F, Kwon CS.Epilepsia. 2024 Aug 27. doi: 10.1111/epi.18102. Online ahead of print.PMID: 39190029

Cost-effectiveness of RSVpreF **vaccine** and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.

Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE, Killikelly A, Siu W, Rafferty E, Brousseau N, Tunis M, Tuite AR.Vaccine. 2024 Aug 30;42(21):126164. doi: 10.1016/j.vaccine.2024.126164. Epub 2024 Jul 30.PMID: 39079810

Timing of pertussis vaccination during pregnancy: Evidence and implementation - A systematic review.

De Weerdt L, Herzog SA, Van Damme P, Maertens K.Vaccine. 2024 Aug 30;42(21):126152. doi: 10.1016/j.vaccine.2024.07.053. Epub 2024 Jul 31.PMID: 39088988

Pediatric Pneumococcal Conjugate **Vaccine** and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece.

Perdrizet JE, Rozenbaum MH, Heffler MJ.Infect Dis Ther. 2024 Sep;13(9):2017-2034. doi: 10.1007/s40121-024-01022-0. Epub 2024 Jul 26.PMID: 39060825

Structural proteomics guided annotation of **vaccine** targets and designing of multi-epitopes **vaccine** to instigate adaptive immune response against Francisella tularensis.

Khan A, Ali SS, Khan A, Zahid MA, Alshabrmi FM, Waheed Y, Agouni A.Microb Pathog. 2024 Sep;194:106777. doi: 10.1016/j.micpath.2024.106777. Epub 2024 Jul 14.PMID: 39002657

Implementation and adherence to regular asymptomatic testing in a COVID-19 **vaccine** trial.

Williams LR, Emary KRW, Phillips DJ, Hay J, Larwood JPJ, Ramasamy MN, Pollard AJ, Grassly NC, Voysey M.Vaccine. 2024 Aug 30;42(21):126167. doi: 10.1016/j.vaccine.2024.126167. Epub 2024 Jul 26.PMID: 39060202

Lactobacillus casei displaying MCP2α and FlaC delivered by PLA microspheres effectively enhances the immune protection of largemouth bass (Micropterus salmoides) against LMBV infection.

Liu Q, Huo X, Wang P, Zhao F, Yuan G, Yang C, Su J.Fish Shellfish Immunol. 2024 Aug 30:109870. doi: 10.1016/j.fsi.2024.109870. Online ahead of print.PMID: 39218416

The importance of 'dread risk' for **vaccine** communication.

Day AM, Volkman JE.J Commun Healthc. 2024 Aug 26:1-8. doi: 10.1080/17538068.2024.2393918. Online ahead of print.PMID: 39186246

Discovering peptides and computational investigations of a multiepitope **vaccine** target Mycobacterium tuberculosis.

Nguyen TL, Kim H.Synth Syst Biotechnol. 2024 Mar 21;9(3):391-405. doi: 10.1016/j.synbio.2024.03.010. eCollection 2024 Sep.PMID: 38585591

Reflections on the Advisory Committee on Immunization Practices During the COVID-19 Pandemic.

Poehling KA, Lee GM.Acad Pediatr. 2024 Sep-Oct;24(7):1038-1046. doi: 10.1016/j.acap.2024.06.019. Epub 2024 Jul 6.PMID: 38972350

Role of the dengue **vaccine** TAK-003 in an outbreak response: Modeling the Sri Lanka experience.

Fernando L, Kastner R, Wickramasinghe P, Fernando AD, Gunasekera D, Nguyen VH, Liu M, LeFevre I, Wallace D, Folschweiller N, Biswal S.PLoS Negl Trop Dis. 2024 Aug 22;18(8):e0012376. doi: 10.1371/journal.pntd.0012376. Online ahead of print.PMID: 39173075

Necrotic enteritis in chickens: a comprehensive review of **vaccine** advancements over the last two decades.

Shamshirgaran MA, Golchin M.Avian Pathol. 2024 Aug 27:1-46. doi: 10.1080/03079457.2024.2398028. Online ahead of print.PMID: 39190009

Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate **vaccine** introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study.

Chen C, Ang G, Akksilp K, Koh J, Scott JAG, Clark A, Jit M.Lancet Glob Health. 2024 Sep;12(9):e1485-e1497. doi: 10.1016/S2214-109X(24)00232-8.PMID: 39151983

A crisis of confidence? Intervening in **vaccine** hesitancy in North Dakota.

Rubinstein EB, Heinemann LL.Med Anthropol Q. 2024 Sep;38(3):298-312. doi: 10.1111/maq.12873. Epub 2024 Jun 7.PMID: 38847386

Non-STEM majors COVID-19 **vaccine** impressions improve, and misconceptions resolve, after podcast assignment.

Morra CN, Adkins SJ, Barnes ME, Pirlo OJ, Fleming R, Convers BJ, Glass SP, Howell ML, Raut SA.J Microbiol Biol Educ. 2024 Aug 29;25(2):e0003423. doi: 10.1128/jmbe.00034-23. Epub 2024 Jun 14.PMID: 38874323

Elevating Home Health Aide Input in Co-Creation of COVID-19 **Vaccine** Messaging.

Lum HD, Fischer S, Ytell K, Scherer L, O'Leary ST, Elk R, Hurley S, Washington KT, DeCamp M.Am J Hosp Palliat Care. 2024 Sep;41(9):1094-1103. doi: 10.1177/10499091231218455. Epub 2023 Nov 22.PMID: 37991051

Telomeric repeats in the commercial SB-1 **vaccine** facilitate viral integration and contribute to **vaccine** efficacy.

You Y, Kheimar AM, Vychodil T, Kossak L, Sabsabi MA, Conradie AM, Reddy SM, Bertzbach LD, Kaufer BB.NPJ Vaccines. 2024 Aug 21;9(1):154. doi: 10.1038/s41541-024-00945-6.PMID: 39169010

Multiple-component interventions to increase rotavirus **vaccine** uptake in children: a randomised controlled trial.

Yeung KHT, Yeung CCW, Tam WH, Liu KS, Fung GPG, Nelson EAS.Lancet Reg Health West Pac. 2024 Aug 5;50:101153. doi: 10.1016/j.lanwpc.2024.101153. eCollection 2024 Sep.PMID: 39211430

Risk factors related to the SARS-CoV-2 **vaccine** additional doses hesitancy among pregnant and non-pregnant people of reproductive age and partners: A Brazilian cross-sectional study.

Charles CM, Noles M, Munezero A, Gallardo N, Bahamondes L, Bento SF, de Pádua KS, Nhauche M, Metelus S, Cecatti JG, Souza RT, Pacagnella RC.Int J Gynaecol Obstet. 2024 Sep;166(3):1144-1160. doi: 10.1002/ijgo.15512. Epub 2024 Mar 26.PMID: 38532554

A naturaly attenuated largemouth bass ranavirus strain provided protection for Micropterus salmoides by immersion immunization.

Fu X, Li W, Liu C, Luo X, Lin Q, Niu Y, Liang H, Ma B, Li N.Fish Shellfish Immunol. 2024 Aug 30:109871. doi: 10.1016/j.fsi.2024.109871. Online ahead of print.PMID: 39218417

HPV infection and vaccination: a cross-sectional study of knowledge, perception, and attitude to **vaccine** uptake among university students in Qatar.

Cheema S, Abraham A, Maisonneuve P, Jithesh A, Chaabna K, Al Janahi R, Sarker S, Hussain A, Rao S, Lowenfels AB, Mamtani R.BMC Public Health. 2024 Aug 26;24(1):2316. doi: 10.1186/s12889-024-19792-0.PMID: 39187821

Therapeutic **vaccine** targeting dual immune checkpoints induces potent multifunctional CD8(+) T cell anti-tumor immunity.

Zheng Y, Lu Z, Zhu F, Zhao G, Shao Y, Lu B, Ding J, Wang G, Fang L, Zheng J, Chai D.Int Immunopharmacol. 2024 Aug 31;142(Pt A):113004. doi: 10.1016/j.intimp.2024.113004. Online ahead of print.PMID: 39217885

The long road for **vaccine** development with difficulties and hopes.

Ge Q, Chen P, Cheng Y, Xiao Y.Emerg Microbes Infect. 2024 Aug 23:2396886. doi: 10.1080/22221751.2024.2396886. Online ahead of print.PMID: 39178195

Preparation and immunological activity evaluation of an intranasal protein subunit **vaccine** against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant.

Chen Y, Wang Y, Li Z, Jiang H, Pan W, Liu M, Jiang W, Zhang X, Wang F.Int J Biol Macromol. 2024 Sep;276(Pt 1):133733. doi: 10.1016/j.ijbiomac.2024.133733. Epub 2024 Jul 11.PMID: 39002905

Effectiveness of an experimental subunit ovine Mannheimia haemolytica respiratory **vaccine** in reducing pneumonia in lambs.

Van Donkersgoed J, Gardner M, Prysliak T, Perez-Casal J.Can Vet J. 2024 Sep;65(9):927-940.PMID: 39219611

Safety and 6-month immune persistence of inactivated poliovirus **vaccine** (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.

Guo S, Li Z, Zheng M, Wu F, Sun J, Tuo L, Li S, Li X, Wei L, Xia Z, Xie P, Chen X, Zhao Y, Gao Y, Yu D.Vaccine. 2024 Aug 30;42(21):126183. doi: 10.1016/j.vaccine.2024.126183. Epub 2024 Jul 31.PMID: 39088987

Pan-beta-coronavirus subunit **vaccine** prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.

Wang G, Verma AK, Guan X, Bu F, Odle AE, Li F, Liu B, Perlman S, Du L.J Virol. 2024 Aug 27:e0037624. doi: 10.1128/jvi.00376-24. Online ahead of print.PMID: 39189731

Mucosal T-cell responses to chronic viral infections: Implications for **vaccine** design.

Al-Talib M, Dimonte S, Humphreys IR.Cell Mol Immunol. 2024 Sep;21(9):982-998. doi: 10.1038/s41423-024-01140-2. Epub 2024 Mar 8.PMID: 38459243

Genotypic analysis of RTS,S/AS01(E) malaria **vaccine** efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.

Juraska M, Early AM, Li L, Schaffner SF, Lievens M, Khorgade A, Simpkins B, Hejazi NS, Benkeser D, Wang Q, Mercer LD, Adjei S, Agbenyega T, Anderson S, Ansong D, Bii DK, Buabeng PBY, English S, Fitzgerald N, Grimsby J, Kariuki SK, Otieno K, Roman F, Samuels AM, Westercamp N, Ockenhouse CF, Ofori-Anyinam O, Lee CK, MacInnis BL, Wirth DF, Gilbert PB, Neafsey DE.Lancet Infect Dis. 2024 Sep;24(9):1025-1036. doi: 10.1016/S1473-3099(24)00179-8. Epub 2024 May 6.PMID: 38723650

Preparation of a novel type I feline coronavirus virus-like particle **vaccine** and its immunogenicity in mice and cats.

Zhou Q, Song X, Li Y, Huang J, Yu QS, Den GN, Zhang JQ, Zhu CX, Zhang B.Microb Pathog. 2024 Sep;194:106795. doi: 10.1016/j.micpath.2024.106795. Epub 2024 Jul 15.PMID: 39019122

Religious beliefs and practices toward HPV **vaccine** acceptance in Islamic countries: A scoping review.

Kisa S, Kisa A.PLoS One. 2024 Aug 29;19(8):e0309597. doi: 10.1371/journal.pone.0309597. eCollection 2024.PMID: 39208300

Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review.

Adams K, Diallo D, Tadount F, Mouajou V, Quach C.Vaccine. 2024 Aug 26;42(23):126246. doi: 10.1016/j.vaccine.2024.126246. Online ahead of print.PMID: 39191181

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunizations: We must do better…now.

Khalil A, Samara A, Campbell H, Ladhani SN, Amirthalingam G.Int J Infect Dis. 2024 Sep;146:107148. doi: 10.1016/j.ijid.2024.107148. Epub 2024 Jul 2.PMID: 38960028

The structure of the Lujo virus spike complex.

Eilon-Ashkenazy M, Cohen-Dvashi H, Borni S, Shaked R, Calinsky R, Levy Y, Diskin R.Nat Commun. 2024 Aug 21;15(1):7175. doi: 10.1038/s41467-024-51606-0.PMID: 39169025

The impact of conspiracy theories and **vaccine** knowledge on vaccination intention: a longitudinal study.

Viscardi LH, Vilanova F, Novaes FC, Michelin L, Costa ÂB.Cien Saude Colet. 2024 Sep;29(9):e00352023. doi: 10.1590/1413-81232024299.00352023. Epub 2023 Sep 20.PMID: 39194099

'Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom exploring why some children are unvaccinated or vaccinated late.

Skirrow H, Lewis C, Haque H, Choudary-Salter L, Foley K, Whittaker E, Costelloe C, Bedford H, Saxena S.Vaccine. 2024 Aug 21;42(22):126172. doi: 10.1016/j.vaccine.2024.126172. Online ahead of print.PMID: 39173435

Lipid nanoparticle-encapsulated DNA **vaccine** confers protection against swine and human-origin H1N1 influenza viruses.

Nguyen TN, Lai DC, Sillman S, Petro-Turnquist E, Weaver EA, Vu HLX.mSphere. 2024 Aug 28;9(8):e0028324. doi: 10.1128/msphere.00283-24. Epub 2024 Aug 1.PMID: 39087764

How to overcome information and communication barriers in Human Papillomavirus vaccination? A SWOT analysis based on the opinions of European family doctors in contact with young people and their parents.

Çevik HS, Peker AGC, Görpelioğlu S, Vinker S, Ungan M.Eur J Gen Pract. 2024 Dec;30(1):2393858. doi: 10.1080/13814788.2024.2393858. Epub 2024 Aug 30.PMID: 39213042

Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.

Griskaitis M, Thielemann I, Schönfeld V, Falman A, Scholz S, Reinacher U, Haas L, Wichmann O, Harder T.J Infect. 2024 Sep;89(3):106228. doi: 10.1016/j.jinf.2024.106228. Epub 2024 Jul 10.PMID: 38996818

Select gut microbiota impede rotavirus **vaccine** efficacy.

Ngo VL, Wang Y, Wang Y, Shi Z, Britton R, Zou J, Ramani S, Jiang B, Gewirtz AT.Cell Mol Gastroenterol Hepatol. 2024 Aug 21:101393. doi: 10.1016/j.jcmgh.2024.101393. Online ahead of print.PMID: 39179176

Immunoinformatic approach for multi-epitope **vaccine** design against Staphylococcus aureus based on hemolysin proteins.

Garrido-Palazuelos LI, Almanza-Orduño AA, Waseem M, Basheer A, Medrano-Félix JA, Mukthar M, Ahmed-Khan H, Shahid F, Aguirre-Sánchez JR.J Mol Graph Model. 2024 Aug 23;132:108848. doi: 10.1016/j.jmgm.2024.108848. Online ahead of print.PMID: 39182254

Cytokine and acute-phase proteins response following vaccination against infectious bronchitis in broilers.

Dana A, Allymehr M, Talebi A, Asri-Rezaei S.Vet Med Sci. 2024 Sep;10(5):e1586. doi: 10.1002/vms3.1586.PMID: 39171612

Pediatric practice experiences with second dose influenza vaccination: An AAP Pediatric Research in Office Settings (PROS) Study.

Wynn CS, Stockwell MS, Nekrasova E, Torres A, Griffith M, Kumar SS, Shone LP, Localio R, Shults J, Unger R, Ware LA, Fiks AG.Public Health. 2024 Aug 21;236:93-98. doi: 10.1016/j.puhe.2024.07.018. Online ahead of print.PMID: 39173545

Cluster-Based BERTopic Modeling on Swedish COVID-19 **Vaccine** Posts.

Kokkinakis D, Hammarlin MM.Stud Health Technol Inform. 2024 Aug 22;316:1906-1910. doi: 10.3233/SHTI240805.PMID: 39176864

Using Digital Storytelling and Social Media to Combat COVID-19 **Vaccine** Hesitancy: A Public Service Social Marketing Campaign.

Dunlap AF, Ciari A, Islam N, Thorpe LE, Khan MR, Huang TTK.J Prev (2022). 2024 Aug 30. doi: 10.1007/s10935-024-00799-7. Online ahead of print.PMID: 39212892

Vital Signs: Trends and Disparities in Childhood Vaccination Coverage by Vaccines for Children Program Eligibility - National Immunization Survey-Child, United States, 2012-2022.

Valier MR, Yankey D, Elam-Evans LD, Chen M, Hill HA, Mu Y, Pingali C, Gomez JA, Arthur BC, Surtees T, Graitcer SB, Dowling NF, Stokley S, Peacock G, Singleton JA.MMWR Morb Mortal Wkly Rep. 2024 Aug 22;73(33):722-730. doi: 10.15585/mmwr.mm7333e1.PMID: 39173180

Vaccination status among children in an urban area and its association with risk factors and some parent health practices: A cross-sectional study.

Bardak F, Kocoglu-Tanyer D.Public Health Nurs. 2024 Sep-Oct;41(5):883-893. doi: 10.1111/phn.13343. Epub 2024 May 28.PMID: 38804032

Use of a meningococcal group B **vaccine** (4CMenB) in populations at high risk of gonorrhoea in the UK.

Ladhani SN, White PJ, Campbell H, Mandal S, Borrow R, Andrews N, Bhopal S, Saunders J, Mohammed H, Drisdale-Gordon L, Callan E, Sinka K, Folkard K, Fifer H, Ramsay ME.Lancet Infect Dis. 2024 Sep;24(9):e576-e583. doi: 10.1016/S1473-3099(24)00031-8. Epub 2024 Mar 20.PMID: 38521080

Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.

Vielot NA, Kelly NK, Ludema C, Rosenberg M, Brown ER, Janes HE, Kublin JG, Stephenson KE, Marcelin JR, Pettifor A.Vaccine. 2024 Aug 24;42(23):126237. doi: 10.1016/j.vaccine.2024.126237. Online ahead of print.PMID: 39182315

Factors affecting COVID-19 **vaccine** uptake in populations with higher education: insights from a cross-sectional study among university students in Malawi.

Madhlopa QK, Mtumbuka M, Kumwenda J, Illingworth TA, Van Hout MC, Mfutso-Bengo J, Mikeka C, Shawa IT.BMC Infect Dis. 2024 Aug 21;24(1):848. doi: 10.1186/s12879-024-09534-3.PMID: 39169315

Proteomics Exploration of Brucella melitensis to Design an Innovative Multi-Epitope mRNA **Vaccine**.

Asadinezhad M, Pakzad I, Asadollahi P, Ghafourian S, Kalani BS.Bioinform Biol Insights. 2024 Aug 30;18:11779322241272404. doi: 10.1177/11779322241272404. eCollection 2024.PMID: 39220468

Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study.

Gram MA, Myrup Thiesson E, Pihlström N, Perälä J, Poukka E, Leino T, Ljung R, Andersson NW, Hviid A.J Infect. 2024 Aug 30:106261. doi: 10.1016/j.jinf.2024.106261. Online ahead of print.PMID: 39218308

Content validation of a Facebook HPV vaccination promotion intervention (#HPVvaxtalks) created for young Black adults (18-26 years old).

Adebola A, Charis E, Tristan N, Melinda I.Public Health Nurs. 2024 Sep-Oct;41(5):1178-1187. doi: 10.1111/phn.13356. Epub 2024 Jun 26.PMID: 38923608

Vaccinating parent flocks against colibacillosis reduces broiler mortality - A retrospective observational study from 2016 to 2019 in Finland.

Biström M, Vennerström P, Pohjanvirta T, Ranta J.Prev Vet Med. 2024 Sep;230:106258. doi: 10.1016/j.prevetmed.2024.106258. Epub 2024 Jun 26.PMID: 38955116

Influence of bovine pestivirus heterogeneity on serological responses to 10 different commercial **vaccine** formulation.

Camargo L, Resende da Silva GF, Baccili CC, Flores EF, Gomes V.Vet Microbiol. 2024 Sep;296:110155. doi: 10.1016/j.vetmic.2024.110155. Epub 2024 Jul 3.PMID: 38996750

Comments on: Human Papilloma Virus **vaccine** and prevention of head and neck cancer, what is the current evidence?

Kannan R.Oral Oncol. 2024 Sep;156:106936. doi: 10.1016/j.oraloncology.2024.106936. Epub 2024 Jul 4.PMID: 38968721

Mitigating Misinformation Toolkit: Online Simulation and Standardized Patient Cases for Interprofessional Students to Address **Vaccine** Hesitancy and Misinformation.

Fusco NM, Foltz-Ramos K, Kruger JS, Vargovich AM, Prescott WA Jr.MedEdPORTAL. 2024 Aug 30;20:11459. doi: 10.15766/mep_2374-8265.11459. eCollection 2024.PMID: 39219741

Did the health care **vaccine** mandate work? An evaluation of the impact of the COVID-19 **vaccine** mandate on **vaccine** uptake and infection risk in a large cohort of Canadian health care workers.

Okpani AI, Lockhart K, Barker S, Grant JM, Yassi A.Am J Infect Control. 2024 Sep;52(9):1065-1072. doi: 10.1016/j.ajic.2024.05.002. Epub 2024 May 14.PMID: 38754783

Stigmatization and Preferences in Monkeypox **Vaccine** Regimens.

Shen YH, Chang HH, Tou CY, Lee YC, Lee YH, Cheng SY, Huang KC, Lu CW.Arch Sex Behav. 2024 Aug 21. doi: 10.1007/s10508-024-02975-6. Online ahead of print.PMID: 39168953

Relative **vaccine** protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.

Moustsen-Helms IR, Bager P, Larsen TG, Møller FT, Vestergaard LS, Rasmussen M, Hansen CH; SSI-DMC Study Group.Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.PMID: 38761806

Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.

Ramírez MA, Loaiza RA, Martínez-Balboa Y, Bruneau N, Ramírez E, González PA, Bueno SM, Kalergis AM.Vaccine. 2024 Aug 22;42(23):126203. doi: 10.1016/j.vaccine.2024.126203. Online ahead of print.PMID: 39178767

The role of mental illness and neurodevelopmental conditions in human papillomavirus vaccination uptake within the Swedish school-based vaccination programme: a population-based cohort study.

Hu K, Barker MM, Herweijer E, Wang J, Feldman AL, Lu D, Valdimarsdóttir U, Sundström K, Fang F.Lancet Public Health. 2024 Sep;9(9):e674-e683. doi: 10.1016/S2468-2667(24)00182-8.PMID: 39214636

Mathematical modeling for estimating influenza **vaccine** efficacy: A case study of the Valencian Community, Spain.

Andreu-Vilarroig C, Villanueva RJ, González-Parra G.Infect Dis Model. 2024 Apr 24;9(3):744-762. doi: 10.1016/j.idm.2024.04.006. eCollection 2024 Sep.PMID: 38689854

Hesitancy toward Childhood and Influenza Vaccines: Experiences from Highly Educated Jordanian Parents.

Al-Iede M, Aljahalin M, Fashho E, Sweis S, Mesmeh R, Hamad LB, Abuzaid L, Sa'ed JA, Elbetar Y, Alabdali AYM, Al-Nawaiseh S, Al-Ani A.Vaccines (Basel). 2024 Aug 22;12(8):945. doi: 10.3390/vaccines12080945.PMID: 39204068

A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity.

Qu L, Cui G, Sun Y, Ye R, Sun Y, Meng F, Wang S, Zhong Z.Adv Mater. 2024 Aug 28:e2409590. doi: 10.1002/adma.202409590. Online ahead of print.PMID: 39194369

Motivation, Cues to Action, and Barriers to COVID-19 **Vaccine** Uptake: A Qualitative Application of the Health Belief Model among Women in Rural Zambia.

Kuhfeldt KJ, Kaiser JL, Morgan AJ, Ngoma T, Hamer DH, Fink G, Rockers PC, Chirwa B, Scott NA.Am J Trop Med Hyg. 2024 Aug 27:tpmd240005. doi: 10.4269/ajtmh.24-0005. Online ahead of print.PMID: 39191235

Erythema Multiforme and Epidermal Necrolysis Following COVID-19 Vaccines: A Systematic Review.

Wu PC, Huang IH, Wang CW, Chung WH, Chen CB.Dermatitis. 2024 Aug 22. doi: 10.1089/derm.2023.0210. Online ahead of print.PMID: 39172639

A review of HSV pathogenesis, **vaccine** development, and advanced applications.

Bai L, Xu J, Zeng L, Zhang L, Zhou F.Mol Biomed. 2024 Aug 29;5(1):35. doi: 10.1186/s43556-024-00199-7.PMID: 39207577

COVID-19 vaccination reluctance across Europe: Lessons for the future.

Suleman A, Vicente P.Vaccine. 2024 Aug 30;42(21):126168. doi: 10.1016/j.vaccine.2024.126168. Epub 2024 Jul 27.PMID: 39069463

Designing and development of efficient multi-epitope-based peptide **vaccine** candidate against emerging avian rotavirus strains: A vaccinomic approach.

Hasan M, Ahmed S, Imranuzzaman M, Bari R, Roy S, Hasan MM, Mia MM.J Genet Eng Biotechnol. 2024 Sep;22(3):100398. doi: 10.1016/j.jgeb.2024.100398. Epub 2024 Jun 27.PMID: 39179326

When reality knocks on the door. The effect of conspiracy beliefs on COVID-19 **vaccine** acceptance and the moderating role of experience with the virus.

Stefkovics Á, Krekó P, Koltai J.Soc Sci Med. 2024 Sep;356:117149. doi: 10.1016/j.socscimed.2024.117149. Epub 2024 Jul 20.PMID: 39059127

Analysis of the Federal Section 317 Immunization Program and Routine Adult Immunization Activities, United States, 2022-2023.

Granade CJ, Crawford NE, Banks M, Graitcer S.Public Health Rep. 2024 Sep-Oct;139(5):626-634. doi: 10.1177/00333549241236085. Epub 2024 Mar 19.PMID: 38504465

Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.

Ogar CK, Gilbert HN, Bloem LT, Leopold C, Bassi PU, Katagum YM, Osakwe AI, Opadeyi AO, Oreagba I, Mbo DND, Mantel-Teeuwisse AK, De Bruin ML.Vaccine. 2024 Aug 22;42(23):126196. doi: 10.1016/j.vaccine.2024.126196. Online ahead of print.PMID: 39178765

Comparison of physiological and clinical reactions to COVID-19 and influenza vaccination.

Yechezkel M, Qian G, Levi Y, Davidovitch N, Shmueli E, Yamin D, Brandeau ML.Commun Med (Lond). 2024 Aug 24;4(1):169. doi: 10.1038/s43856-024-00588-7.PMID: 39181950

Efficacy of an inactivated EHDV-8 **vaccine** in preventing viraemia and clinical signs in experimentally infected cattle.

Spedicato M, Ronchi GF, Profeta F, Traini S, Capista S, Leone A, Iorio M, Portanti O, Palucci C, Pulsoni S, Testa L, Serroni A, Rossi E, Armillotta G, Laguardia C, D'Alterio N, Savini G, Di Ventura M, Lorusso A, Mercante MT.Virus Res. 2024 Sep;347:199416. doi: 10.1016/j.virusres.2024.199416. Epub 2024 Jun 27.PMID: 38897236

Strategic deactivation of mRNA COVID-19 vaccines: New applications for siRNA therapy and RIBOTACs.

Hulscher N, McCullough PA, Marotta DE.J Gene Med. 2024 Sep;26(9):e3733. doi: 10.1002/jgm.3733.PMID: 39183706

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza **Vaccine** Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide **Vaccine** in Adults Aged 60 Years and Older.

Zhu Z, Sun J, Xie Y, Lu X, Tang W, Zhao Y, Shen L, Liu H, Yu Y, Zhou S, Huo L, Jiao P, Jiang X.Vaccines (Basel). 2024 Aug 22;12(8):935. doi: 10.3390/vaccines12080935.PMID: 39204058

Navigating Pakistan's immunization landscape: Progress and pitfalls.

Ashraf MF, Daim SUR, Fayyaz H, Ashraf MA, Ashraf M.IJID Reg. 2024 Jun 3;12:100382. doi: 10.1016/j.ijregi.2024.100382. eCollection 2024 Sep.PMID: 39036066

Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.

Butler AM, Newland JG, Sahrmann JM, O'Neil CA, McGrath LJ.Vaccine. 2024 Aug 30;42(21):126179. doi: 10.1016/j.vaccine.2024.126179. Epub 2024 Aug 7.PMID: 39116485

Design a novel of Brucellosis preventive **vaccine** based on IgV_CTLA-4 and multiple epitopes via immunoinformatics approach.

He Y, Zhu Y, Yin Z, Shi J, Shang K, Tian T, Shi H, Ding J, Zhang F.Microb Pathog. 2024 Aug 30:106909. doi: 10.1016/j.micpath.2024.106909. Online ahead of print.PMID: 39218373

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.

Walimbwa SI, Maly P, Kafkova LR, Raska M.J Biomed Sci. 2024 Aug 21;31(1):83. doi: 10.1186/s12929-024-01073-y.PMID: 39169357

Displaying alphavirus physicochemical consensus antigens on immunogenic liposomes enhances antibody elicitation in mice.

Huang WC, Baker WS, Lovell JF, Schein CH.Virology. 2024 Sep;597:110152. doi: 10.1016/j.virol.2024.110152. Epub 2024 Jun 20.PMID: 38968676

Population-Based Influenza **Vaccine** Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season.

Gào X, Sun Y, Shen P, Guo J, Chen Y, Yin Y, Liu Z, Zhan S.Open Forum Infect Dis. 2024 Aug 21;11(9):ofae456. doi: 10.1093/ofid/ofae456. eCollection 2024 Sep.PMID: 39220659

A Click-Type Enzymatic Method for Antigen-Adjuvant Conjugation.

Sun Y, Li T, Guo Y, Sun P, Wu J, Pan C, Wang H, Zhu L.Small Methods. 2024 Aug 23:e2401116. doi: 10.1002/smtd.202401116. Online ahead of print.PMID: 39177201

Endogenous capsid-forming protein ARC for self-assembling nanoparticle vaccines.

Li Y, Zhao X, Tang J, Yi M, Zai X, Zhang J, Cheng G, Yang Y, Xu J.J Nanobiotechnology. 2024 Aug 27;22(1):513. doi: 10.1186/s12951-024-02767-z.PMID: 39192264

Seroprevalence of SARS-CoV-2 antibodies among children receiving primary care in Toronto, Ontario.

Aglipay M, Kwong JC, Colwill K, Gringas AC, Tuite A, Mamdani M, Keown-Stoneman C, Birken C, Maguire J; TARGet Kids! Collaboration.Can J Public Health. 2024 Aug 21. doi: 10.17269/s41997-024-00916-3. Online ahead of print.PMID: 39168962

Pneumococcal **vaccine** in adults with immune-mediated inflammatory diseases.

Kapetanovic MC.Lancet Rheumatol. 2024 Sep;6(9):e591-e592. doi: 10.1016/S2665-9913(24)00185-1. Epub 2024 Jul 24.PMID: 39067458

Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza **vaccine** viruses with appropriate antigenicity.

Harada Y, Takahashi H, Fujimoto T, Horikoshi F, Chida S, Tanaka K, Minari K, Tanimoto Y, Fujisaki S, Miura H, Nakauchi M, Shimasaki N, Suzuki Y, Arita T, Hamamoto I, Yamamoto N, Hasegawa H, Odagiri T, Tashiro M, Nobusawa E.Vaccine. 2024 Aug 29;42(23):126242. doi: 10.1016/j.vaccine.2024.126242. Online ahead of print.PMID: 39213922

β-Glucan-A promising immunocyte-targeting drug delivery vehicle: Superiority, applications and future prospects.

He L, Zhu Z, Qi C.Carbohydr Polym. 2024 Sep 1;339:122252. doi: 10.1016/j.carbpol.2024.122252. Epub 2024 May 11.PMID: 38823919

National Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2023.

Pingali C, Yankey D, Chen M, Elam-Evans LD, Markowitz LE, DeSisto CL, Schillie SF, Hughes M, Valier MR, Stokley S, Singleton JA.MMWR Morb Mortal Wkly Rep. 2024 Aug 22;73(33):708-714. doi: 10.15585/mmwr.mm7333a1.PMID: 39173168

Consequences of COVID-19 **Vaccine** Hesitancy Among Healthcare Providers During the First 10 Months of **Vaccine** Availability: Scoping Review.

Wilpstra CD, Morrell S, Mirza NA, Ralph JL.Can J Nurs Res. 2024 Sep;56(3):204-224. doi: 10.1177/08445621241251711. Epub 2024 May 2.PMID: 38693882

COVID-19 vaccination campaigns in fragile and conflict-affected settings, Somalia.

Farid M, Ibrahim A, Mohammad H, Hassan Q, Omar MA, Ismael MA, Shidane AM, Mohamud MF, Shube M, Jama MA, Musanhu P, Hafiz R, Malik SMMR.Bull World Health Organ. 2024 Sep 1;102(9):674-680. doi: 10.2471/BLT.23.291105. Epub 2024 Jul 11.PMID: 39219761

Development of an ancestral DC and TLR4-inducing multi-epitope peptide **vaccine** against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches.

Aram C, Alijanizadeh P, Saleki K, Karami L.Biochem Biophys Rep. 2024 Jun 12;39:101745. doi: 10.1016/j.bbrep.2024.101745. eCollection 2024 Sep.PMID: 38974021

Study on the interference of **vaccine** antibodies with the serological diagnosis of leptospirosis in cattle.

Martínez ML, Esteban M, Sánchez C, Saraullo V, Hamer M, Samartino L, Brihuega B.Vet Microbiol. 2024 Sep;296:110169. doi: 10.1016/j.vetmic.2024.110169. Epub 2024 Jul 9.PMID: 39032443

Efficacy of typhoid conjugate **vaccine** in Malawian children.

Obaro S.Lancet. 2024 Aug 24;404(10454):747-748. doi: 10.1016/S0140-6736(24)01508-3.PMID: 39181587

Structure-Activity Relationship Studies in Benzothiadiazoles as Novel **Vaccine** Adjuvants.

Belsuzarri MM, Sako Y, Brown TD, Chan M, Cozza R, Jin J, Sato-Kaneko F, Yao S, Pu M, Messer K, Hayashi T, Cottam HB, Corr M, Carson DA, Shukla NM.J Med Chem. 2024 Aug 22;67(16):13703-13722. doi: 10.1021/acs.jmedchem.4c00491. Epub 2024 Aug 8.PMID: 39115891

Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.

Aizawa Y, Sato I, Abe Y, Sasagawa F, Saitoh A.Vaccine. 2024 Aug 30;42(21):126137. doi:

Immunogenicity, safety and dual DIVA-like character of a recombinant candidate **vaccine** against neosporosis in cattle.

Mendoza-Morales LF, Fiorani F, Morán KD, Hecker YP, Cirone KM, Sánchez-López EF, Ramos-Duarte VA, Corigliano MG, Bilbao MG, Clemente M, Moore DP, Sander VA.Acta Trop. 2024 Sep;257:107293. doi: 10.1016/j.actatropica.2024.107293. Epub 2024 Jun 18.PMID: 38901525

Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens.

Nuqui X, Casalino L, Zhou L, Shehata M, Wang A, Tse AL, Ojha AA, Kearns FL, Rosenfeld MA, Miller EH, Acreman CM, Ahn SH, Chandran K, McLellan JS, Amaro RE.Nat Commun. 2024 Aug 27;15(1):7370. doi: 10.1038/s41467-024-50976-9.PMID: 39191724

Risk of COVID-19 Reinfection and **Vaccine** Breakthrough Infection, Madera County, California, 2021.

Nguyen M, Paul E, Mills PK, Paul S.Am J Epidemiol. 2024 Aug 27:kwae308. doi: 10.1093/aje/kwae308. Online ahead of print.PMID: 39191647

Ascorbic Acid and alpha-Tocopherol in the Inactivated SARS-CoV-2 **Vaccine** Formulation: Induction of the Th1 Pattern in Aged Mice.

Asefi N, Pakzad P, Khorasani A, Taghizadeh M, Amirkhani Z, Yazdi MH, Shahverdi AR, Mahdavi M.Viral Immunol. 2024 Aug 30. doi: 10.1089/vim.2024.0023. Online ahead of print.PMID: 39212606

NIH Starts Testing Nasal COVID-19 **Vaccine** in US.

Harris E.JAMA. 2024 Aug 27;332(8):610. doi: 10.1001/jama.2024.13769.PMID: 39093575

A field evaluation of a new porcine circovirus type 2d and Mycoplasma hyopneumoniae bivalent **vaccine** in herds suffering from subclinical PCV2d infection and enzootic pneumonia.

Ham S, Suh J, Kim C, Seo BJ, Park GS, Chae C.Vet Med Sci. 2024 Sep;10(5):e70001. doi: 10.1002/vms3.70001.PMID: 39189840

Development of antibody levels and subsequent decline in individuals with **vaccine** induced and hybrid immunity to SARS-CoV-2.

Reekie J, Stovring H, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Iversen K, Mustafa AB, Petersen KT, Juhl MR, Knudsen LS, Iversen MB, Andersen SD, Larsen FD, Baerends EAM, Lindvig SO, Rasmussen LD, Madsen LW, Bannister W, Jensen TO, Dietz LL, Ostrowski SR, Østergaard L, Tolstrup M, Lundgren JD, Søgaard OS; ENFORCE study group.Int J Infect Dis. 2024 Sep;146:107111. doi: 10.1016/j.ijid.2024.107111. Epub 2024 May 25.PMID: 38801970

Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.

MacKay H, Gretton JD, Chyderiotis S, Elliott S, Howarth A, Guo C, Mastroianni A, Kormos C, Leifer J, Conway L, Morrissey MD.Vaccine. 2024 Aug 31;42(24):126236. doi: 10.1016/j.vaccine.2024.126236. Online ahead of print.PMID: 39217774

The COVID-19 Pandemic, Geroscience, and Intersectional Dimensions of Health and Well-being.

McDougle L, Smith JT.J Gerontol A Biol Sci Med Sci. 2024 Sep 1;79(9):glae019. doi: 10.1093/gerona/glae019.PMID: 39126343

Breast Milk-Derived Antibodies Impair **Vaccine** Immunity in Suckling Mice.

Dangi T, Sanchez S, Awakoaiye B, Lew MH, Irani N, Penaloza-MacMaster P.J Immunol. 2024 Sep 1;213(5):612-618. doi: 10.4049/jimmunol.2400277.PMID: 39007643

Original antigenic sin: A potential double-edged effect for **vaccine** improvement.

Ding X, Zhao F, Liu Z, Yao J, Yu H, Zhang X.Biomed Pharmacother. 2024 Sep;178:117187. doi: 10.1016/j.biopha.2024.117187. Epub 2024 Jul 30.PMID: 39084082

Prevalence and trends of hepatitis B and C virus biomarkers in Zimbabwe: comparative analyses of a nation's blood-donor surveillance data and meta-analyses of population studies.

Mabaya S, Munongo E, Mapako T, Marowa L, Gasasira AN, Pasipanodya JG, Mutenherwa M.Infect Dis (Lond). 2024 Sep;56(9):759-775. doi: 10.1080/23744235.2024.2351045. Epub 2024 May 14.PMID: 38743051

Effectiveness of inactivated influenza **vaccine** in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.

Shinjoh M, Yaginuma M, Yamaguchi Y, Tamura K, Furuichi M, Tsumura Y, Itaki R, Iqbal A, Maeda N, Narabayashi A, Kamei A, Shibata A, Yamada G, Nishida M, Kenichiro T, Chiga M, Shimoyamada M, Yoshida M, Fukushima N, Nakata Y, Fukushima H, Kawakami C, Narumi S, Sugaya N; Keio Pediatric Influenza Research Group.Vaccine. 2024 Aug 22;42(23):126241. doi: 10.1016/j.vaccine.2024.126241. Online ahead of print.PMID: 39178768

Severity-dependent test-seeking behaviors and test-negative designs: impact on estimated **vaccine** effectiveness and utility of analytic and design choices.

Amin AB, Hitchings MDT, Ranzani OT, Andrews JR, Cummings DAT, Ko AI, Croda J, Dean NE.Am J Epidemiol. 2024 Aug 27:kwae303. doi: 10.1093/aje/kwae303. Online ahead of print.PMID: 39191656

Exploring the associations between gut microbiota composition and SARS-CoV-2 inactivated **vaccine** response in mice with type 2 diabetes mellitus.

Liu L, He X, Wang J, Li M, Wei X, Yang J, Cheng G, Du W, Liu Z, Xiao X.mSphere. 2024 Aug 27:e0038024. doi: 10.1128/msphere.00380-24. Online ahead of print.PMID: 39189780

Conserved moonlighting protein pyruvate dehydrogenase induces robust protection against *Staphylococcus aureus* infection.

Wang X, Dou Y, Hu J, Chan CH, Li R, Rong L, Gong H, Deng J, Yuen TT, Lin X, He Y, Su C, Zhang BZ, Chan JF, Yuen KY, Chu H, Huang JD.Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2321939121. doi: 10.1073/pnas.2321939121. Epub 2024 Aug 26.PMID: 39186649

Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.

Sanada T, Honda T, Kohara M.Vaccine. 2024 Aug 30;42(21):126146. doi: 10.1016/j.vaccine.2024.07.047. Epub 2024 Jul 20.PMID: 39033078 **Free article.**

For example, as the number of booster vaccinations increases, there are uncertainties regarding how long effects of a **vaccine** will last and how much individual variability exists. In this study, to predict the duration of **vaccine** efficacy, we modeled the kinetics of …

☐ 202

Cite

Share

Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives.

Kung YA, Chuang CH, Chen YC, Yang HP, Li HC, Chen CL, Janapatla RP, Chen CJ, Shih SR, Chiu CH.J Formos Med Assoc. 2024 Aug 22:S0929-6646(24)00389-9. doi: 10.1016/j.jfma.2024.08.021. Online ahead of print.PMID: 39179492

Tracking **vaccine** effectiveness in an evolving pandemic, countering misleading hot takes and epidemiological fallacies.

Morris JS.Am J Epidemiol. 2024 Aug 31:kwae280. doi: 10.1093/aje/kwae280. Online ahead of print.PMID: 39218423

Evaluation of protective immune response of immersion inactivated **vaccine** against Singapore grouper iridovirus.

Xu W, Liu M, Qin Q, Chen J, Mu G, Zhang D, Huang X, Huang Y.Fish Shellfish Immunol. 2024 Aug 22;153:109855. doi: 10.1016/j.fsi.2024.109855. Online ahead of print.PMID: 39181523

Successes and Shortcomings of COVID-19 **Vaccine** Access for Older Americans.

Travers JL, Sadarangani T, David D.J Gerontol Nurs. 2024 Sep;50(9):12-17. doi: 10.3928/00989134-20240809-04. Epub 2024 Sep 1.PMID: 39194325

The role of influenza Hemagglutination-Inhibition antibody as a **vaccine** mediator in children.

Motaghi S, Pullenayegum E, Morgan RL, Loeb M.Vaccine. 2024 Aug 30;42(21):126122. doi: 10.1016/j.vaccine.2024.07.023. Epub 2024 Jul 28.PMID: 39074996

Determinants of potential HIV **vaccine** uptake among young sexual minoritized men 17-24 years old.

John SA, Walsh JL, Doherty RM, Rine SR, O'Neil AM, Dang M, Quinn KG.J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003517. Online ahead of print.PMID: 39171988

Optimization of the 5' untranslated region of mRNA vaccines.

Ma Q, Zhang X, Yang J, Li H, Hao Y, Feng X.Sci Rep. 2024 Aug 27;14(1):19845. doi: 10.1038/s41598-024-70792-x.PMID: 39191885

Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment.

Chyderiotis S, Sicsic J, Gagneux-Brunon A, Raude J, Barret AS, Bruel S, Gauchet A, Le Duc Banaszuk AS, Michel M, Giraudeau B, Thilly N, Mueller JE; PrevHPV Consortium.Patient. 2024 Sep;17(5):575-588. doi: 10.1007/s40271-024-00687-6. Epub 2024 May 1.PMID: 38693318

Pivoting From Influenza to COVID-19 Vaccinations: How a Minnesota Vaccination Program Reduced Barriers for Refugee, Immigrant, and Migrant Communities Accessing Vaccines During the COVID-19 Pandemic.

Johansen I, Selim M, J Hoffman S, Dawson-Hahn E, Yu K.J Public Health Manag Pract. 2024 Sep-Oct 01;30(5):701-709. doi: 10.1097/PHH.0000000000001931. Epub 2024 Jul 22.PMID: 39041765

Individual and familial factors associated with mRNA COVID-19 **vaccine** uptake in pregnancy: A large-scale registry-based linkage study.

Elyass J, Desalegn A, Trinh NTH, Orangzeb S, Zidan M, Nordeng H, Lupattelli A.Vaccine. 2024 Aug 30;42(21):126171. doi: 10.1016/j.vaccine.2024.126171. Epub 2024 Jul 30.PMID: 39079814

What happens at two? Immunisation stakeholders' perspectives on factors influencing sub-optimal childhood **vaccine** uptake for toddlers in regional and remote Western Australia.

Carlson SJ, Tomkinson S, Hannah A, Attwell K.BMC Health Serv Res. 2024 Aug 22;24(1):968. doi: 10.1186/s12913-024-11371-8.PMID: 39175040

Evaluation of Rhode Island's Early Geographic COVID-19 **Vaccine** Prioritization Policy.

Fortnam TM, Chambers LC, Bilinski A, DeVito R, Gargano L, Wilson M, Hogan JW.Am J Public Health. 2024 Aug 28:e1-e10. doi: 10.2105/AJPH.2024.307741. Online ahead of print.PMID: 39197141

CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B **Vaccine** in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection.

Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K, Wilcox MH, Lawrence J, Bouguermouh S, Zhang H, Koury K, Bailey R, Smith HM, Lockhart S, Lamberth E, Kalina WV, Pride MW, Webber C, Anderson AS, Jansen KU, Gruber WC, Kitchin N.Clin Infect Dis. 2024 Aug 24:ciae410. doi: 10.1093/cid/ciae410. Online ahead of print.PMID: 39180325

Manganese-Modified Aluminum Adjuvant Enhances both Humoral and Cellular Immune Responses.

Li Y, Wang C, Lv H, Li J, Zhang X, Zhang S, Shen Q, Wu Q, Liu Y, Peng R, Liu Z.Adv Healthc Mater. 2024 Aug 23:e2401675. doi: 10.1002/adhm.202401675. Online ahead of print.PMID: 39177146

Usage of social media and Covid 19 **vaccine** hesitancy among medical students in Kericho County.

Anino CO, Sanga P.PLOS Glob Public Health. 2024 Aug 22;4(8):e0003529. doi: 10.1371/journal.pgph.0003529. eCollection 2024.PMID: 39173009

Influence of membrane on the antigen presentation of the HIV-1 envelope membrane proximal external region (MPER).

López CA, Alam SM, Derdeyn CA, Haynes BF, Gnanakaran S.Curr Opin Struct Biol. 2024 Aug 21;88:102897. doi: 10.1016/j.sbi.2024.102897. Online ahead of print.PMID: 39173417

Advancing **Vaccine** Uptake in People With HIV: A Call for Research on Trust and Intellectual Humility in Health Care.

Barr EA, Celniker JB, Ballantyne N.J Assoc Nurses AIDS Care. 2024 Sep-Oct 01;35(5):456-459. doi: 10.1097/JNC.0000000000000482. Epub 2024 Jul 23.PMID: 39042495

Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 **vaccine**-induced antibody responses.

Ge Y, Lu Y, Allen JD, Einav T, Nkaleke DI, Bai F, Handel A, Ross TM, Shen Y.Vaccine. 2024 Aug 30;42(21):126149. doi: 10.1016/j.vaccine.2024.07.050. Epub 2024 Jul 29.PMID: 39079813

Polyelectrolyte-coated liposomes microfluidically assembled in one-step for enhancing cell endocytosis and in-vivo immune responses.

Chen XA, Chuang CC, Chen CC, Lee CY, Chin CY, Young JJ, Bai MY, Chuang CC.Colloids Surf B Biointerfaces. 2024 Sep;241:114030. doi: 10.1016/j.colsurfb.2024.114030. Epub 2024 Jun 14.PMID: 38901267

Production and evaluation of three kinds of vaccines against largemouth bass virus, and DNA vaccines show great application prospects.

Hu T, Wang Y, Wang Y, Cui H, Zhang J, Chen H, Wu B, Hao S, Chu CC, Wu Y, Zeng W.Fish Shellfish Immunol. 2024 Aug 22;153:109841. doi: 10.1016/j.fsi.2024.109841. Online ahead of print.PMID: 39173984

Autochthonous dengue outbreak in Rome, Italy, in 2023.

Salvo PF, Baldin G, Raffaelli F, Ciccullo A, Borghetti A, Tamburrini E, Ricci R, Di Donato M, Di Giambenedetto S, Torti C.J Travel Med. 2024 Aug 24:taae111. doi: 10.1093/jtm/taae111. Online ahead of print.PMID: 39180338

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.

Langley JM, Nolan TM, Rämet M, Richmond PC, Rosário Filho N, Haazen W, van den Berg SPH, Williams K, Bastian AR, Omoruyi E, Williams Durkin J, Salisch N, Van Geet G, van Duijnhoven W, Heijnen E, Callendret B.Open Forum Infect Dis. 2024 Aug 8;11(9):ofae453. doi: 10.1093/ofid/ofae453. eCollection 2024 Sep.PMID: 39220658

Effect of dry period immunization of Salmonella Dublin latent carriers with a commercial live culture **vaccine** on intrauterine transmission based on the presence of precolostral antibodies in offspring.

Castro-Vargas RE, Cullens-Nobis FM, Mani R, Roberts JN, Abuelo A.J Dairy Sci. 2024 Aug 29:S0022-0302(24)01083-X. doi: 10.3168/jds.2024-24945. Online ahead of print.PMID: 39216525

Mapping the existing body of knowledge on new and repurposed TB **vaccine** implementation: A scoping review.

Buis JS, Jerene D, Gebhard A, Bakker R, Majidulla A, Kerkhoff AD, Limaye RJ, Pelzer PT.PLOS Glob Public Health. 2024 Aug 22;4(8):e0002885. doi: 10.1371/journal.pgph.0002885. eCollection 2024.PMID: 39172796

Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.

Cao Y, Hayashi CTH, Araujo MDS, Tripathi AK, Andrade AO, Medeiros JF, Vinetz J, Kumar N.Vaccine. 2024 Aug 30;42(21):126140. doi: 10.1016/j.vaccine.2024.07.041. Epub 2024 Jul 20.PMID: 39033079

Hospitalisations and humoral COVID-19 **vaccine** response in vaccinated rituximab-treated multiple sclerosis patients.

Torgauten HM, Onyango TB, Ljostveit S, Hallin EI, Serkland TT, Skrede S, Langeland N, Cox RJ, Wergeland S, Myhr KM, Torkildsen Ø.Mult Scler Relat Disord. 2024 Sep;89:105770. doi: 10.1016/j.msard.2024.105770. Epub 2024 Jul 15.PMID: 39029342

COVID-19 **vaccine** hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.

Ferreira-Silva SN, Soares MEM, Vasconcelos R, Barbieri C, Junior LF, Medeiros T, de Souza Amorim Matos CC, Couto MT, Avelino-Silva VI.Vaccine. 2024 Aug 27;42(24):126247. doi: 10.1016/j.vaccine.2024.126247. Online ahead of print.PMID: 39197220

Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.

Kamigaki T, Takimoto R, Okada S, Ibe H, Oguma E, Goto S.Anticancer Res. 2024 Sep;44(9):3713-3724. doi: 10.21873/anticanres.17196.PMID: 39197920

Review of the past and present status of respiratory syncytial virus and rotavirus infections that commonly affect children.

Tsutsumi H, Tsugawa T.J Infect Chemother. 2024 Sep;30(9):825-831. doi: 10.1016/j.jiac.2024.05.008. Epub 2024 May 31.PMID: 38823679

A Semisynthetic Oligomannuronic Acid-Based Glycoconjugate **Vaccine** against Pseudomonas aeruginosa.

Zhang Y, Wang X, Liang Y, Zhang L, Fan J, Yang Y.ACS Cent Sci. 2024 Jul 10;10(8):1515-1523. doi: 10.1021/acscentsci.4c00387. eCollection 2024 Aug 28.PMID: 39220693

Establishment of an A/T-Rich Specifically MGB Probe digital droplet PCR Assays Based on SNP for Brucella wild strains and **vaccine** strains.

Li W, Zhang S, Dang S, Gao L, Li G, Cheng D, Jiang L, Huang T, Zhai J.Diagn Microbiol Infect Dis. 2024 Sep;110(1):116432. doi: 10.1016/j.diagmicrobio.2024.116432. Epub 2024 Jul 17.PMID: 39024932

HA antigenic variation and phylogenetic analysis of influenza B virus in Shiraz, Iran.

Dastyar H, Edalat F, Pirbonyeh N, Letafati A, Soheili R, Moattari A.Acta Trop. 2024 Sep;257:107292. doi: 10.1016/j.actatropica.2024.107292. Epub 2024 Jun 17.PMID: 38897314

Bacillus toyonensis amplifies the immunogenicity of an experimental recombinant tetanus **vaccine** in horses.

Abreu MC, Conrad NL, Gonçalves VS, Leite FPL.J Equine Vet Sci. 2024 Sep;140:105135. doi: 10.1016/j.jevs.2024.105135. Epub 2024 Jun 22.PMID: 38914241

Advancement in the Antigenic Epitopes and **Vaccine** Adjuvants of African Swine Fever Virus.

Wu Q, Li C, Zhu B, Zhu J, Yang K, Liu Z, Liu W, Gao T, Yuan F, Guo R, Tian Y, Zhou D.Pathogens. 2024 Aug 21;13(8):706. doi: 10.3390/pathogens13080706.PMID: 39204306

Multi-epitope **vaccine** design of African swine fever virus considering T cell and B cell immunogenicity.

Chen TY, Ho YJ, Ko FY, Wu PY, Chang CJ, Ho SY.AMB Express. 2024 Aug 31;14(1):95. doi: 10.1186/s13568-024-01749-6.PMID: 39215890

Tetanus prophylaxis in horses: guidelines for New Zealand and Australia based on a critical appraisal of the evidence.

Lovett AL, Riley CB, Chapman V, Bell B, Bishop B, Grierson A, Johnstone LJ, Sykes BW.N Z Vet J. 2024 Sep;72(5):241-255. doi: 10.1080/00480169.2024.2365283. Epub 2024 Jun 23.PMID: 38910032

Intranasal administration of octavalent next-generation influenza **vaccine** elicits protective immune responses against seasonal and pre-pandemic viruses.

Uno N, Ebensen T, Guzman CA, Ross TM.J Virol. 2024 Aug 22:e0035424. doi: 10.1128/jvi.00354-24. Online ahead of print.PMID: 39171925

Immunological effects of DNA vaccination and interleukin utilization as an adjuvant in Astyanax lacustris immunized against Ichthyophthirius multifiliis.

Meira CM, Carriero MM, Pereira NL, Rihs PGM, Lázaro TM, Rocha NRA, Maia AAM.J Fish Dis. 2024 Sep;47(9):e13979. doi: 10.1111/jfd.13979. Epub 2024 Jun 16.PMID: 38879867

Investigation of the Hepatitis-B **Vaccine**'s Immune Response in a Non-Alcoholic Fatty Liver Disease Mouse Model.

Kütük T, Onbaşilar İ, Oskay-Halaçli S, Babaoğlu B, Ayhan S, Yalçin SS.Vaccines (Basel). 2024 Aug 22;12(8):934. doi: 10.3390/vaccines12080934.PMID: 39204057

The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA.

Barbieri BD, Peeler DJ, Samnuan K, Day S, Hu K, Sallah HJ, Tregoning JS, McKay PF, Shattock RJ.J Control Release. 2024 Aug 21;374:280-292. doi: 10.1016/j.jconrel.2024.08.016. Online ahead of print.PMID: 39142355

The life cycle of vaccines evaluated by the European Medicines Agency.

Gräf DD, Westphal L, Hallgreen CE.Vaccine. 2024 Aug 30;42(21):126186. doi: 10.1016/j.vaccine.2024.126186. Epub 2024 Aug 8.PMID: 39121512

Assessing sociodemographic disparities in HPV **vaccine** uptake among grade 6 and 9 students in the Vancouver Coastal Health region.

Lawal S, St-Jean M, Hu Y, Bakos B, Dawar M, Thumath M, MacDonald A.Vaccine. 2024 Aug 30;42(21):126147. doi: 10.1016/j.vaccine.2024.07.048. Epub 2024 Jul 26.PMID: 39060199

Potential impact of replacing the 13-valent pneumococcal conjugate **vaccine** with 15-valent or 20-valent pneumococcal conjugate **vaccine** in the 1 + 1 infant schedule in England: a modelling study.

Choi YH, Bertran M, Litt DJ, Ladhani SN, Miller E.Lancet Public Health. 2024 Sep;9(9):e654-e663. doi: 10.1016/S2468-2667(24)00161-0. Epub 2024 Aug 14.PMID: 39153492

Predictors of Human Papillomavirus **Vaccine** Intention and Uptake Among US Hispanic Parents: A Cross-Sectional Study.

Fernandez-Pineda M, Melendez CR, Fernandez M, Cianelli R, Roman J, Villegas N, Matsuda Y, Montano NP.Hisp Health Care Int. 2024 Sep;22(3):142-149. doi: 10.1177/15404153241229688. Epub 2024 Feb 6.PMID: 38321763

Innate immune responses against mRNA **vaccine** promote cellular immunity through IFN-beta at the injection site.

Kim S, Jeon JH, Kim M, Lee Y, Hwang YH, Park M, Li CH, Lee T, Lee JA, Kim YM, Kim D, Lee H, Kim YJ, Kim VN, Park JE, Yeo J.Nat Commun. 2024 Aug 27;15(1):7226. doi: 10.1038/s41467-024-51411-9.PMID: 39191748

Update on Hepatitis C **Vaccine**: Results and Challenges.

Garbuglia AR, Pauciullo S, Zulian V, Del Porto P.Viruses. 2024 Aug 21;16(8):1337. doi: 10.3390/v16081337.PMID: 39205311

Rational Design of a Multi-epitope **Vaccine** Using Neoantigen Against Colorectal Cancer Through Structural Immunoinformatics and ML-Enabled Simulation Approach.

Bhattacharya M, Sarkar A, Wen ZH, Wu YJ, Chakraborty C.Mol Biotechnol. 2024 Aug 27. doi: 10.1007/s12033-024-01242-2. Online ahead of print.PMID: 39190054

Prediction of post-PCV13 pneumococcal evolution using invasive disease data enhanced by inverse-invasiveness weighting.

Qiu X, McGee L, Hammitt L, Grant LR, O'Brien KL, Hanage WP, Lipsitch M.mBio. 2024 Aug 29:e0335523. doi: 10.1128/mbio.03355-23. Online ahead of print.PMID: 39207103

Mathematical modelling of the 100-day target for **vaccine** availability after the detection of a novel pathogen: A case study in Indonesia.

Bilgin GM, Munira SL, Lokuge K, Glass K.Vaccine. 2024 Aug 30;42(21):126163. doi: 10.1016/j.vaccine.2024.126163. Epub 2024 Jul 26.PMID: 39060201

Residency in Long-Term Care Facilities: An Important Risk Factor for RSV Hospitalization.

Branche AR, Falsey AR, Finelli L, Walsh EE.J Infect Dis. 2024 Aug 23:jiae424. doi: 10.1093/infdis/jiae424. Online ahead of print.PMID: 39177782

The time-dependent Poisson-gamma model in practice: Recruitment forecasting in HIV trials.

Turchetta A, Moodie EEM, Stephens DA, Savy N, Moodie Z.Contemp Clin Trials. 2024 Sep;144:107607. doi: 10.1016/j.cct.2024.107607. Epub 2024 Jun 20.PMID: 38908745

Increasing Oral Health Team's Knowledge, Attitudes, and Intention to Recommend the HPV **Vaccine**.

Oliphant JA, Crespo E.J Cancer Educ. 2024 Aug 30. doi: 10.1007/s13187-024-02489-8. Online ahead of print.PMID: 39212908

Is gravidity associated with COVID-19 vaccination among pregnant women in Jamaica?

Pinkney JA, Bogart LM, Carroll KN, Bryan LR, Witter GA, Ashour D, Hoeppner SS, Hurtado RM, Goldfarb IT, Psaros C, Hyle EP, Ojikutu BO.Reprod Female Child Health. 2024 Sep;3(3):e100. doi: 10.1002/rfc2.100. Epub 2024 Jul 4.PMID: 39036365

Monitoring the VDPV2 outbreak in Egypt during 2020-2021 highlights the crucial role of environmental surveillance and boosting immunization in combating Poliovirus.

Shabana MR, Zaghloul AY, El Shaarawy TH, Elleboudy NS, Aboshanab KM.BMC Infect Dis. 2024 Aug 26;24(1):866. doi: 10.1186/s12879-024-09731-0.PMID: 39187787

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster **Vaccine** in Canadian Adults Aged 50 Years and Older.

George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N.Pharmacoecon Open. 2024 Sep;8(5):785. doi: 10.1007/s41669-024-00502-w.PMID: 39017906

Mental health and lower adolescent HPV **vaccine** coverage.

Ellingson MK, Brewer NT.Lancet Public Health. 2024 Sep;9(9):e642-e643. doi: 10.1016/S2468-2667(24)00190-7.PMID: 39214634

A novel virus-like particles **vaccine** induces broad immune protective against deltacoronavirus in piglets.

Zhang B, Li S, Zhou J, Wang W, Xiao L, Yuan X, Yi X, Fan L, Fan B, Zhu X, Li J, Li B.Virology. 2024 Sep;597:110150. doi: 10.1016/j.virol.2024.110150. Epub 2024 Jun 21.PMID: 38917690

Prevalence of hepatitis and HIV infection among 18-months old children in Guinea-Bissau before vaccination.

Dutschke A, Agergaard J, Medina C, Hønge BL.Trop Med Int Health. 2024 Aug 26. doi: 10.1111/tmi.14045. Online ahead of print.PMID: 39187275

Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis.

Rossotti R, Nava A, Baiguera C, Baldassari L, Moioli MC, Fanti D, D'Amico F, Calzavara D, Bossolasco S, Tamburini AM, Canetti D, Bana NB, Cernuschi M, Vismara C, Puoti M.Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1847-1854. doi: 10.1007/s10096-024-04887-8. Epub 2024 Jul 2.PMID: 38954164

Acute extensive pulmonary embolism after mRNA SARS-CoV-2 immunization.

Daim SUR, Alsermani A, Althomali RK, Ashraf MF, AlSermani M.Radiol Case Rep. 2024 Jul 13;19(9):4087-4090. doi: 10.1016/j.radcr.2024.06.022. eCollection 2024 Sep.PMID: 39104450

Computational detection of antigen-specific B cell receptors following immunization.

Abbate MF, Dupic T, Vigne E, Shahsavarian MA, Walczak AM, Mora T.Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2401058121. doi: 10.1073/pnas.2401058121. Epub 2024 Aug 20.PMID: 39163333

Clinical and genomic diversity of Treponema pallidum subspecies pallidum to inform **vaccine** research: an international, molecular epidemiology study.

Seña AC, Matoga MM, Yang L, Lopez-Medina E, Aghakhanian F, Chen JS, Bettin EB, Caimano MJ, Chen W, Garcia-Luna JA, Hennelly CM, Jere E, Jiang Y, Juliano JJ, Pospíšilová P, Ramirez L, Šmajs D, Tucker JD, Vargas Cely F, Zheng H, Hoffman IF, Yang B, Moody MA, Hawley KL, Salazar JC, Radolf JD, Parr JB.Lancet Microbe. 2024 Aug 21:100871. doi: 10.1016/S2666-5247(24)00087-9. Online ahead of print.PMID: 39181152

Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia.

Zhang P, Wang T, Cui G, Ye R, Wan W, Liu T, Zheng Y, Zhong Z.Adv Mater. 2024 Aug 22:e2407189. doi: 10.1002/adma.202407189. Online ahead of print.PMID: 39171954

Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults ≥65 Years of Age.

Ku JH, Rayens E, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Modha PP, Park Y, Sun T, Anderson EJ, Tseng HF.Clin Infect Dis. 2024 Aug 21:ciae375. doi: 10.1093/cid/ciae375. Online ahead of print.PMID: 39166857

Closing the gaps in adolescent vaccinations: Rhode Island's Vaccinate Before You Graduate program as a model for other jurisdictions.

Dumont DM, Levy JS, Gargano LM, White JC.Prev Med Rep. 2024 Jul 23;45:102837. doi: 10.1016/j.pmedr.2024.102837. eCollection 2024 Sep.PMID: 39175591

Adenovirus **vaccine** targeting kinases induces potent antitumor immunity in solid tumors.

Zhu F, Lu Z, Tang W, Zhao G, Shao Y, Lu B, Ding J, Zheng Y, Fang L, Li H, Wang G, Chen R, Zheng J, Chai D.J Immunother Cancer. 2024 Aug 28;12(8):e009869. doi: 10.1136/jitc-2024-009869.PMID: 39209449

Extinction of influenza B Yamagata: Its impact on public health and **vaccine** implications.

Ashraf MA, Raza MA, Amjad MN.J Biomed Res. 2024 Aug 25:1-4. doi: 10.7555/JBR.38.20240158. Online ahead of print.PMID: 39164195

Unmasking the interplay between political identity, COVID-19 **vaccine** side effects and recommendation patterns.

Ningrum VS.J Public Health (Oxf). 2024 Aug 25;46(3):e552. doi: 10.1093/pubmed/fdae013.PMID: 38304988

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.

Gao Y, Yang L, Li Z, Peng X, Li H.Biomark Res. 2024 Aug 31;12(1):93. doi: 10.1186/s40364-024-00644-3.PMID: 39217377

The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in mice.

Spencer Clinton JL, Hoornweg TE, Tan J, Peng R, Schaftenaar W, Rutten VPMG, de Haan CAM, Ling PD.Vaccine. 2024 Aug 23;42(23):126227. doi: 10.1016/j.vaccine.2024.126227. Online ahead of print.PMID: 39180978

Current Shingles **Vaccine** Associated With Lower Risk of Dementia.

Anderer S.JAMA. 2024 Aug 23. doi: 10.1001/jama.2024.15879. Online ahead of print.PMID: 39177991

Coronavirus Nucleocapsid-based **Vaccine** Provides Partial Protection against Hetero-species Coronavirus in Murine Models.

Lee P, Kim J, Oh H, Kim CU, Jeong AY, Lee MS, Jang MS, Hong JJ, Park JE, Kim DJ.Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991. Online ahead of print.PMID: 39181216

Leveraging the potential of bacterial lateral gene transfer in boosting the efficacy of an edible probiotic prototype yogurt **vaccine** for COVID-19.

Vissapragada M, Addala S, Aggunna M, Sodasani M, Grandhi AVKS, Yedidi RS.Biochem Biophys Res Commun. 2024 Aug 29;734:150622. doi: 10.1016/j.bbrc.2024.150622. Online ahead of print.PMID: 39216410

Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit **vaccine** immunogenicity.

Zou GQ, Li K, Yan C, Li YQ, Xian MY, Hu X, Luo R, Liu Z.Vaccine. 2024 Aug 30;42(21):126145. doi: 10.1016/j.vaccine.2024.07.046. Epub 2024 Jul 20.PMID: 39034218

Patient subtyping analysis of baseline multi-omic data reveals distinct pre-immune states associated with antibody response to seasonal influenza vaccination.

Sevim Bayrak C, Forst CV, Jones DR, Gresham DJ, Pushalkar S, Wu S, Vogel C, Mahal LK, Ghedin E, Ross T, García-Sastre A, Zhang B.Clin Immunol. 2024 Sep;266:110333. doi: 10.1016/j.clim.2024.110333. Epub 2024 Jul 30.PMID: 39089348

Epidemiology of Mpox Cases, and Tecovirimat and JYNNEOS Utilization, Alameda County, California, June-October 2022.

Ouyang ML, Marusinec R, Bayard PJ, Edmunds M, Johnson M, Lai S, Menker K, Moore C, Moss N, Nguyen M, Peña A, Rajagopal S, Shemsu M, Sheppard I, Slome S, Tang M, Trivedi KK, Yette E, Dunne EF, Ayala G, Chitnis A.J Public Health Manag Pract. 2024 Sep-Oct 01;30(5):744-752. doi: 10.1097/PHH.0000000000002010. Epub 2024 Jul 22.PMID: 39041768

An Overview of the Types of Adjuvants Used in the Vaccination Industry And Their Mechanisms of Action.

Shams N, Jaydari A, Najafi H, Hataminejad M, Khanizadeh S, Pouladi I.Viral Immunol. 2024 Aug 22. doi: 10.1089/vim.2024.0032. Online ahead of print.PMID: 39172659

Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.

Addetia A, Stewart C, Seo AJ, Sprouse KR, Asiri AY, Al-Mozaini M, Memish ZA, Alshukairi AN, Veesler D.Cell Rep. 2024 Aug 27;43(8):114530. doi: 10.1016/j.celrep.2024.114530. Epub 2024 Jul 25.PMID: 39058596

An avian-origin internal backbone effectively increases the H5 subtype avian influenza **vaccine** candidate yield in both chicken embryonated eggs and MDCK cells.

Yang F, Zhao X, Huo C, Miao X, Qin T, Chen S, Peng D, Liu X.Poult Sci. 2024 Sep;103(9):103988. doi: 10.1016/j.psj.2024.103988. Epub 2024 Jun 18.PMID: 38970848

Patients with immune mediated inflammatory diseases are insufficiently protected against **vaccine**-preventable infections.

van de Pol N, van der Woude CJ, Vis M, van Doorn MBA, Schrauwen SL, Cetinözman-Teunissen F, West RL, de Vries AC.Infection. 2024 Aug 22. doi: 10.1007/s15010-024-02373-z. Online ahead of print.PMID: 39172350

Factors Influencing Older People's Intentions to Vaccinate.

Olds R, Seibert C, Metzger AH, Chen AMH.Sr Care Pharm. 2024 Sep 1;39(9):333-339. doi: 10.4140/TCP.n.2024.333.PMID: 39180180

Engineered Carrier-Free Nanosystem-Induced In Situ Therapeutic Vaccines for Potent Cancer Immunotherapy.

Zhang M, Zhao Y, Lv B, Jiang H, Li Z, Cao J.ACS Appl Mater Interfaces. 2024 Aug 27. doi: 10.1021/acsami.4c09925. Online ahead of print.PMID: 39189605

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season.

Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J.MMWR Recomm Rep. 2024 Aug 29;73(5):1-25. doi: 10.15585/mmwr.rr7305a1.PMID: 39197095

Characterization of a triple-type chimeric **vaccine** against human papillomavirus types 18, 45, and 59.

Chi X, Han F, Jiang Y, Cao L, Chen J, Qian C, Zhang S, Li J, Guo X, Jiang M, Zheng Q, Xia N, Li S, Gu Y.Vaccine. 2024 Aug 30;42(24):126245. doi: 10.1016/j.vaccine.2024.126245. Online ahead of print.PMID: 39216181

Community-engaged randomised controlled trial to disseminate COVID-19 **vaccine**-related information and increase uptake among Black individuals in two US cities with rheumatic conditions.

Sirek G, Erickson D, Muhammad LN, Losina E, Chandler MT, Son MB, Crespo-Bosque M, York M, Jean-Jacques M, Milaeger H, Pillai N, Roberson T, Chung A, Shramuk M, Osaghae E, Williams J, Ojikutu BO, Dhand A, Ramsey-Goldman R, Feldman CH.BMJ Open. 2024 Aug 24;14(8):e087918. doi: 10.1136/bmjopen-2024-087918.PMID: 39181556

Parameterisation of a bluetongue virus mathematical model using a systematic literature review.

de Klerk J, Tildesley M, Robbins A, Gorsich E.Prev Vet Med. 2024 Aug 23;232:106328. doi: 10.1016/j.prevetmed.2024.106328. Online ahead of print.PMID: 39191049

How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 **vaccine** in England added to evidence about its cross-protective effects?

Navarro-Torné A, Anderson A, Panwar K, Ghys E, Benninghoff B, Weynants V, Beddows S, Checchi M.Vaccine. 2024 Aug 29;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Online ahead of print.PMID: 39213982

Coverage of cervical cancer prevention interventions among people in Australia who inject drugs.

Price O, Machalek DA, Sutherland R, Gibbs D, Colledge-Frisby S, Read P, Peacock A.Int J Drug Policy. 2024 Aug 21;132:104566. doi: 10.1016/j.drugpo.2024.104566. Online ahead of print.PMID: 39173252

Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection: Repeat analyses with updated data for the prospective cohort study in the Netherlands from July 2021 to June 2022.

Huiberts AJ, van den Hof S, Knol MJ.Int J Infect Dis. 2024 Sep;146:107127. doi: 10.1016/j.ijid.2024.107127. Epub 2024 Jun 18.PMID: 38901730

Shared human papillomavirus **vaccine** readiness within families: A psychometric analysis of parent-adolescent dyads in France.

Oudin Doglioni D, Gauchet A, Gagneux-Brunon A, Bruel S, Banaszuk AS, Thilly N, Sicsic J, Raude J, Mueller JE; PrevHPV Consortium.Health Psychol. 2024 Aug 22. doi: 10.1037/hea0001387. Online ahead of print.PMID: 39172389

The impact of COVID-19 **vaccine** spring boosters on COVID-19 hospital admissions in England 2022/23.

Andrews N, Osuntoki I, Stowe J, Kirsebom FCM, Allen A, Lopez Bernal J.J Infect. 2024 Sep;89(3):106221. doi: 10.1016/j.jinf.2024.106221. Epub 2024 Jul 10.PMID: 38996819

Efficacy comparison in cap VLPs of PCV2 and PCV3 as swine **vaccine** vehicle.

Qiu H, Sun M, Wang N, Zhang S, Deng Z, Xu H, Yang H, Gu H, Fang W, He F.Int J Biol Macromol. 2024 Aug 21;278(Pt 3):134955. doi: 10.1016/j.ijbiomac.2024.134955. Online ahead of print.PMID: 39173309

Vaccine hesitancy throughout the COVID-19 vaccination trajectory among immigrant and non-immigrant older adults: a cohort study.

Zlotnick C, Cohen Castel O.Public Health. 2024 Sep;234:105-111. doi: 10.1016/j.puhe.2024.06.007. Epub 2024 Jul 6.PMID: 38972228

Enhancing NA immunogenicity through novel VLP designs.

Guzman Ruiz L, Zollner AM, Hoxie I, Küchler J, Hausjell C, Mesurado T, Krammer F, Jungbauer A, Pereira Aguilar P, Klausberger M, Grabherr R.Vaccine. 2024 Aug 27;42(24):126270. doi: 10.1016/j.vaccine.2024.126270. Online ahead of print.PMID: 39197219

Healthcare provider Communication and Data-Informed Message Strategies for Encouraging Older Adults to Stay up to Date on COVID-19 Vaccination.

Totzkay D, Fraustino JD, Costello LM, Kunkle CE.J Appl Gerontol. 2024 Sep;43(9):1228-1240. doi: 10.1177/07334648241238314. Epub 2024 Mar 28.PMID: 38546107

Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.

Kim J, Villar Z, Jobe O, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, O'Connell RJ, Ake JA, Vasan S, Rao VB, Rao M.Virology. 2024 Sep;597:110158. doi: 10.1016/j.virol.2024.110158. Epub 2024 Jun 21.PMID: 38941746

Development of a Shigella conjugate **vaccine** targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.

Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.Vaccine. 2024 Aug 31;42(24):126263. doi: 10.1016/j.vaccine.2024.126263. Online ahead of print.PMID: 39217775

Altered epitopes enhance macrophage-mediated anti-tumour immunity to low-immunogenic tumour mutations.

Yu Q, Zhang T, He T, Yang Y, Zhang W, Kang Y, Wu Z, Xie W, Zheng J, Qian Q, Li G, Zhang D, Mao Q, Gao Z, Wang X, Shi X, Huang S, Guo H, Zhang H, Chen L, Li X, Deng D, Zhang L, Tong Y, Yao W, Gao X, Tian H.Immunology. 2024 Aug 22. doi: 10.1111/imm.13854. Online ahead of print.PMID: 39174487

The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations.

Shukla P, Sharma N, Shaia JK, Cohen DA, Singh RP, Talcott KE.Ophthalmology. 2024 Sep;131(9):1076-1082. doi: 10.1016/j.ophtha.2024.02.024. Epub 2024 Feb 24.PMID: 38408705

Shedding reduction and immunity modulation in piglets with an inactivated Mycoplasma hyopneumoniae **vaccine** encapsulated in nanostructured SBA-15 silica.

Petri FAM, Malcher CS, Mechler-Dreibi ML, Panneitz AK, Braga ER, Aguiar GA, Toledo LT, Martins TS, Cides-da-Silva LC, Fantini MCA, Sant'Anna OA, Montassier HJ, Oliveira LG.Vaccine. 2024 Aug 28;42(24):126268. doi: 10.1016/j.vaccine.2024.126268. Online ahead of print.PMID: 39208565

Uniform Polymeric Nanovaccine Platform for Improving the Availability and Efficacy of Neoantigen Peptides.

Chen H, Zhu Z, Lv K, Qi Y, Si X, Ma S, Song W, Chen X.Nano Lett. 2024 Aug 21;24(33):10114-10123. doi: 10.1021/acs.nanolett.4c02196. Epub 2024 Aug 7.PMID: 39109634

Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.

Li J, Xu J, Liu Y, Chen L, Yu L, Xiao X, Wang Q.Hum Vaccin Immunother. 2024 Dec 31;20(1):2389602. doi: 10.1080/21645515.2024.2389602. Epub 2024 Aug 22.PMID: 39171541

Adeno-Associated Virus 5 Protein Particles Produced by *E. coli* Cell-Free Protein Synthesis.

Deuker D, Asilonu E, Bracewell DG, Frank S.ACS Synth Biol. 2024 Aug 23. doi: 10.1021/acssynbio.4c00403. Online ahead of print.PMID: 39178386

Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.

Jena D, Ghosh A, Jha A, Prasad P, Raghav SK.Vaccine. 2024 Aug 30;42(21):126153. doi: 10.1016/j.vaccine.2024.07.054. Epub 2024 Jul 26.PMID: 39060204

Evaluation of protective immunity induced by a DNA **vaccine** encoding SAG2 and SRS2 against Toxoplasma gondii infection in mice.

Guo XD, Zhou CX, Cui LL, Qiu HJ, Wang YL, Fu M, Liu DA, Han B, Zhou HY, Zhou DH.Acta Trop. 2024 Sep;257:107302. doi: 10.1016/j.actatropica.2024.107302. Epub 2024 Jul 2.PMID: 38959992

Intestinal helminth infection impairs **vaccine**-induced T cell responses and protection against SARS-CoV-2 in mice.

Desai P, Karl CE, Ying B, Liang CY, Garcia-Salum T, Santana AC, Ten-Caten F, Joseph F Urban Jr, Elbashir SM, Edwards DK, Ribeiro SP, Thackray LB, Sekaly RP, Diamond MS.Sci Transl Med. 2024 Aug 21;16(761):eado1941. doi: 10.1126/scitranslmed.ado1941. Epub 2024 Aug 21.PMID: 39167662

Health beliefs and associated factors related to HPV and HPV vaccination in a sample of Turkish women: A cross-sectional study.

Gürdal Y, İlhan N.Public Health Nurs. 2024 Aug 29. doi: 10.1111/phn.13408. Online ahead of print.PMID: 39206496

Color-Tunable $CsCdCl_3$ Perovskite for Low-Temperature Anticounterfeiting and Information Storage Applications.

Hao X, Wang T, Zhu X, Hou L, Nie L, Liu H, Yue Y, An X, He Q, Yu X.Inorg Chem. 2024 Aug 26;63(34):16047-16055. doi: 10.1021/acs.inorgchem.4c02629. Epub 2024 Aug 13.PMID: 39138609

SARS-CoV-2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations.

Zhang X, Li M, Zhang N, Li Y, Teng F, Li Y, Zhang X, Xu X, Li H, Zhu Y, Wang Y, Jia Y, Qin C, Wang B, Guo S, Wang Y, Yu X.Adv Sci (Weinh). 2024 Aug 29:e2402639. doi: 10.1002/advs.202402639. Online ahead of print.PMID: 39206813

Vaccination with OprB porin, and its epitopes offers protection against A. baumannii infections in mice.

Raoufi Z, Abdollahi S.Int Immunopharmacol. 2024 Aug 25;141:112972. doi: 10.1016/j.intimp.2024.112972. Online ahead of print.PMID: 39186832

Pertussis upsurge, age shift and **vaccine** escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China.

Fu P, Yan G, Li Y, Xie L, Ke Y, Qiu S, Wu S, Shi X, Qin J, Zhou J, Lu G, Yang C, Wang C.Clin Microbiol Infect. 2024 Aug 27:S1198-743X(24)00415-4. doi: 10.1016/j.cmi.2024.08.016. Online ahead of print.PMID: 39209267

Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate **vaccine**.

Li G, Ren T, Zhang H, Ti J, Chang X, Yin S, Guan Y, Liu G, Liang Q, Liu J.Vaccine. 2024 Aug 31;42(24):126209. doi: 10.1016/j.vaccine.2024.126209. Online ahead of print.PMID: 39217777

Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA **vaccine**.

Yu G, Lin Y, Wang J, Zhou L, Lu Y, Fei X, Gu X, Song S, Wang J, Liu Y, Yang Q, Zhan M, Seo SY, Xu B.Expert Rev Vaccines. 2024 Aug 28. doi: 10.1080/14760584.2024.2396086. Online ahead of print.PMID: 39193620

Low-Dose Mildronate-Derived Lipidoids for Efficient mRNA **Vaccine** Delivery with Minimal Inflammation Side Effects.

Liu J, Xiao B, Yang Y, Jiang Y, Wang R, Wei Q, Pan Y, Chen Y, Wang H, Fan J, Li R, Xu H, Piao Y, Xiang J, Shao S, Zhou Z, Shen Y, Sun W, Tang J.ACS Nano. 2024 Aug 27;18(34):23289-23300. doi: 10.1021/acsnano.4c06160. Epub 2024 Aug 16.PMID: 39151414

An immunoinformatics approach for design and validation of multi-subunit **vaccine** against Plasmodium falciparum from essential hypothetical proteins.

Ritaparna P, Ray M, Dhal AK, Mahapatra RK.J Parasit Dis. 2024 Sep;48(3):593-609. doi: 10.1007/s12639-024-01696-w. Epub 2024 Jun 23.PMID: 39145352

A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.

Khanafer N, Oudot S, Maligeay M, Planckaert C, Mena C, Mandel NT, Bouhalila R, Ader F, Berard F, Bouhour F, Chapurlat R, Charriere S, Confavreux C, Devouassoux G, Disse E, Fouque D, Ghesquieres H, Hyvert S, Jolivot A, Durand A, Martin-Gaujard G, Mornex JF, Nicolino M, André-Obadia N, Raverot G, Reix P, Ruffion A, Seve P, Hermann R, Zoulim F, Clamens J, Ayala MP, Vanhems P.Vaccine. 2024 Aug 30;42(21):126160. doi: 10.1016/j.vaccine.2024.126160. Epub 2024 Jul 26.PMID: 39068066

Recurrent cardiac tamponade following coronavirus disease 2019 mRNA vaccination: A case report.

Kaimori R, Nishida H, Yahiro T, Miura T, Iwami T, Daa T.Cardiovasc Pathol. 2024 Sep-Oct;72:107668. doi: 10.1016/j.carpath.2024.107668. Epub 2024 Jun 10.PMID: 38866088

Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data.

Nazar W, Romantowski J, Niedoszytko M, Daniłowicz-Szymanowicz L.Eur Heart J Cardiovasc Pharmacother. 2024 Aug 22:pvae063. doi: 10.1093/ehjcvp/pvae063. Online ahead of print.PMID: 39174484

Operationalizing the Behaviour Change Wheel and APEASE criteria to co-develop recommendations with stakeholders to address barriers to school-based immunization programs.

Gallant AJ, Steenbeek A, Halperin SA, Parsons Leigh J, Curran JA.Vaccine. 2024 Aug 21;42(23):126226. doi: 10.1016/j.vaccine.2024.126226. Online ahead of print.PMID: 39173194

Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.

Ren J, Huang Z, Tian J, Li Z, Shen S, Yan H, Wang N, Hu J, Ma X, Ma Z, Liu J, Lu Y, Sun X.Vaccine. 2024 Aug 30;42(21):126162. doi: 10.1016/j.vaccine.2024.126162. Epub 2024 Jul 27.PMID: 39069462

Synergistic effects of oral inoculation with a recombinant Lactobacillus plantarum NC8 strain co-expressing interleukin-2 and interleukin-17B on the efficacy of the infectious bronchitis **vaccine** in chickens.

Guo S, Peng J, Xiao Y, Chen J, Gao R.Poult Sci. 2024 Sep;103(9):103908. doi: 10.1016/j.psj.2024.103908. Epub 2024 May 31.PMID: 38981363

Kikuchi Disease After SARS-CoV-2 Vaccination: A Case Report With Immunohistochemical Analyses.

Hamamoto Y, Kawamura M, Mori H, Uchida H, Hiramatsu K, Katori C, Asai H, Kawasaki H, Minamino T, Hashimoto M, Nakatsuka SI, Yoshida K.Int J Surg Pathol. 2024 Sep;32(6):1123-1128. doi: 10.1177/10668969231212428. Epub 2023 Nov 19.PMID: 37981745

A Rationally Designed H5 Hemagglutinin Subunit **Vaccine** Provides Broad-Spectrum Protection against Various H5Nx Highly Pathogenic Avian Influenza Viruses in Chickens.

Zhang X, Zhang F, Chen N, Cui X, Guo X, Sun Z, Guo P, Liao M, Li X.Vaccines (Basel). 2024 Aug 21;12(8):932. doi: 10.3390/vaccines12080932.PMID: 39204055

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.

Liu D, Liu L, Li X, Wang S, Wu G, Che X.Vaccines (Basel). 2024 Aug 22;12(8):950. doi: 10.3390/vaccines12080950.PMID: 39204073

The Reasoning through Evidence versus Advice (EvA) Scale: Scale Development and Validation.

Shin H, Shah P, Preston SD.J Pers Assess. 2024 Sep-Oct;106(5):681-695. doi: 10.1080/00223891.2023.2297266. Epub 2024 Jan 25.PMID: 38271474

Development of cashew-alginate microbeads and powdered dose forms: prospects for oral **vaccine** delivery in chickens.

Ola OO, Emikpe BO, Kuntworbe N, Odeniyi MA, Jarikre TA, Onilude OM, Osei YA, Asare DA.J Immunoassay Immunochem. 2024 Aug 21:1-17. doi: 10.1080/15321819.2024.2393184. Online ahead of print.PMID: 39169555

Prenatal RSV **Vaccine** Not Tied to Higher Risk of Preterm Births.

Harris E.JAMA. 2024 Aug 27;332(8):610-611. doi: 10.1001/jama.2024.13773.PMID: 39093559

Development and evaluation of immunological effects of a DNA **vaccine** encoding phosphoketolase family protein against Nocardia seriolae in hybrid snakehead.

Zhang Z, Chen G, Li N, Li Y, Sirimanapong W, Chen J, Xia L.Fish Shellfish Immunol. 2024 Sep;152:109773. doi: 10.1016/j.fsi.2024.109773. Epub 2024 Jul 15.PMID: 39019124

Contradictory mortality results in early 2-dose measles **vaccine** trials: Interactions with oral polio **vaccine** may explain differences.

Nielsen S, Fisker AB, Sie A, Müller O, Nebie E, Becher H, van der Klis F, Biering-Sørensen S, Byberg S, Thysen SM, da Silva I, Rodrigues A, Martins C, Whittle HC, Aaby P, Benn CS.Int J Infect Dis. 2024 Aug 30:107224. doi: 10.1016/j.ijid.2024.107224. Online ahead of print.PMID: 39218141

Identification of tumor-antigen signatures and immune subtypes for messenger RNA **vaccine** selection in advanced clear cell renal cell carcinoma.

Xu Z, Wu Y, Chen X, Jin B.Surgery. 2024 Sep;176(3):785-797. doi: 10.1016/j.surg.2024.04.027. Epub 2024 Jun 8.PMID: 38851900

A stochastic modeling study of quarantine strategies against foot-and-mouth disease risks through cattle trades across the Thailand-Myanmar border.

Wongnak P, Yano T, Sekiguchi S, Chalvet-Monfray K, Premashthira S, Thanapongtharm W, Wiratsudakul A.Prev Vet Med. 2024 Sep;230:106282. doi: 10.1016/j.prevetmed.2024.106282. Epub 2024 Jul 10.PMID: 39033658

Quantifying Stated Preferences for Meningococcal Vaccines Among Adolescents/Young Adults and Parents of Adolescents in the United States: A Discrete Choice Experiment.

Begum S, Cabrera ES, Restrepo OH, Burman C, Sohn WY, Kuylen E, Shah H, Kocaata Z.Infect Dis Ther. 2024 Sep;13(9):2001-2015. doi: 10.1007/s40121-024-01017-x. Epub 2024 Jul 24.PMID: 39044053

Relative **vaccine** effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.

McGovern I, Chastek B, Bancroft T, Webb N, Imran M, Pelton SI, Haag MDM.Int J Infect Dis. 2024 Sep;146:107160. doi: 10.1016/j.ijid.2024.107160. Epub 2024 Jul 3.PMID: 38969330

Indirect effectiveness of a novel SAR-COV-2 **vaccine** (SCB-2019) in unvaccinated household contacts in the Philippines: a cluster randomised analysis.

Aziz AB, Sugimoto JD, Hong SL, You YA, Bravo L, Roa C Jr, Borja-Tabora C, Montellano MEB, Carlos J, de Los Reyes MRA, Alberto ER, Salvani-Bautista M, Kim HY, Njau I, Clemens R, Marks F, Tadesse BT.J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260. Online ahead of print.PMID: 39218309

Efficacy of typhoid conjugate **vaccine** in Malawian children - Authors' reply.

Neuzil KM, Patel PD, Ndeketa L, Laurens MB, Gordon MA.Lancet. 2024 Aug 24;404(10454):748. doi: 10.1016/S0140-6736(24)01507-1.PMID: 39181588

The end of toxoid **vaccine** development for preventing Clostridioides difficile infections?

Kuijper EJ, Gerding DN.Clin Infect Dis. 2024 Aug 24:ciae412. doi: 10.1093/cid/ciae412. Online ahead of print.PMID: 39178347

Global burden of **vaccine**-associated angioedema and their related vaccines, 1967-2023: Findings from the global pharmacovigilance database.

Jeong YD, Lee K, Park J, Lee J, Kang J, Yeo SG, Smith L, Lee H, Yon DK.Allergy. 2024 Aug 30. doi: 10.1111/all.16304. Online ahead of print.PMID: 39212223

The contributions of T cell-mediated immunity to protection from **vaccine**-preventable diseases: A primer.

Shapiro JR, Corrado M, Perry J, Watts TH, Bolotin S.Hum Vaccin Immunother. 2024 Dec 31;20(1):2395679. doi: 10.1080/21645515.2024.2395679. Epub 2024 Aug 29.PMID: 39205626

Worth a Shot: Experience and Lessons From an Unsuccessful Pediatric Immunization Quality Improvement Effort in a Large Health System During the COVID-19 Pandemic.

Howard B, Gorman G.Mil Med. 2024 Aug 30;189(9-10):e2284-e2289. doi: 10.1093/milmed/usae323.PMID: 38935398

Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1.

Muik A, Quandt J, Lui BG, Bacher M, Lutz S, Grünenthal M, Toker A, Grosser J, Ozhelvaci O, Blokhina O, Shpyro S, Vogler I, Salisch N, Türeci Ö, Sahin U.Cell Rep. 2024 Aug 27;43(8):114567. doi: 10.1016/j.celrep.2024.114567. Epub 2024 Aug 3.PMID: 39097927

Correlates of Nucleocapsid Antibodies and a Combination of Spike and Nucleocapsid Antibodies Against Protection of SARS-CoV-2 Infection During the Omicron XBB.1.16/EG.5-Predominant Wave.

Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Tan T, Horii K, Okudera K, Konishi M, Mizoue T, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N.Open Forum Infect Dis. 2024 Aug 28;11(9):ofae455. doi: 10.1093/ofid/ofae455. eCollection 2024 Sep.PMID: 39220657

Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.

Ji J, Tang T, Zhu M, Wu Z, Zhang J, Shi D, Zhu L, Zhang X, Lu X, Chen L, Yao H.Antiviral Res. 2024 Sep;229:105954. doi: 10.1016/j.antiviral.2024.105954. Epub 2024 Jul 2.PMID: 38964615

WHO Announces Project to Develop an mRNA H5N1 **Vaccine** for Humans.

Anderer S.JAMA. 2024 Aug 30. doi: 10.1001/jama.2024.15887. Online ahead of print.PMID: 39212971

Otitis media sequelae and hearing in adolescence after administration of an 11-valent conjugate pneumococcal **vaccine** in infancy: a prospective cohort study with long-term follow-up of the ARIVAC trial.

Simões EAF, Carosone-Link P, Sanvictores DM, Uhler KM, Lucero M, Tallo V, Chan KH.Lancet Child Adolesc Health. 2024 Sep;8(9):647-655. doi: 10.1016/S2352-4642(24)00128-7. Epub 2024 Jul 31.PMID: 39096922

Hepatitis B **vaccine** responders show higher frequencies of CD8(+) effector memory and central memory T cells compared to non-responders.

Vakili ME, Mashhadi N, Ataollahi MR, Meri S, Kabelitz D, Kalantar K.Scand J Immunol. 2024 Aug 27:e13402. doi: 10.1111/sji.13402. Online ahead of print.PMID: 39189677

Delayed peak antibody titers after the second dose of SARS-CoV-2 **vaccine** in solid organ transplant recipients: Prospective cohort study.

Unagami K, Yoshikawa M, Egawa H, Ohfuji S, Natori Y, Oki R, Mori T, Hattori H, Ishiwatari A, Kanzawa T, Shimizu T, Omoto K, Inui M, Masano Y, Ito T, Nakajima D, Babazono T, Takagi T, Nunoda S, Tomimaru Y, Imamura R, Miyagawa S, Toda K, Hatano E, Date H, Kyakuno M, Takahara S, Yuzawa K, Tanimine N, Ohdan H, Ishida H, Hirota Y; Japan Solid Organ Transplantation COVID-19 Countermeasure Group.Vaccine. 2024 Aug 23;42(23):126221. doi: 10.1016/j.vaccine.2024.126221. Online ahead of print.PMID: 39180977

Development of a Ferritin-Based Nanoparticle **Vaccine** against Classical Swine Fever.

Song Y, Yuan Z, Ji J, Ruan Y, Li X, Wang L, Zeng W, Wu K, Hu W, Yi L, Ding H, Zhao M, Fan S, Li Z, Chen J.Vaccines (Basel). 2024 Aug 22;12(8):948. doi: 10.3390/vaccines12080948.PMID: 39204071

XBB.1.16-RBD-based trimeric protein **vaccine** can effectively inhibit XBB.1.16-included XBB subvariant infection.

Peng D, He C, Chen Z, Lei H, Huang X, Ye C, Wang B, Hao Y, Du X, Lu S, Hu H, Cheng W, Dong H, Lei J, Zhou X, Song X, Lu G, Wei X.MedComm (2020). 2024 Aug 16;5(9):e687. doi: 10.1002/mco2.687. eCollection 2024 Sep.PMID: 39156763

[Proposals and recommendations due to the increased number of pertussis cases in Hungary].

Tróbert-Sipos D, Pék T, Kulcsár A, Farkas FB, Szabó A.Orv Hetil. 2024 Aug 25;165(34):1307-1318. doi: 10.1556/650.2024.33127. Print 2024 Aug 25.PMID: 39182219 Hungarian.

Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients.

Wang C, Lv L, Ma P, Zhang Y, Li M, Deng J, Zhang Y.Aging (Albany NY). 2024 Aug 29;16. doi: 10.18632/aging.206068. Online ahead of print.PMID: 39213256

Postexposure prophylaxis after receipt of MMR **vaccine** prior to emergent heart transplant.

Casias M, Page RL 2nd, Campbell T.Transpl Infect Dis. 2024 Aug 26:e14365. doi: 10.1111/tid.14365. Online ahead of print.PMID: 39185759

Letter from Hong Kong: Vaccination trends for respiratory viral infections in Hong Kong.

Chan KKP, Hui DSC.Respirology. 2024 Aug 27. doi: 10.1111/resp.14824. Online ahead of print.PMID: 39188253

Influenza vaccination stimulates maturation of the human T follicular helper cell response.

Schattgen SA, Turner JS, Ghonim MA, Crawford JC, Schmitz AJ, Kim H, Zhou JQ, Awad W, Mettelman RC, Kim W, McIntire KM, Haile A, Klebert MK, Suessen T, Middleton WD, Teefey SA, Presti RM, Ellebedy AH, Thomas PG.Nat Immunol. 2024 Sep;25(9):1742-1753. doi: 10.1038/s41590-024-01926-6. Epub 2024 Aug 20.PMID: 39164477

Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study.

von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S, Quan V, du Plessis M, von Mollendorf C, Crowther-Gibson P, Avenant T, du Plessis N, Kularatne R, Chibabhai V, Madhi SA, Klugman KP, Whitney CG, Cohen C; GERMS-SA.Lancet Glob Health. 2024 Sep;12(9):e1470-e1484. doi: 10.1016/S2214-109X(24)00263-8.PMID: 39151982

Neutralizing and binding antibody responses to SARS-CoV-2 with hybrid immunity in pregnancy.

Li L, Matsui Y, Prahl MK, Cassidy AG, Golan Y, Jigmeddagva U, Ozarslan N, Lin CY, Buarpung S, Gonzalez VJ, Chidboy MA, Basilio E, Lynch KL, Song D, Jegatheesan P, Rai DS, Govindaswami B, Needens J, Rincon M, Myatt L, Taha TY, Montano M, Ott M, Greene WC, Gaw SL.NPJ Vaccines. 2024 Aug 27;9(1):156. doi: 10.1038/s41541-024-00948-3.PMID: 39191763

Mathematical modelling to accurately quantify the benefits of pneumococcal conjugate **vaccine**.

Shrestha S, Shrestha A.Lancet Glob Health. 2024 Sep;12(9):e1377-e1378. doi: 10.1016/S2214-109X(24)00323-1.PMID: 39151965

Measles Population Immunity Profiles: Updated Methods and Tools.

Li X, Goodson JL, Perry RT.Vaccines (Basel). 2024 Aug 22;12(8):937. doi: 10.3390/vaccines12080937.PMID: 39204060

Optic Neuritis After COVID-19 Vaccination: A Case Series and a Review of Literature.

Yang SC, Lee YK, Chuang MT, Hsu HW, Chang HY, Chang YS.J Neuroophthalmol. 2024 Sep 1;44(3):330-336. doi: 10.1097/WNO.0000000000002161. Epub 2024 Jun 3.PMID: 38829714

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.

Da Costa RM, Rooke JL, Wells TJ, Cunningham AF, Henderson IR.NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6.PMID: 39218947

Genetic substructure and host-specific natural selection trend across **vaccine**-candidate ORF-2 capsid protein of hepatitis-E virus.

Khan N, Kakakhel S, Malik A, Nigar K, Akhtar S, Khan AA, Khan A.J Viral Hepat. 2024 Sep;31(9):524-534. doi: 10.1111/jvh.13959. Epub 2024 May 28.PMID: 38804127

Limitations in the clinical utility of **vaccine** challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders.

Ameratunga R, Longhurst H, Leung E, Steele R, Lehnert K, Woon ST.Clin Immunol. 2024 Sep;266:110320. doi: 10.1016/j.clim.2024.110320. Epub 2024 Jul 25.PMID: 39025346

Application of nervous necrosis virus capsid protein-based antigen-presenting particles for **vaccine** development.

Wayha S, Koiwai K, Sano M, Hirono I, Kondo H.Fish Shellfish Immunol. 2024 Sep;152:109803. doi: 10.1016/j.fsi.2024.109803. Epub 2024 Aug 2.PMID: 39096980

Sustained release of inactivated H1N1 virus from degradable microparticles for extended vaccination.

Sparks Z, Wen Y, Hawkins I, Lednicky J, Abboud G, Nelson C, Driver JP, Chauhan A.Eur J Pharm Biopharm. 2024 Sep;202:114388. doi: 10.1016/j.ejpb.2024.114388. Epub 2024 Jun 28.PMID: 38945409

Humoral immunity after a booster dose of COVID-19 **vaccine** in patients with psoriasis treated with methotrexate and biologics: a cohort study.

Kvist-Hansen A, Hansen CB, Hamm SR, Pérez-Alós L, Zachariae C, Nielsen SD, Garred P, Skov L.Clin Exp Dermatol. 2024 Aug 22:llae349. doi: 10.1093/ced/llae349. Online ahead of print.PMID: 39172535

The long-term efficacy of a respiratory syncytial virus **vaccine** for older adults.

Sande CJ.Lancet Infect Dis. 2024 Sep;24(9):941-942. doi: 10.1016/S1473-3099(24)00290-1. Epub 2024 May 24.PMID: 38801825

The World Needs a Staph **Vaccine**-New Research Could Bring It a Step Closer.

Coffey D.JAMA. 2024 Aug 27;332(8):607-609. doi: 10.1001/jama.2024.1015.PMID: 39093572

Mitigating Misinformation Toolkit: A Medical Student Role-Play Curriculum on Communication Techniques to Facilitate **Vaccine** Misinformation Conversations.

Pelin C, Vasser M, Cavuoto Petrizzo M, Cassara M, McLeod-Sordjan R, Weiner J, Ginzburg S.MedEdPORTAL. 2024 Aug 27;20:11439. doi: 10.15766/mep_2374-8265.11439. eCollection 2024.PMID: 39193179

Sequence and phylogenetic analysis of FMD virus isolated from two outbreaks in Egypt.

Al-Ebshahy E, El-Ansary RE, Zhang J, Badr Y, Rady A, El-Ashram S, Ma Y, Yuan M, Elgendy E.Infect Genet Evol. 2024 Sep;123:105651. doi: 10.1016/j.meegid.2024.105651. Epub 2024 Jul 31.PMID: 39089501

Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV-2.

Maxwell JWC, Stockdale S, Stewart EL, Ashley CL, Smith LJ, Steain M, Triccas JA, Byrne SN, Britton WJ, Ashhurst AS, Payne RJ.ACS Infect Dis. 2024 Aug 28. doi: 10.1021/acsinfecdis.4c00544. Online ahead of print.PMID: 39196071

Relapsing polychondritis after COVID-19 vaccination.

Ito K, Ogawa T, Igarashi S, Miyai K, Sato K, Kawana A, Kimizuka Y.Respirol Case Rep. 2024 Aug 30;12(9):e70008. doi: 10.1002/rcr2.70008. eCollection 2024 Sep.PMID: 39220095

Immunogenicity and Protective Efficacy of Dose-Sparing Epigraph **Vaccine** against H3 Swine Influenza A Virus.

Petro-Turnquist E, Madapong A, Steffen D, Weaver EA.Vaccines (Basel). 2024 Aug 22;12(8):943. doi: 10.3390/vaccines12080943.PMID: 39204066

The synergy of recombinant NSP4 and VP4 from porcine rotavirus elicited a strong mucosal response.

Li S, Tang X, Zhou J, Bian X, Wang J, Gu L, Zhu X, Tao R, Sun M, Zhang X, Li B.Virology. 2024 Sep;597:110130. doi: 10.1016/j.virol.2024.110130. Epub 2024 Jun 4.PMID: 38850894

Highly atypical lymphoid proliferation after COVID-19 **vaccine**, with spontaneous regression.

Li J, Ruskova A, Hanna M.J Hematop. 2024 Sep;17(3):171-174. doi: 10.1007/s12308-024-00587-6. Epub 2024 May 22.PMID: 38776051

Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2.

Cohen CA, Leung NHL, Kaewpreedee P, Lee KWK, Jia JZ, Cheung AWL, Cheng SMS, Mori M, Ip DKM, Poon LLM, Peiris JSM, Cowling BJ, Valkenburg SA.Nat Commun. 2024 Aug 27;15(1):7358. doi: 10.1038/s41467-024-51427-1.PMID: 39191745

Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.

Matsumoto N, Sasaki A, Kadowaki T, Mitsuhashi T, Takao S, Yorifuji T.Vaccine. 2024 Aug 30;42(21):126156. doi: 10.1016/j.vaccine.2024.126156. Epub 2024 Jul 31.PMID: 39088986

The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance.

Rota PA, Evans R, Ben Mamou MC, Rey-Benito G, Sangal L, Dosseh A, Ghoniem A, Byabamazima CR, Demanou M, Anderson R, Kim G, Bankamp B, Beard RS, Crooke SN, Ramachandran S, Penedos A, Stambos V, Nicholson S, Featherstone D, Mulders MN.Vaccines (Basel). 2024 Aug 22;12(8):946. doi: 10.3390/vaccines12080946.PMID: 39204069

Polyphenol-Enabled 2D Nanopatch for Enhanced Nasal Mucoadhesion and Immune Activation.

Han JP, Nam YR, Chung HY, Lee H, Yeom SC.Nano Lett. 2024 Aug 21;24(33):10380-10387. doi: 10.1021/acs.nanolett.4c03228. Epub 2024 Aug 9.PMID: 39120059

Antibody response of endangered riparian brush rabbits to vaccination against rabbit hemorrhagic disease virus 2.

Moriarty ME, Rudd JL, Takahashi F, Hopson E, Kinzley C, Minier D, Herman A, Berninger ML, Mohamed F, Makhdoomi M, Woods LW, Ip HS, Clifford DL.J Vet Diagn Invest. 2024 Aug 23:10406387241267850. doi: 10.1177/10406387241267850. Online ahead of print.PMID: 39175363

Novel multi-cluster workflow system to support real-time HPC-enabled epidemic science: Investigating the impact of **vaccine** acceptance on COVID-19 spread.

Bhattacharya P, Machi D, Chen J, Hoops S, Lewis B, Mortveit H, Venkatramanan S, Wilson ML, Marathe A, Porebski P, Klahn B, Outten J, Vullikanti A, Xie D, Adiga A, Brown S, Barrett C, Marathe M.J Parallel Distrib Comput. 2024 Sep;191:104899. doi: 10.1016/j.jpdc.2024.104899. Epub 2024 May 4.PMID: 38774820

Key factors in complex public health interventions to address **vaccine** hesitancy using a multidisciplinary approach: the VAX-TRUST project.

Ferrara M, Langiano E, Esposito M, Lo Moro G, Lombardi R, Vuolanto P, De Vito E.Health Educ Res. 2024 Aug 23:cyae027. doi: 10.1093/her/cyae027. Online ahead of print.PMID: 39178122

Vaccination with a Lawsonia intracellularis subunit water in oil emulsion **vaccine** mitigated some disease parameters but failed to affect shedding.

Fourie KR, Jeffery A, Chand D, Choudhary P, Ng SH, Liu H, Magloire D, Khatooni Z, Berberov E, Wilson HL.Vaccine. 2024 Aug 29;42(24):126254. doi: 10.1016/j.vaccine.2024.126254. Online ahead of print.PMID: 39213981

Induction of antigen-specific immunity by mesoporous silica nanoparticles incorporating antigen peptides.

Goto K, Ueno T, Sakaue S.J Biosci Bioeng. 2024 Sep;138(3):254-260. doi: 10.1016/j.jbiosc.2024.05.013. Epub 2024 Jun 17.PMID: 38890051

Failure to address crucial biases other than the healthy vaccinee effect.

Jedlička P.Int J Infect Dis. 2024 Sep;146:107143. doi: 10.1016/j.ijid.2024.107143. Epub 2024 Jun 21.PMID: 38908819

High Cellular Internalization of Virus-Like Mesoporous Silica Nanoparticles Enhances Adaptive Antigen-Specific Immune Responses against Cancer.

Phan NM, Nguyen TL, Choi Y, Mo XW, Trinh TA, Yi GR, Kim J.ACS Appl Mater Interfaces. 2024 Aug 23. doi: 10.1021/acsami.4c07106. Online ahead of print.PMID: 39178210

Semisynthetic Glycoconjugates as Potential **Vaccine** Candidates Against Haemophilus influenzae Type a.

Kohout CV, Del Bino L, Petrosilli L, D'Orazio G, Romano MR, Codée JDC, Adamo R, Lay L.Chemistry. 2024 Aug 22;30(47):e202401695. doi: 10.1002/chem.202401695. Epub 2024 Jul 30.PMID: 38889267

The workup process of vaccination in IBD patients needs a change-Insights from a multinational survey.

Abreu C, Monteiro C, Santiago M, Sarmento A, Magro F.Dig Liver Dis. 2024 Aug 28:S1590-8658(24)00895-8. doi: 10.1016/j.dld.2024.07.031. Online ahead of print.PMID: 39209595

Age-dependent decrease of circulating T follicular helper cells correlates with disease severity in elderly patients with COVID-19.

Wang Y, Wang Q, He F, Qiao N, Li X, Wei L, Sun L, Dai W, Li Y, Pang X, Hu J, Huang C, Yang G, Pang C, Hu Z, Xing M, Wan C, Zhou D.Clin Immunol. 2024 Sep;266:110329. doi: 10.1016/j.clim.2024.110329. Epub 2024 Jul 25.PMID: 39067679

Correction to: Immunogenicity and Safety of a Purified Vero Rabies **Vaccine**-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.

[No authors listed]Clin Infect Dis. 2024 Aug 28:ciae390. doi: 10.1093/cid/ciae390. Online ahead of print.PMID: 39196975

Regional differences in pediatric pneumococcal **vaccine** schedules for Indigenous children in Canada: an environmental scan.

Mahon S, Reifferscheid L, Kenzie L, MacDonald SE.BMC Health Serv Res. 2024 Aug 26;24(1):990. doi: 10.1186/s12913-024-11400-6.PMID: 39187809

Acute hepatitis B in a hepatitis B **vaccine** non-responder.

Seneviratne K, Scott J, Cherif S.Int J STD AIDS. 2024 Sep;35(10):822-824. doi: 10.1177/09564624241258277. Epub 2024 May 31.PMID: 38819810

Heightened incidence of adverse events associated with a live attenuated varicella **vaccine** strain that lacks critical genetic polymorphisms in ORF62.

Kim YJ, Oh D, Kim J, Son J, Moon JY, Kim YK, Ahn B, Kang KR, Park D, Kang HM.Clin Microbiol Infect. 2024 Aug 27:S1198-743X(24)00417-8. doi: 10.1016/j.cmi.2024.08.018. Online ahead of print.PMID: 39209266

From both sides of the needle: Understanding effective interventions for facilitating non-national immunization program **vaccine** decision making in China.

Jiang M, Yan X, Jiang W, Ma H, Zhou S, Ying X.Hum Vaccin Immunother. 2024 Dec 31;20(1):2389578. doi: 10.1080/21645515.2024.2389578. Epub 2024 Aug 22.PMID: 39171499

Reverse vaccinology approaches to design a potent multiepitope **vaccine** against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches.

Hashempour A, Khodadad N, Akbarinia S, Ghasabi F, Ghasemi Y, Nazar MMKA, Falahi S.BMC Infect Dis. 2024 Aug 28;24(1):873. doi: 10.1186/s12879-024-09775-2.PMID: 39198721

Detection of Brucella S19 **Vaccine** Strain DNA in Domestic and Wild Ungulates from Brazilian Pantanal.

Carvalho de Macedo G, Trindade CSPC, Dos Santos CP, Santos LGRO, Santos FM, de Assis WO, de Castro AP, Gonçalves ERA, Bruno SF, Herrera HM, Elisei de Oliveira C.Curr Microbiol. 2024 Aug 30;81(10):333. doi: 10.1007/s00284-024-03847-x.PMID: 39212759

Mathematical assessment of the roles of age heterogeneity and vaccination on the dynamics and control of SARS-CoV-2.

Pant B, Gumel AB.Infect Dis Model. 2024 Apr 26;9(3):828-874. doi: 10.1016/j.idm.2024.04.007. eCollection 2024 Sep.PMID: 38725431

Cold-adapted influenza **vaccine** carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.

Xu Y, Sun F, Chuai Z, Wang J, Bai Z, Bian C, Wang X, Zhao Z, Liu Y, Yang P.Antiviral Res. 2024 Sep;229:105960. doi: 10.1016/j.antiviral.2024.105960. Epub 2024 Jul 8.PMID: 38986872

Effect of telephone reminders on adherence to anti-rabies **vaccine** amongst animal bite patients in North India: A randomised, single-blind, parallel-group, single-centre, interventional superiority trial.

Singh AD, Oberoi S, Kaler N, Singh N, Kaur J, Vig A.IJID Reg. 2024 Jun 22;12:100386. doi: 10.1016/j.ijregi.2024.100386. eCollection 2024 Sep.PMID: 39129822

Health and economic impacts of Lassa vaccination campaigns in West Africa.

Smith DRM, Turner J, Fahr P, Attfield LA, Bessell PR, Donnelly CA, Gibb R, Jones KE, Redding DW, Asogun D, Ayodeji OO, Azuogu BN, Fischer WA 2nd, Jan K, Olayinka AT, Wohl DA, Torkelson AA, Dinkel KA, Nixon EJ, Pouwels KB, Hollingsworth TD.Nat Med. 2024 Aug 28. doi: 10.1038/s41591-024-03232-y. Online ahead of print.PMID: 39198710

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

Ying B, Liang C-Y, Desai P, Scheaffer SM, Elbashir SM, Edwards DK, Thackray LB, Diamond MS.J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574-24. Online ahead of print.PMID: 39194250

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

Ying B, Liang C-Y, Desai P, Scheaffer SM, Elbashir SM, Edwards DK, Thackray LB, Diamond MS.J Virol. 2024 Aug 28:e0057424. doi: 10.1128/jvi.00574-24. Online ahead of print.PMID: 39194250

The potential role of the 4CMenB **vaccine** in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial.

White PJ, Leng T, Nikitin D, Whittles LK.Lancet Infect Dis. 2024 Sep;24(9):e543. doi: 10.1016/S1473-3099(24)00452-3. Epub 2024 Jul 17.PMID: 39032496

Contraceptive effect of a gonadotropin-releasing hormone **vaccine** on captive male brown bears (Ursus arctos).

Matsumoto N, Tomiyasu J, Hagino K, Matsui M, Yanagawa Y.Reprod Domest Anim. 2024 Sep;59(9):e14707. doi: 10.1111/rda.14707.PMID: 39205472

Comparative safety and efficacy of autogenous **vaccine** administrated by different routes against furunculosis caused by Aeromonas salmonicida sub. salmonicida in large Rainbow trout (Oncorhynchus mykiss).

Moreau E, Marie S, Bachelet F, Pineau L, Calvez S.Fish Shellfish Immunol. 2024 Sep;152:109757. doi: 10.1016/j.fsi.2024.109757. Epub 2024 Jul 11.PMID: 39002556

Outer membrane vesicles from X-ray-irradiated Pseudomonas aeruginosa alleviate lung injury caused by P. aeruginosa infection-mediated sepsis.

Bi H, Qin J, Huang J, Zhong C, Liu Y.APMIS. 2024 Sep;132(9):646-656. doi: 10.1111/apm.13444. Epub 2024 Jun 5.PMID: 38837446

Hepatitis B Virus Treatment in Children: Common Challenges and Management Options in a Case-Based Format.

Ravanbakhsh N, Campana AR, Chapin C, Jhaveri R.J Pediatric Infect Dis Soc. 2024 Aug 22:piae084. doi: 10.1093/jpids/piae084. Online ahead of print.PMID: 39171575

Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant **Vaccine** (IndoVac()) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.

Fadlyana E, Rusmil K, Dwi Putra MG, Fulendry FP, Somantri NK, Putri AD, Sari RM, Puspita M, Dewi GP.Vaccines (Basel). 2024 Aug 22;12(8):938. doi: 10.3390/vaccines12080938.PMID: 39204062

Neutralization potency of the 2023-24 seasonal influenza **vaccine** against circulating influenza H3N2 strains.

Huang X, Cheng Z, Lv Y, Li W, Liu X, Huang W, Zhao C.Hum Vaccin Immunother. 2024 Dec 31;20(1):2380111. doi: 10.1080/21645515.2024.2380111. Epub 2024 Aug 29.PMID: 39205645

Gut membrane proteins as candidate antigens for immunization of mice against the tick Amblyomma sculptum.

Costa GCA, Ribeiro ICT, Giunchetti RC, Gontijo NF, Sant'Anna MRV, Pereira MH, Pessoa GCD, Koerich LB, Oliveira F, Valenzuela JG, Fujiwara RT, Bartholomeu DC, Araujo RN.Vaccine. 2024 Aug 30;42(21):126141. doi: 10.1016/j.vaccine.2024.07.042. Epub 2024 Jul 20.PMID: 39033080

Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of a Candida albicans extracellular vesicle-based **vaccine** prototype in murine systemic candidiasis.

Honorato L, Bonilla JJA, Valdez AF, Frases S, Araújo GRdS, Sabino ALRdN, da Silva NM, Ribeiro L, Ferreira MdS, Kornetz J, Rodrigues ML, Cunningham I, Gow NAR, Gacser A, Guimarães AJ, Dutra FF, Nimrichter L.mSphere. 2024 Aug 28;9(8):e0046724. doi: 10.1128/msphere.00467-24. Epub 2024 Jul 22.PMID: 39037263

Human Papillomavirus Vaccination in the Postpartum Period: A Systematic Review.

Brenner SE, Modesitt S, Bednarczyk RA, Dilley SE.Obstet Gynecol. 2024 Aug 29. doi: 10.1097/AOG.0000000000005718. Online ahead of print.PMID: 39208443

Does the Duty of Rescue support a moral obligation to vaccinate? Seasonal influenza and the Institutional Duty of Rescue.

Harmer AS.J Med Ethics. 2024 Aug 21;50(9):618-621. doi: 10.1136/jme-2023-109545.PMID: 38041664

Purification and characterization of soluble recombinant Crimean-Congo hemorrhagic fever virus glycoprotein Gc expressed in mammalian 293F cells.

Makoah NA, Litabe MM, Simo FBN, Maboho KK, Burt FJ.BMC Biotechnol. 2024 Aug 27;24(1):59. doi: 10.1186/s12896-024-00885-y.PMID: 39192233

Challenging the 'acceptable option': Public health's advocacy for continued care in the case of pediatric **vaccine** refusal.

Silver ER, Fink L, Baylis KR, Faust RA, Guzman K, Hribar C, Martin L, Navin MC.Vaccine. 2024 Aug 30;42(21):126144. doi: 10.1016/j.vaccine.2024.07.045. Epub 2024 Jul 23.PMID: 39048468

The relative effectiveness of a high-dose quadrivalent influenza **vaccine** versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-22 influenza season.

Bricout H, Levant MC, Assi N, Crépey P, Descamps A, Mari K, Gaillat J, Gavazzi G, Grenier B, Launay O, Mosnier A, Raguideau F, Watier L, Harris RC, Chit A.Clin Microbiol Infect. 2024 Aug 24:S1198-743X(24)00410-5. doi: 10.1016/j.cmi.2024.08.012. Online ahead of print.PMID: 39187126

Cd loop fusion enhances the immunogenicity and the potential transmission blocking activity of Plasmodium falciparum generative cell specific 1 (GCS1) antigen.

Nourani L, Ayoub Meigouni M, Afzali S, Zargar M, Pourhashem Z, Yousefi H, Sani JJ, Vand-Rajabpour H, Pirahmadi S, Raz A, Abouie Mehrizi A.Biochem Biophys Res Commun. 2024 Aug 23;733:150599. doi: 10.1016/j.bbrc.2024.150599. Online ahead of print.PMID: 39208643

Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients.

Kawana S, Sugimoto S, Matsubara K, Choshi H, Tanaka S, Ishihara M, Habu T, Hashimoto K, Suzawa K, Shien K, Miyoshi K, Okazaki M, Nakayama M, Toyooka S.Respir Investig. 2024 Sep;62(5):804-810. doi: 10.1016/j.resinv.2024.07.004. Epub 2024 Jul 13.PMID: 39002293

Whole-genome sequence analysis of canine parvovirus reveals replacement with a novel CPV-2c strain throughout India.

Reddy H, Srinivas MV, Vasu J, Prabavathy A, Dhodapkar R, Mukhopadhyay HK.Arch Virol. 2024 Aug 27;169(9):189. doi: 10.1007/s00705-024-06096-2.PMID: 39192096

SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner.

Jung W, Abdelnour A, Kaplonek P, Herrero R, Shih-Lu Lee J, Barbati DR, Chicz TM, Levine KS, Fantin RC; RESPIRA study group; Loria V, Porras C, Lauffenburger DA, Gail MH, Aparicio A, Hildesheim A, Alter G, McNamara RP.Cell Rep. 2024 Aug 29;43(9):114684. doi: 10.1016/j.celrep.2024.114684. Online ahead of print.PMID: 39213155

Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines.

Zhang HQ, Zhang YN, Deng CL, Zhu QX, Zhang ZR, Li XD, Yuan ZM, Zhang B.Mol Ther. 2024 Aug 31:S1525-0016(24)00582-3. doi: 10.1016/j.ymthe.2024.08.026. Online ahead of print.PMID: 39217415

Characterization of Tenacibaculum maritimum isolated from diseased salmonids farmed in Chile reveals high serological and genetic heterogeneity.

Avendaño-Herrera R, Lopez P, Echeverría-Bugueño M, Araya-León H, Irgang R.J Fish Dis. 2024 Sep;47(9):e13965. doi: 10.1111/jfd.13965. Epub 2024 May 27.PMID: 38801516

Recent research advances in the development of Dabie Banda virus vaccines.

Yu C, Lin Y, Dai Y, Wu B, Qi Z, Qian X.PLoS Negl Trop Dis. 2024 Aug 29;18(8):e0012411. doi: 10.1371/journal.pntd.0012411. eCollection 2024 Aug.PMID: 39207951

Understanding antibody magnitude and durability following vaccination against SARS-CoV-2.

Murphy QM, Lewis GK, Sajadi MM, Forde JE, Ciupe SM.Math Biosci. 2024 Aug 30:109274. doi: 10.1016/j.mbs.2024.109274. Online ahead of print.PMID: 39218212

Health Behaviors and Experiences of LGBTQ + Individuals during 2022 Mpox Outbreak: Findings from the QVax Study.

Krause KD, Lewis K, Scrofani S, Guo TY, Goulbourne D, Halkitis PN.J Community Health. 2024 Aug 25. doi: 10.1007/s10900-024-01383-0. Online ahead of print.PMID: 39183233

Comparison of the sensitivity and specificity of commercial anti-dengue virus IgG tests to identify persons eligible for dengue vaccination.

Medina FA, Vila F, Adams LE, Cardona J, Carrion J, Lamirande E, Acosta LN, De León-Rodríguez CM, Beltran M, Grau D, Rivera-Amill V, Balmaseda A, Harris E, Madewell ZJ, Waterman SH, Paz-Bailey G, Whitehead S, Muñoz-Jordán JL.J Clin Microbiol. 2024 Aug 28:e0059324. doi: 10.1128/jcm.00593-24. Online ahead of print.PMID: 39194193

TgVax452, an epitope-based candidate **vaccine** targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence (SRS) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches.

Majidiani H, Pourseif MM, Kordi B, Sadeghi MR, Najafi A.BMC Infect Dis. 2024 Aug 29;24(1):886. doi: 10.1186/s12879-024-09807-x.PMID: 39210269

Iridaea cordata lipid extract associated with the rCP01850 protein of C. pseudotuberculosis elicited a Th1 immune response in immunized sheep.

Barbosa TN, Ferreira MRA, Scholl NR, Pegoraro HG, de Oliveira Silva MT, Sousa FSS, Seixas FK, Collares TV, Leitte FL, de Pereira CMP, Mansilla A, Borsuk S.Vaccine. 2024 Aug 24;42(23):126220. doi: 10.1016/j.vaccine.2024.126220. Online ahead of print.PMID: 39182314

Fatal viscerotropic and neurotropic disease after yellow fever **vaccine**: a rare manifestation leading to diagnosis of severe combined immunodeficiency in an infant.

Vieira LJT, Goebel GA, Barcelos Y, Cunha LO, Santos LTM, Romanelli RMC, Minafra FG, Carvalho AL, Carvalho LFA, Diniz LMO.Rev Inst Med Trop Sao Paulo. 2024 Aug 26;66:e50. doi: 10.1590/S1678-9946202466050. eCollection 2024.PMID: 39194142

The transmission dynamics of an infectious disease model in fractional derivative with vaccination under real data.

Khan MA, DarAssi MH, Ahmad I, Seyam NM, Alzahrani E.Comput Biol Med. 2024 Aug 24;181:109069. doi: 10.1016/j.compbiomed.2024.109069. Online ahead of print.PMID: 39182370

Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY **vaccine**.

Adams L, Prasinou AK, Hadley L, Ramsay M, Campbell H, Trotter C.Vaccine. 2024 Aug 22;42(23):126240. doi: 10.1016/j.vaccine.2024.126240. Online ahead of print.PMID: 39178766

A Minimalist Pathogen-Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy.

Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, Chen L, Liu Y, Liu N, Zhu J, Yang Y, Chen Q.Adv Mater. 2024 Aug 29:e2410715. doi: 10.1002/adma.202410715. Online ahead of print.PMID: 39210649

Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study.

Choi YJ, Lim J, Bea S, Lee J, Choi JY, Rho SY, Lee DI, Na JO, Kim HK.Eur Heart J. 2024 Aug 21;45(32):2983-2991. doi: 10.1093/eurheartj/ehae335.PMID: 38993069

Using Regular High-Quality Serosurveys to Identify and Close National Immunity Gaps-Measles and Rubella Elimination in Japan.

Sunagawa T, Kobayashi Y, Takashima Y, Kamiya H, Shimada T, Nakashima K, Arai S, Taniguchi K, Tanaka-Taya K, Okabe N.Vaccines (Basel). 2024 Aug 22;12(8):939. doi: 10.3390/vaccines12080939.PMID: 39204061

Constructing vaccination slogans in the late stage of **vaccine** launch: an experimental study based on the framing effect theory.

Gong Z, Li J, Yu C, Feng K.J Public Health (Oxf). 2024 Aug 29:fdae168. doi: 10.1093/pubmed/fdae168. Online ahead of print.PMID: 39205622

Expression and purification of an NP-hoc fusion protein: Utilizing influenza a nucleoprotein and phage T4 hoc protein.

Balderas-Cisneros FJ, León-Buitimea A, Zarate X, Morones-Ramírez JR.Protein Expr Purif. 2024 Sep;221:106506. doi: 10.1016/j.pep.2024.106506. Epub 2024 May 19.PMID: 38772430

What Goes Down Must Come Up? Pandemic- Related Misinformation Search Behavior During an Unplanned Facebook Outage.

Motta M, Hwang J, Stecula D.Health Commun. 2024 Sep;39(10):2041-2052. doi: 10.1080/10410236.2023.2254583. Epub 2023 Sep 6.PMID: 37674255

The Influence of a COVID-19 **Vaccine** Mandate on Vaccination Rates in a University Setting.

Figueroa EB, Bohn B, Oakes JM, Demmer RT.Am J Public Health. 2024 Aug 29:e1-e6. doi: 10.2105/AJPH.2024.307804. Online ahead of print.PMID: 39208356

Onward transmission of measles virus among vaccinated cases in a large community outbreak in Auckland, New Zealand, 2019.

Evans I, Jury S, Morrison A, Best E, King V, Reynolds E.Vaccine. 2024 Aug 26;42(23):126257. doi: 10.1016/j.vaccine.2024.126257. Online ahead of print.PMID: 39191179

RLpMIEC: High-Affinity Peptide Generation Targeting Major Histocompatibility Complex-I Guided and Interpreted by Interaction Spectrum-Navigated Reinforcement Learning.

Deng Q, Wang Z, Xiang S, Wang Q, Liu Y, Hou T, Sun H.J Chem Inf Model. 2024 Aug 26;64(16):6432-6449. doi: 10.1021/acs.jcim.4c01153. Epub 2024 Aug 8.PMID: 39118363

Understanding the epidemiology of iNTS disease in Africa in preparation for future iNTS- **vaccine** studies in endemic countries: Seroepidemiology in Africa of iNTS (SAiNTS) Study Protocol: Malawi site [Version 9.0].

Dale H, Chirwa E, Patel P, Makuta G, Mwakiseghile F, Misiri T, Kadwala I, Mbewe M, Banda H, Silungwe N, Chizani K, Kambiya P, Henrion M, French N, Nyirenda T, Gordon M; Vacc-iNTS.Wellcome Open Res. 2024 Aug 21;8:27. doi: 10.12688/wellcomeopenres.18054.2. eCollection 2023.PMID: 39183741

Single Cell Expression Systems for the Production of Recombinant Proteins for Immunodiagnosis and Immunoprophylaxis of Toxoplasmosis.

Sołowińska K, Holec-Gąsior L.Microorganisms. 2024 Aug 22;12(8):1731. doi: 10.3390/microorganisms12081731.PMID: 39203573

An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection.

Zhou D, Cheng R, Yao Y, Zhang G, Li X, Wang B, Wang Y, Yu F, Yang S, Liu H, Gao G, Peng Y, Chen M, Deng Z, Zhao H.NPJ Vaccines. 2024 Aug 31;9(1):158. doi: 10.1038/s41541-024-00954-5.PMID: 39217188

A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework'.

Volkman HR, Nguyen JL, Jodar L, McLaughlin JM.Infect Dis Ther. 2024 Aug 24. doi: 10.1007/s40121-024-01019-9. Online ahead of print.PMID: 39180645

Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a **Vaccine**.

Gastineau T, Ban C, Basso A, Brehme F, Silva AL, Faure O, Palaire LL, Persaud P, Rodriguez H.PDA J Pharm Sci Technol. 2024 Aug 23;78(4):388-398. doi: 10.5731/pdajpst.2023.012850.PMID: 37973190

Ad26.M.Env ZIKV **vaccine** protects pregnant rhesus macaques and fetuses against Zika virus infection.

Martinot AJ, Cox F, Abbink P, Hecht JL, Bronson R, Borducchi EN, Rinaldi WJ, Ferguson MJ, De La Barrera RA, Zahn R, van der Fits L, Barouch DH.NPJ Vaccines. 2024 Aug 28;9(1):157. doi: 10.1038/s41541-024-00927-8.PMID: 39198466

Socio-demographic factors affecting the first and second dose of measles vaccination status among under-five children: Perspectives from South Asian countries.

Mahazabin M, Tabassum N, Syfullah SMK, Majumder UK, Islam MA.Prev Med Rep. 2024 Jul 31;45:102839. doi: 10.1016/j.pmedr.2024.102839. eCollection 2024 Sep.PMID: 39188972

Effectiveness of quadrivalent meningococcal conjugate **vaccine** against meningococcal carriage and genotype character changes: A secondary analysis of prospective cohort study in Korean military trainees.

Kim YR, Hyun H, Kim EJ, Choi YH, Yoo JS, Lee Y, Oh HS, Heo JY.Int J Infect Dis. 2024 Sep;146:107150. doi: 10.1016/j.ijid.2024.107150. Epub 2024 Jun 22.PMID: 38914368

Bilateral Relentless Placoid Chorioretinitis Following Pfizer-BioNTech COVID-19 Vaccination: Specific Antigenic Trigger or Nonspecific Immune Activation?

Dutt DDCS, Lam J, Richards J.Ocul Immunol Inflamm. 2024 Sep;32(7):1498-1503. doi: 10.1080/09273948.2023.2239338. Epub 2023 Aug 8.PMID: 37552853

Astragalus Polysaccharide improves immunogenicity of influenza **vaccine** as well as modulate gut microbiota in BALB/c mice.

Wan C, Yan S, Lu R, Zhu C, Yang Y, Wu X, Yu Z, Jiang M, Peng W, Song W, Wu H, Fang B, He Y.Microb Pathog. 2024 Aug 27;195:106893. doi: 10.1016/j.micpath.2024.106893. Online ahead of print.PMID: 39197333

The response to influenza vaccination is associated with DNA methylation-driven regulation of T cell innate antiviral pathways.

Fu H, Pickering H, Rubbi L, Ross TM, Zhou W, Reed EF, Pellegrini M.Clin Epigenetics. 2024 Aug 21;16(1):114. doi: 10.1186/s13148-024-01730-x.PMID: 39169387

Long-term follow up of patients treated with a DNA **vaccine** (pTVG-hp) for PSA-recurrent prostate cancer.

Tonelli TP, Eickhoff JC, Johnson LE, Liu G, McNeel DG.Hum Vaccin Immunother. 2024 Dec 31;20(1):2395680. doi: 10.1080/21645515.2024.2395680. Epub 2024 Aug 29.PMID: 39208856

Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.

Kanu FA, Freeland C, Nwokoro UU, Mohammed Y, Ikwe H, Uba B, Sandhu H, An Q, Asekun A, Akataobi C, Adewole A, Fadahunsi R, Wisdom M, Akudo OL, Ugbenyo G, Simple E, Waziri N, Vasumu JJ, Bahuli AU, Bashir SS, Isa A, Ugwu G, Obi EI, Binta H, Bassey BO, Shuaib F, Bolu O, Tohme RA.Vaccine. 2024 Aug 27;42(24):126222. doi: 10.1016/j.vaccine.2024.126222. Online ahead of print.PMID: 39197221

Codon optimization of voraxin alpha sequence enhances the immunogenicity of a recombinant **vaccine** against Hyalomma anatolicum infestation in rabbits.

Monjezi Z, Rooshanfekr HA, Nazari M, Salabi F, Tabandeh MR.Vet Immunol Immunopathol. 2024 Aug 25;275:110817. doi: 10.1016/j.vetimm.2024.110817. Online ahead of print.PMID: 39197300

The amino acid variation at hemagglutinin sites 145, 153, 164 and 200 modulate antigenicity andreplication of H9N2 avian influenza virus.

Wu J, Wan Z, Qian K, Shao H, Ye J, Qin A.Vet Microbiol. 2024 Sep;296:110188. doi: 10.1016/j.vetmic.2024.110188. Epub 2024 Jul 15.PMID: 39018942

Computational analysis of spike protein of SARS-CoV-2 (Omicron variant) for development of peptide-based therapeutics and diagnostics.

Pritam M, Dutta S, Medicherla KM, Kumar R, Singh SP.J Biomol Struct Dyn. 2024 Sep;42(14):7321-7339. doi: 10.1080/07391102.2023.2239932. Epub 2023 Jul 27.PMID: 37498146

Influence of waning immunity on vaccination decision-making: A multi-strain epidemic model with an evolutionary approach analyzing cost and efficacy.

Khan MM, Tanimoto J.Infect Dis Model. 2024 Mar 24;9(3):657-672. doi: 10.1016/j.idm.2024.03.004. eCollection 2024 Sep.PMID: 38628352

The importance of Haemophilus influenzae in community-acquired pneumonia: an emerging pathogen in the elderly regardless of comorbidities compared to Streptococcus pneumoniae.

Yamba Yamba L, Hansen K, Wasserstrom L, Su YC, Ahl J, Riesbeck K.Pneumonia (Nathan). 2024 Aug 25;16(1):15. doi: 10.1186/s41479-024-00136-w.PMID: 39182132

Impact of High Covid-19 Vaccination Rate in an Aging Population: Estimating Averted Hospitalizations and Deaths in the Basque Country, Spain Using Counterfactual Modeling.

Estadilla CDS, Mar J, Ibarrondo O, Stollenwerk N, Aguiar M.J Epidemiol Glob Health. 2024 Aug 26. doi: 10.1007/s44197-024-00286-6. Online ahead of print.PMID: 39186212

Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen **Vaccine** Delivery.

Mixová G, Tihlaříková E, Zhu Y, Schindler L, Androvič L, Kracíková L, Hrdá E, Porsch B, Pechar M, Garliss CM, Wilson D, Welles HC, Holechek J, Ren Q, Lynn GM, Neděla V, Laga R.Bioconjug Chem. 2024 Aug 21;35(8):1218-1232. doi: 10.1021/acs.bioconjchem.4c00273. Epub 2024 Jul 31.PMID: 39081220

Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza **vaccine** in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.

Gao Y, Yang X, Li X, Chen H, Li Y, Tan X, Yu D, Feng T, Zhou S, Lei S, Zhao C, Wang J, Guan Q.Vaccine. 2024 Aug 30;42(21):126182. doi: 10.1016/j.vaccine.2024.126182. Epub 2024 Aug 6.PMID: 39116486

Determinants of timely administration of the birth dose of hepatitis B **vaccine** in Senegal in 2019: Secondary analysis of the demographic and health survey.

Bassoum O, Ba MF, Sougou NM, Sow A, Seck I.PLOS Glob Public Health. 2024 Aug 27;4(8):e0002734. doi: 10.1371/journal.pgph.0002734. eCollection 2024.PMID: 39190637

Immune response and protection efficacy of formalin-killed vaccines against Streptococcus iniae in four-finger threadfin Eleutheronema tetradactylum.

Shi YZ, Giovanni A, Cheng LW, Huang WR, Wang PC, Chen SC.J Fish Dis. 2024 Aug 29:e14009. doi: 10.1111/jfd.14009. Online ahead of print.PMID: 39207865

Waning Humoral Immune Response Following the Third and Fourth SARS-COV-2 **Vaccine**: A Cohort Study in Healthcare Workers.

Süner AF, Ergör G, Çağlayan D, Türe N, Güzel I, Irmak Ç, Işık E, Appak Ö, Çelik M, Öztürk G, Çavuş SA, Sayiner A, Ergör A, Demiral Y, Kilic B.Influenza Other Respir Viruses. 2024 Sep;18(9):e70003. doi: 10.1111/irv.70003.PMID: 39189319

Occupational Exposure to Aerosolized Human Papillomavirus: Assessing and Addressing Perceptions of and Barriers to Vaccination of at-Risk Health Care Workers.

Mercier AM, Allison MK, Greulich J, Alston A, Racher ML.J Public Health Manag Pract. 2024 Sep-Oct 01;30(5):681-687. doi: 10.1097/PHH.0000000000001908. Epub 2024 Jul 22.PMID: 39041764

A Response to: A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework'.

Beck E, Bausch-Jurken MT, Van de Velde N, Wang X, Malmenäs M.Infect Dis Ther. 2024 Aug 24. doi: 10.1007/s40121-024-01020-2. Online ahead of print.PMID: 39180646

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent **vaccine**.

Gressens SB, Enouf V, Créon A, Melica G, Lemonnier F, Dupuis J, El Gnaoui T, Hammoud M, Belhadj K, Haioun C, Le Bouter A, Gallien S, Bras FL, Fourati S.Int J Infect Dis. 2024 Sep;146:107108. doi: 10.1016/j.ijid.2024.107108. Epub 2024 May 23.PMID: 38795841

Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).

Goh YS, Fong SW, Hor PX, Loh CY, Tay MZ, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Lee IR, Rao S, Chia PY; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L.Int J Infect Dis. 2024 Sep;146:107147. doi: 10.1016/j.ijid.2024.107147. Epub 2024 Jun 28.PMID: 38945433

Strengthening of **Vaccine**-Preventable Disease (VPD) Surveillance to Enhance National Health Capacity and Security: Perspective from India.

Kumar A, Murugan R, Donkatti S, Sharma D, Kaundal N, Avagyan T, Kumar P, Bahl S, Khanal S, Bura V.Vaccines (Basel). 2024 Aug 22;12(8):941. doi: 10.3390/vaccines12080941.PMID: 39204063

A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV.

Zhang Z, Chi XY, Zhang GY, Zhang Z, Lu SH, Li MJ, Li LJ, Zhang JL, Shao FZ, Zhang Y, Hou LH, Chen W.Emerg Microbes Infect. 2024 Dec;13(1):2396875. doi: 10.1080/22221751.2024.2396875. Epub 2024 Aug 30.PMID: 39178194

Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis **vaccine** candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.

Bézay N, Wagner L, Kadlecek V, Obersriebnig M, Wressnigg N, Hochreiter R, Schneider M, Dubischar K, Derhaschnig U, Klingler A, Larcher-Senn J, Eder-Lingelbach S, Bender W.Lancet Infect Dis. 2024 Sep;24(9):1045-1058. doi: 10.1016/S1473-3099(24)00175-0. Epub 2024 May 31.PMID: 38830375

Immune stimulus exposure as a trigger for the development of chronic pruritus and circulating blood type 2 inflammation.

Manjunath J, Liao V, Kambala A, Bao A, Kollhoff AL, Ma EZ, Imo BU, Cornman H, Reddy SV, Lee KK, Lu W, Yossef SM, Kwatra MM, Kwatra SG.JAAD Int. 2024 Apr 7;16:97-102. doi: 10.1016/j.jdin.2024.03.022. eCollection 2024 Sep.PMID: 38868400

Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide.

Zhu H, Li X, Li X, Chen H, Qian P.Virology. 2024 Sep;597:110162. doi: 10.1016/j.virol.2024.110162. Epub 2024 Jun 27.PMID: 38955082

Exploring **vaccine** acceptance: altruism's insufficiency in promoting uptake.

Toledo JPC.J Public Health (Oxf). 2024 Aug 25;46(3):e570. doi: 10.1093/pubmed/fdae081.PMID: 38823038

Glycan masking of NTD loops with a chimeric RBD of the spike protein as a **vaccine** design strategy against emerging SARS-CoV-2 Omicron variants.

Hung HC, Tan BF, Lin WS, Wu SC.J Med Virol. 2024 Sep;96(9):e29893. doi: 10.1002/jmv.29893.PMID: 39192804

Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria.

Tang WK, Salinas ND, Kolli SK, Xu S, Urusova DV, Kumar H, Jimah JR, Subramani PA, Ogbondah MM, Barnes SJ, Adams JH, Tolia NH.Nat Commun. 2024 Aug 29;15(1):7487. doi: 10.1038/s41467-024-51701-2.PMID: 39209843

Viral Vector-Based *Chlamydia trachomatis* Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.

Andreacchio G, Longo Y, Moreno Mascaraque S, Anandasothy K, Tofan S, Özün E, Wilschrey L, Ptok J, Huynh DT, Luirink J, Drexler I.Vaccines (Basel). 2024 Aug 22;12(8):944. doi: 10.3390/vaccines12080944.PMID: 39204067

B cell-based therapy produces antibodies that inhibit glioblastoma growth.

Wang S, Castro BA, Katz JL, Arrieta VA, Najem H, Vazquez-Cervantes GI, Wan H, Olson IE, Hou D, Dapash M, Billingham LK, Chia TY, Wei C, Rashidi A, Platanias LC, McCortney K, Horbinski CM, Stupp R, Zhang P, Ahmed AU, Sonabend AM, Heimberger AB, Lesniak MS, Riviere-Cazaux C, Burns TC, Miska J, Fischietti M,

Lee-Chang C.J Clin Invest. 2024 Aug 29:e177384. doi: 10.1172/JCI177384. Online ahead of print.PMID: 39207859

Real-world effectiveness of influenza **vaccine** against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study.

Mi J, Wang J, Chen L, Guo Z, Lei H, Chong MK, Talifu J, Yang S, Luotebula K, Ablikemu M, Ma C, Lu W, Luo Z, Liu C, Sun S, Dai J, Wang K, Wang K, Zhao S.Hum Vaccin Immunother. 2024 Dec 31;20(1):2394255. doi: 10.1080/21645515.2024.2394255. Epub 2024 Aug 29.PMID: 39208849

Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis **vaccine** MTBVAC.

Calvo S, Rodrigo-Muñoz JM, Tarancón R, Uranga S, Martín C, Pozo VD, Aguiló N.EBioMedicine. 2024 Aug 21;107:105272. doi: 10.1016/j.ebiom.2024.105272. Online ahead of print.PMID: 39173529

Genome-wide analysis of Brucella melitensis growth in spleen of infected mice allows rational selection of new **vaccine** candidates.

Barbieux E, Potemberg G, Stubbe FX, Fraikin A, Poncin K, Reboul A, Rouma T, Zúñiga-Ripa A, De Bolle X, Muraille E.PLoS Pathog. 2024 Aug 26;20(8):e1012459. doi: 10.1371/journal.ppat.1012459. eCollection 2024 Aug.PMID: 39186777

Comparison of Sucrose vs. Swaddling in Pain Management during Birth Dose of Hepatitis B **Vaccine**: A Randomized Control Trial.

Nimbalkar SM, Thakkar FA, Thacker JP, Phatak AG, Shinde MK.Indian J Pediatr. 2024 Sep;91(9):893-898. doi: 10.1007/s12098-023-04900-6. Epub 2023 Nov 22.PMID: 37991714

Well-being amongst undergraduate students during the dual pandemic: an exploratory study.

Hamamouche K, Angstmann JL, Sorge B, Day B, Trueblood E, Rosen L, Williamson F, Fore GA.J Am Coll Health. 2024 Aug 27:1-10. doi: 10.1080/07448481.2024.2393107. Online ahead of print.PMID: 39190626

Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.

Brackenridge S, John N, He W, Früh K, Borrow P, McMichael A.J Virol. 2024 Aug 29:e0120624. doi: 10.1128/jvi.01206-24. Online ahead of print.PMID: 39207137

Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA **vaccine** booster.

Wang Q, Mellis IA, Guo Y, Gherasim C, Valdez R, Gordon A, Ho DD, Liu L.Cell Rep Med. 2024 Aug 23:101701. doi: 10.1016/j.xcrm.2024.101701. Online ahead of print.PMID: 39208800

"I Don't Understand How These Two Things Go Together": Toward a Theory of Risk Ecologies.

Carrion ML.Health Commun. 2024 Aug 26:1-9. doi: 10.1080/10410236.2024.2394259. Online ahead of print.PMID: 39185706

Fatal hemophagocytic lymphohistiocytosis with intravascular large B-cell lymphoma following coronavirus disease 2019 vaccination in a patient with systemic lupus erythematosus: an intertwined case.

Ueda Y, Sakai T, Yamada K, Arita K, Ishige Y, Hoshi D, Yanagisawa H, Iwao-Kawanami H, Kawanami T, Mizuta S, Fukushima T, Yamada S, Yachie A, Masaki Y.Immunol Med. 2024 Sep;47(3):192-199. doi: 10.1080/25785826.2024.2338594. Epub 2024 Apr 15.PMID: 38619098

Correction to: The Respiratory Syncytial Virus Prefusion F Protein **Vaccine** Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults 60 Years of Age.

[No authors listed]Influenza Other Respir Viruses. 2024 Sep;18(9):e13364. doi: 10.1111/irv.13364.PMID: 39192516

Prevalence, serotype distribution and antimicrobial susceptibility profile of Streptococcus pneumoniae in sea nomads children <5 years of age in Wakatobi, Southeast Sulawesi, Indonesia: A cross-sectional study.

Daningrat WOD, Paramaiswari WT, Putri HFM, Aanensen D, Safari D.J Glob Antimicrob Resist. 2024 Aug 26:S2213-7165(24)00159-0. doi: 10.1016/j.jgar.2024.08.006. Online ahead of print.PMID: 39197656

Natural genetic diversity of the DBL domain of a novel member of the Plasmodium vivax erythrocyte binding-like proteins (EBP2) in the Amazon rainforest.

Fernandes GM, Rodrigues-Mattos GH, Torres LM, Guedes KS, Fontes CJF, Ntumngia FB, Adams JH, Brito CFA, Kano FS, de Sousa TN, Carvalho LH.Infect Genet Evol. 2024 Sep;123:105628. doi: 10.1016/j.meegid.2024.105628. Epub 2024 Jun 25.PMID: 38936525

Using matrix assisted laser desorption ionisation mass spectrometry combined with machine learning for **vaccine** authenticity screening.

Clarke R, Bharucha T, Arman BY, Gangadharan B, Gomez Fernandez L, Mosca S, Lin Q, Van Assche K, Stokes R, Dunachie S, Deats M, Merchant HA, Caillet C, Walsby-Tickle J, Probert F, Matousek P, Newton PN, Zitzmann N, McCullagh JSO.NPJ Vaccines. 2024 Aug 28;9(1):155. doi: 10.1038/s41541-024-00946-5.PMID: 39198486

Severe measles with pneumonitis in an immunocompetent adult.

Lee D, Mercer O, Halai V, Gill L, Macleod C, Lampejo T.Clin Med (Lond). 2024 Aug 27:100239. doi: 10.1016/j.clinme.2024.100239. Online ahead of print.PMID: 39208983

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA **vaccine**.

Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG).Vaccine. 2024 Aug 27;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Online ahead of print.PMID: 39197299

Effectively protecting health care workers as clade 1 mpox epidemic complexifies: a call for **vaccine** and antivirals deployment.

Musumeci S, Jacquerioz F, Segeral O, Calmy A.J Travel Med. 2024 Aug 29:taae120. doi: 10.1093/jtm/taae120. Online ahead of print.PMID: 39209326

Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination.

Meyers E, De Rop L, Engels F, Gioveni C, Coen A, De Burghgraeve T, Digregorio M, Van Ngoc P, De Clercq N, Buret L, Coenen S, Deschepper E, Padalko E, Callens S, Duysburgh E, De Sutter A, Scholtes B, Verbakel JY, Heytens S, Cools P.Vaccines (Basel). 2024 Aug 22;12(8):951. doi: 10.3390/vaccines12080951.PMID: 39204074

Characterizing human respiratory syncytial virus among children admitted with acute respiratory tract infections from 2019 to 2022.

Philomenadin FS, Mohammed S, Jayagandan S, Ramamurthy N, Ratchagadasse VR, Chandrasekaran V, Dhodapkar R.J Med Virol. 2024 Sep;96(9):e29896. doi: 10.1002/jmv.29896.PMID: 39206836

An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines.

Portilho AI, Silva VO, Da Costa HHM, Yamashiro R, de Oliveira IP, de Campos IB, Prudencio CR, Matsuda EM, de Macedo Brígido LF, De Gaspari E.Sci Rep. 2024 Aug 28;14(1):20003. doi: 10.1038/s41598-024-71047-5.PMID: 39198569

Isotype-aware inference of B cell clonal lineage trees from single-cell sequencing data.

Weber LL, Reiman D, Roddur MS, Qi Y, El-Kebir M, Khan AA.Cell Genom. 2024 Aug 23:100637. doi: 10.1016/j.xgen.2024.100637. Online ahead of print.PMID: 39208795

Determination of G and P genotypes of bovine group A rotavirus with emergence of unusual G- and P-type combinations from neonatal calf diarrhea in Kashmir, India.

Hassan MN, Shah IH, Farooq S, Wani SA, Qureshi S.Acta Vet Hung. 2024 Aug 27. doi: 10.1556/004.2024.01020. Online ahead of print.PMID: 39190486

Fatal case of meningococcal meningitis in a child from rural Bhutan: A case report.

Bhandari P, Dorji T, Sharma TR, Mynak ML.Clin Case Rep. 2024 Aug 28;12(9):e9396. doi: 10.1002/ccr3.9396. eCollection 2024 Sep.PMID: 39210925

Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate **Vaccine** in Adults Aged 18 Years.

[No authors listed]Clin Infect Dis. 2024 Aug 29:ciae389. doi: 10.1093/cid/ciae389. Online ahead of print.PMID: 39207764

Group B Streptococcus and Intraamniotic Inflammation and Infection.

Afsari M, White A, Adhikari EH.Clin Obstet Gynecol. 2024 Sep 1;67(3):576-588. doi: 10.1097/GRF.0000000000000884. Epub 2024 Jul 25.PMID: 39061126

A single-dose intranasal live-attenuated codon deoptimized **vaccine** provides broad protection against SARS-CoV-2 and its variants.

Liu X, Ng WH, Zusinaite E, Freitas J, Taylor A, Yerragunta V, Aavula SM, Gorriparthi S, Ponsekaran S, Bonda RL, Mani P, Nimmagadda SV, Wang S, Lello LS, Zaid A, Dua U, Taft-Benz SA, Anderson E, Baxter VK, Sarkar S, Ling ZL, Ashhurst TM, Cheng SMS, Pattnaik P, Kanakasapapathy AK, Baric RS, Burt FJ, Peiris M, Heise MT, King NJC, Merits A, Lingala R, Mahalingam S.Nat Commun. 2024 Aug 26;15(1):7225. doi: 10.1038/s41467-024-51535-y.PMID: 39187479

Tuberculosis prevention: current strategies and future directions.

Vasiliu A, Martinez L, Gupta RK, Hamada Y, Ness T, Kay A, Bonnet M, Sester M, Kaufmann SHE, Lange C, Mandalakas AM.Clin Microbiol Infect. 2024 Sep;30(9):1123-1130. doi: 10.1016/j.cmi.2023.10.023. Epub 2023 Oct 31.PMID: 37918510

COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People.

Walker VM, Patalay P, Cuitun Coronado JI, Denholm R, Forbes H, Stafford J, Moltrecht B, Palmer T, Walker A, Thompson EJ, Taylor K, Cezard G, Horne EMF, Wei Y, Al Arab M, Knight R, Fisher L, Massey J, Davy S, Mehrkar A, Bacon S, Goldacre B, Wood A, Chaturvedi N, Macleod J, John A, Sterne JAC; Longitudinal Health and Wellbeing COVID-19 National Core Study.JAMA Psychiatry. 2024 Aug 21:e242339. doi: 10.1001/jamapsychiatry.2024.2339. Online ahead of print.PMID: 39167370

Evolution of Pyrrolysyl-tRNA Synthetase: From Methanogenesis to Genetic Code Expansion.

Koch NG, Budisa N.Chem Rev. 2024 Aug 28;124(16):9580-9608. doi: 10.1021/acs.chemrev.4c00031. Epub 2024 Jul 2.PMID: 38953775

The impact of Plasmodium-driven immunoregulatory networks on immunity to malaria.

Boyle MJ, Engwerda CR, Jagannathan P.Nat Rev Immunol. 2024 Sep;24(9):637-653. doi: 10.1038/s41577-024-01041-5. Epub 2024 Jun 11.PMID: 38862638

Knowledge, and attitude of medical students about role of human papilloma virus, and **vaccine** in head and neck cancer.

Mahdi AGM.Oral Oncol. 2024 Sep;156:106939. doi: 10.1016/j.oraloncology.2024.106939. Epub 2024 Jul 10.PMID: 38991396

Lymph node-targeted STING agonist nanovaccine against chronic HBV infection.

Hu Y, Yang A, Li H, Zhao R, Bao C, Yu Y, Wang Y, Wang Z, Zhuo L, Han Q, Zhang Z, Zhang J, Zhao H.Cell Mol Life Sci. 2024 Aug 28;81(1):372. doi: 10.1007/s00018-024-05404-y.PMID: 39196331

Characterization of IgD and IgT with their expressional analysis following subtype II megalocytivirus vaccination and infection in rock bream (Oplegnathus fasciatus).

Ko S, Hong S.Dev Comp Immunol. 2024 Aug 29:105248. doi: 10.1016/j.dci.2024.105248. Online ahead of print.PMID: 39216776

Predicting COVID-19 Vaccination Intentions to Inform Evidence-Based Messaging for Building **Vaccine** Confidence Among Rural Americans.

Totzkay D, Fraustino JD, Smith BT, Jarrett T, Dino GA, Costello LM, Kristjansson AL.Am J Health Promot. 2024 Sep;38(7):1004-1013. doi: 10.1177/08901171241249281. Epub 2024 Apr 23.PMID: 38652835

B-cell characteristics define HCV reinfection outcome.

Underwood AP, Gupta M, Wu BR, Eltahla AA, Boo I, Wang JJ, Agapiou D, Abayasingam A, Reynaldi A, Keoshkerian E, Zhao Y, Brasher N, Walker MR, Bukh J, Maher L, Gordon T, Davenport MP, Luciani F, Drummer HE, Lloyd AR, Bull RA.J Hepatol. 2024 Sep;81(3):415-428. doi: 10.1016/j.jhep.2024.04.004. Epub 2024 Apr 10.PMID: 38604387

Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides.

Fu Q, Luo Y, Li J, Zhang P, Tang S, Song X, Fu J, Liu M, Mo R, Wei M, Li H, Liu X, Wang T, Ni G.Hum Vaccin Immunother. 2024 Dec 31;20(1):2385654. doi: 10.1080/21645515.2024.2385654. Epub 2024 Aug 28.PMID: 39193797

Unlocking influenza B: exploring molecular biology and reverse genetics for epidemic control and **vaccine** innovation.

Din GU, Wu C, Tariq Z, Hasham K, Amjad MN, Shen B, Yue L, Raza MA, Ashraf MA, Chen L, Hu Y.Virol J. 2024 Aug 23;21(1):196. doi: 10.1186/s12985-024-02433-8.PMID: 39180083

Effects of Message Framing and Narrative Format on Promoting Persuasive Conversations with Others About the Flu **Vaccine**.

Lewis N, Atad E.Health Commun. 2024 Sep;39(10):2110-2122. doi: 10.1080/10410236.2023.2257427. Epub 2023 Sep 21.PMID: 37733019

Waning of Humoral Immunity to **Vaccine**-Preventable Diseases in Children Treated for Acute Lymphoblastic Leukemia: A Single-Center Retrospective Cross-Sectional Analysis.

İnce T, Tüfekçi Gürocak Ö, Totur G, Yılmaz Ş, Ören H, Aydın A.Turk J Haematol. 2024 Aug 28;41(3):160-166. doi: 10.4274/tjh.galenos.2024.2024.0150. Epub 2024 May 27.PMID: 38801016

Tracking Measles and Rubella Elimination Progress-World Health Organization African Region, 2022-2023.

Masresha BG, Wiysonge CS, Katsande R, O'Connor PM, Lebo E, Perry RT.Vaccines (Basel). 2024 Aug 22;12(8):949. doi: 10.3390/vaccines12080949.PMID: 39204072

Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases.

Teles MS, Brundage J, Chiang TP, Alejo JL, Henriquez N, Wallwork R, Christopher-Stine L, Massie A, Segev DL, Connolly CM, Paik JJ, Werbel WA.J Rheumatol. 2024 Sep 1;51(9):928-933. doi: 10.3899/jrheum.2023-1212.PMID: 38950954

Visceral Adiposity and Neutralizing Antibody Expression: An Adult-Based Cross-Sectional Study.

Wang H, Xiao D, Zhou H, Chen S, Xiao G, Hu J, Quan H, Luo M, Zhang S.J Inflamm Res. 2024 Aug 26;17:5633-5643. doi: 10.2147/JIR.S477526. eCollection 2024.PMID: 39219813

Ethical issues in Nipah virus control and research: addressing a neglected disease.

Johnson T, Jamrozik E, Hurst T, Cheah PY, Parker MJ.J Med Ethics. 2024 Aug 21;50(9):612-617. doi: 10.1136/jme-2023-109469.PMID: 38071589

Genome sequencing of canine distemper virus isolates from unvaccinated dogs in Mongolia.

Munkhtsetseg A, Batmagnai E, Odonchimeg M, Ganbat G, Enkhmandakh Y, Ariunbold G, Dolgorsuren T, Odbileg R, Dulam P, Tuvshintulga B, Sugimoto C, Sakoda Y, Yamagishi J, Erdenechimeg D.Vet J. 2024 Aug 28;308:106231. doi: 10.1016/j.tvjl.2024.106231. Online ahead of print.PMID: 39209147

Investigating the Immune-Stimulating Potential of β-Glucan from *Aureobasidium pullulans* in Cancer Immunotherapy.

Jeong JH, Kim DJ, Hong SJ, Ahn JH, Lee DJ, Jang AR, Kim S, Cho HJ, Lee JY, Park JH, Kim YM, Ko HJ.Biomol Ther (Seoul). 2024 Sep 1;32(5):556-567. doi: 10.4062/biomolther.2024.047. Epub 2024 Aug 2.PMID: 39091181

Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.

Liu J, Cui Y, Cabral H, Tong A, Yue Q, Zhao L, Sun X, Mi P.ACS Nano. 2024 Aug 28. doi: 10.1021/acsnano.4c09053. Online ahead of print.PMID: 39196858

Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies.

Araujo AE, Bentler M, Perez Garmendia X, Kaleem A, Fabian C, Morgan M, Hacker UT, Büning H.Hum Gene Ther. 2024 Aug 28. doi: 10.1089/hum.2024.114. Online ahead of print.PMID: 39193633

Maternal Helminth Infection Causes Dysfunctional B Cell Development in Male Offspring.

Gibbs LC, Oviedo JM, Ondigo BN, Fairfax KC.J Immunol. 2024 Aug 26:ji2400158. doi: 10.4049/jimmunol.2400158. Online ahead of print.PMID: 39185897

Impact of equine herpesvirus-1 ORF15 (EUL45) on viral replication and neurovirulence.

Kasem S, Yu MHH, Alkhalefa N, Ata EB, Nayel M, Abdo W, Abdel-Moneim AS, Fukushi H.Vet Microbiol. 2024 Aug 22;298:110234. doi: 10.1016/j.vetmic.2024.110234. Online ahead of print.PMID: 39180797

IgT-mediated mucosal immunity and microbiota dynamics in snakehead (Channa argus) post Aeromonas veronii TH0426 and Aeromonas hydrophila TPS infection: implications for aquaculture disease management.

Liu YM, Li XT, Zhang CY, Li CH, Wang HY, Zhang DX, Zhang L, Sun WW, Tao LT, Shan XF.Int Microbiol. 2024 Aug 22. doi: 10.1007/s10123-024-00581-z. Online ahead of print.PMID: 39172273

Lessons Learned From Bhutan on extending Girls-Only HPV Vaccination Program to Boys: A Qualitative Study.

Yangchen S, Felsher M, Acosta D, Sukarom I, Wu L, Phuntsho S, Chozom T, Dawa T, Tobgay KL.Asia Pac J Public Health. 2024 Aug 21:10105395241273296. doi: 10.1177/10105395241273296. Online ahead of print.PMID: 39169479

Global Status Report for the Verification of Measles and Rubella Elimination, 2022.

O'Connor P, Masresha B, Pastor D, Musa N, Hagan J, Khanal S, Lee CW, Crowcroft N.Vaccines (Basel). 2024 Aug 22;12(8):947. doi: 10.3390/vaccines12080947.PMID: 39204070

Onward Virus Transmission after Measles Secondary Vaccination Failure.

Tranter I, Smoll N, Lau CL, Williams DL, Neucom D, Barnekow D, Dyda A.Emerg Infect Dis. 2024 Sep;30(9):1747-1754. doi: 10.3201/eid3009.240150.PMID: 39173667

Inhibition of falcilysin from Plasmodium falciparum by interference with its closed-to-open dynamic transition.

Lin J, Yan X, Chung Z, Liew CW, El Sahili A, Pechnikova EV, Preiser PR, Bozdech Z, Gao YG, Lescar J.Commun Biol. 2024 Aug 31;7(1):1070. doi: 10.1038/s42003-024-06774-6.PMID: 39217277

Genomic insight into the diversity of *Glaesserella parasuis* isolates from 19 countries.

Gong X, Cui Q, Zhang W, Shi Y, Zhang P, Zhang C, Hu G, Sahin O, Wang L, Shen Z, Fu M.mSphere. 2024 Aug 28:e0023124. doi: 10.1128/msphere.00231-24. Online ahead of print.PMID: 39194201

Bivalent Omicron BA.4/BA.5 BNT162b2 **Vaccine** in 6-Month- to <12-Year-Olds.

Sher LD, Boakye-Appiah JK, Hill S, Wasserman E, Xu X, Maldonado Y, Walter EB, Muñoz FM, Paulsen GC, Englund JA, Talaat KR, Barnett ED, Kamidani S, Senders S, Simões EAF, Belanger K, Parikh V, Ma H, Wang X, Lu C, Cooper D, Koury K, Anderson AS, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Gurtman A, Kitchin N, Sabharwal C.J Pediatric Infect Dis Soc. 2024 Aug 24;13(8):421-429. doi: 10.1093/jpids/piae062.PMID: 38860591

Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study.

Meslé MMI, Brown J, Mook P, Katz MA, Hagan J, Pastore R, Benka B, Redlberger-Fritz M, Bossuyt N, Stouten V, Vernemmen C, Constantinou E, Maly M, Kynčl J, Sanca O, Krause TG, Vestergaard LS, Leino T, Poukka E, Gkolfinopoulou K, Mellou K, Tsintziloni M, Molnár Z, Aspelund G, Thordardottir M, Domegan L, Kelly E, O'Donell J, Urdiales AM, Riccardo F, Sacco C, Bumšteinas V, Liausediene R, Mossong J, Vergison A, Borg ML, Melillo T, Kocinski D, Pollozhani E, Meijerink H, Costa D, Gomes JP, Leite PP, Druc A, Gutu V, Mita V, Lazar M, Popescu R, Popovici O, Musilová M, Mrzel M, Socan M, Učakar V, Limia A, Mazagatos C, Olmedo C, Dabrera G, Kall M, Sinnathamby M, McGowan G, McMenamin J, Morrison K, Nitzan D, Widdowson MA, Smallwood C, Pebody R; WHO European Respiratory Surveillance Network.Lancet Respir Med. 2024 Sep;12(9):714-727. doi: 10.1016/S2213-2600(24)00179-6. Epub 2024 Aug 7.PMID: 39127051

Unraveling spontaneous humoral immune responses against human cancer: A road to novel immunotherapies.

Conejo-Garcia JR, Lopez-Bailon LU, Anadon CM.J Leukoc Biol. 2024 Aug 27:qiae179. doi: 10.1093/jleuko/qiae179. Online ahead of print.PMID: 39190797

The inhibitory effect of swine TAB1 on the replication of pseudorabies virus.

Xia X, Wu X, Jiang D, Hu Y, Cong X, Li J, Dai M, Du Y, Qi J.Vet Microbiol. 2024 Sep;296:110172. doi: 10.1016/j.vetmic.2024.110172. Epub 2024 Jul 2.PMID: 38971118

Restriction & evasion: a review of IFNγ-mediated cell-autonomous defense pathways during genital Chlamydia infection.

Reitano JR, Coers J.Pathog Dis. 2024 Aug 29:ftae019. doi: 10.1093/femspd/ftae019. Online ahead of print.PMID: 39210512

Precision Nanovaccines for Potent Vaccination.

Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z, Liu L, Chen Y.JACS Au. 2024 Jul 31;4(8):2792-2810. doi: 10.1021/jacsau.4c00568. eCollection 2024 Aug 26.PMID: 39211600

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists.

Ding D, Gao R, Lei Y, Liu J, Zhou C, Wen Y, Zhou S, Guo J, Li T.Eur J Med Chem. 2024 Aug 26;278:116792. doi: 10.1016/j.ejmech.2024.116792. Online ahead of print.PMID: 39217861

Identification and characterization of new Siberian subtype of tick-borne encephalitis virus isolates revealed genetic variations of the Chinese strains.

Bai Y, Xiao J, Moming A, Fu J, Wang J, Zhou M, Chen C, Shi J, Zhang J, Fan Z, Tang S, Wang B, Deng F, Shen S.Infect Genet Evol. 2024 Aug 22;124:105660. doi: 10.1016/j.meegid.2024.105660. Online ahead of print.PMID: 39179014

A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites.

Angage D, Chmielewski J, Maddumage JC, Hesping E, Caiazzo S, Lai KH, Yeoh LM, Menassa J, Opi DH, Cairns C, Puthalakath H, Beeson JG, Kvansakul M, Boddey JA, Wilson DW, Anders RF, Foley M.Nat Commun. 2024 Aug 22;15(1):7206. doi: 10.1038/s41467-024-50770-7.PMID: 39174515

Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.

Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA, Chen Y, van Schooten J, Eudailey J, Isaac J, Memon S, Weinbaum C, Gao H, Stanfield-Oakley S, Byrd A, Chutkan S, Berendam S, Cronin K, Yasmeen A, Alam S, LaBranche CC, Rogers K, Shirreff L, Cupo A, Derking R, Villinger F, Klasse PJ, Ferrari G, Williams WB, Hudgens MG, Ward AB, Montefiori DC, Van Rompay KKA, Wiehe K, Moore JP, Sanders RW, De Paris K, Permar SR.Sci Immunol. 2024 Aug 30;9(98):eadm7097. doi: 10.1126/sciimmunol.adm7097. Epub 2024 Aug 30.PMID: 39213340

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.

Caniels TG, Medina-Ramìrez M, Zhang S, Kratochvil S, Xian Y, Koo JH, Derking R, Samsel J, van Schooten J, Pecetta S, Lamperti E, Yuan M, Carrasco MR, Del Moral Sánchez I, Allen JD, Bouhuijs JH, Yasmeen A, Ketas TJ, Snitselaar JL, Bijl TPL, Martin IC, Torres JL, Cupo A, Shirreff L, Rogers K, Mason RD, Roederer M, Greene KM, Gao H, Silva CM, Baken IJL, Tian M, Alt FW, Pulendran B, Seaman MS, Crispin M, van Gils MJ,

Montefiori DC, McDermott AB, Villinger FJ, Koup RA, Moore JP, Klasse PJ, Ozorowski G, Batista FD, Wilson IA, Ward AB, Sanders RW.Sci Immunol. 2024 Aug 30;9(98):eadk9550. doi: 10.1126/sciimmunol.adk9550. Epub 2024 Aug 30.PMID: 39213338

Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: From viral life cycle to **vaccine** development.

El-Maradny YA, Badawy MA, Mohamed KI, Ragab RF, Moharm HM, Abdallah NA, Elgammal EM, Rubio-Casillas A, Uversky VN, Redwan EM.Int J Biol Macromol. 2024 Aug 29:135201. doi: 10.1016/j.ijbiomac.2024.135201. Online ahead of print.PMID: 39216563

Modeling and analysis of a human papilloma virus transmission model with impact of media.

Liu H, Lin X, Zhu X, Zhang Q, Wei Y, Ma G.Math Biosci. 2024 Sep;375:109247. doi: 10.1016/j.mbs.2024.109247. Epub 2024 Jul 3.PMID: 38969058

Enhancement of HPV therapeutic peptide-based **vaccine** efficacy through combination therapies and improved delivery strategies: A review.

Liu R, He X, Bao W, Li Z.Hum Vaccin Immunother. 2024 Dec 31;20(1):2396710. doi: 10.1080/21645515.2024.2396710. Epub 2024 Aug 28.PMID: 39193781

Narratives, Information and Manifestations of Resistance to Persuasion in Online Discussions of HPV Vaccination.

Semino E, Coltman-Patel T, Dance W, Deignan A, Demjén Z, Hardaker C, Mackey A.Health Commun. 2024 Sep;39(10):2123-2134. doi: 10.1080/10410236.2023.2257428. Epub 2023 Sep 21.PMID: 37733392

Pertussis vaccination in adults in France: Overview and suggestions for improvement.

Blanchard E, Chavade D, de Wazières B, Bakhache P, Fumet T, Guiso N.Infect Dis Now. 2024 Sep;54(6):104961. doi: 10.1016/j.idnow.2024.104961. Epub 2024 Aug 2.PMID: 39098758

Coverage and determinants of COVID-19 child vaccination in Munich, Germany in October 2022-January 2023: Results of the COVIP-Virenwächter study.

van de Berg S, Coyer L, von Both U, Scheuerer T, Kolberg L, Hoch M, Böhmer MM.Eur J Pediatr. 2024 Sep;183(9):3727-3738. doi: 10.1007/s00431-024-05617-0. Epub 2024 Jun 8.PMID: 38850330

Relative Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza **Vaccine** in Older Adults with Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial.

Christensen J, Johansen ND, Modin D, Janstrup KH, Nealon J, Samson SI, Loiacono MM, Harris R, Larsen CS, Jensen AMR, Landler NE, Claggett BL, Solomon SD, Gislason GH, Køber L, Landray MJ, Sivapalan P, Jensen JUS, Biering-Sørensen T.Circ Cardiovasc Qual Outcomes. 2024 Aug 31. doi: 10.1161/CIRCOUTCOMES.124.011496. Online ahead of print.PMID: 39215646

Large Language Models Can Enable Inductive Thematic Analysis of a Social Media Corpus in a Single Prompt: Human Validation Study.

Deiner MS, Honcharov V, Li J, Mackey TK, Porco TC, Sarkar U.JMIR Infodemiology. 2024 Aug 29;4:e59641. doi: 10.2196/59641.PMID: 39207842

Comparative analysis of COVID-19 diagnoses and mortality among hospitalized indigenous and non-indigenous populations in Chile: 2020-2021.

Dahal S, Delgado I, Sattenspiel L, Mamelund SE, Chowell G.BMC Public Health. 2024 Aug 28;24(1):2337. doi: 10.1186/s12889-024-19756-4.PMID: 39198791

Adenovirus infections: new insights for the clinical laboratory.

Kajon AE.J Clin Microbiol. 2024 Aug 27:e0083622. doi: 10.1128/jcm.00836-22. Online ahead of print.PMID: 39189703

The impact of N-glycans on the immune response of plant-produced SARS-CoV-2 RBD-Fc proteins.

Srisangsung T, Phetphoung T, Manopwisedjaroen S, Rattanapisit K, Bulaon CJI, Thitithanyanont A, Limprasutr V, Strasser R, Phoolcharoen W.Biotechnol Rep (Amst). 2024 Jun 20;43:e00847. doi: 10.1016/j.btre.2024.e00847. eCollection 2024 Sep.PMID: 39040987

Aloperine Inhibits ASFV via Regulating PRLR/JAK2 Signaling Pathway In Vitro.

Geng R, Shao H, Qian K, Chen H, Qin A.Int J Mol Sci. 2024 Aug 21;25(16):9083. doi: 10.3390/ijms25169083.PMID: 39201769

Generation and evaluation of Salmonella entericaserovar Choleraesuis mutant strains as a potential live-attenuated **vaccine**.

Huang X, Yang S, Zhao J, Yang J, Jiang H, Li S, Wang C, Liu G.Vaccine. 2024 Aug 27;42(24):126262. doi: 10.1016/j.vaccine.2024.126262. Online ahead of print.PMID: 39197218

Fighting Fire or Fighting War: Examining the Framing Effects of COVID-19 Metaphors.

Tao R, Kim SJ, Lu L, Kang J, McLeod D.Health Commun. 2024 Sep;39(10):2026-2040. doi: 10.1080/10410236.2023.2253398. Epub 2023 Sep 3.PMID: 37661328

Fostering Trust in Public Health Messaging: Tailoring Communication for Rural Parents.

Passmore SR, Henning E, Margalit Cotter L, Bhattar M, Yang S, Latham E, Schultz D, Jones M.Am J Health Promot. 2024 Aug 30:8901171241278886. doi: 10.1177/08901171241278886. Online ahead of print.PMID: 39212087

Identification of two novel B-cell epitopes located on the spike protein of swine acute diarrhea syndrome coronavirus.

Zhang L, Yang X, Shi H, Zhang J, Feng T, Liu D, Zhang X, Chen J, Shi D, Feng L.Int J Biol Macromol. 2024 Aug 23;278(Pt 4):135049. doi: 10.1016/j.ijbiomac.2024.135049. Online ahead of print.PMID: 39182883

Comprehensive review of Argulus infestations in aquaculture: Biological impacts and advanced management strategies.

Haridevamuthu B, Raj D, Arshad A, Arockiaraj J.Fish Shellfish Immunol. 2024 Aug 21;153:109851. doi: 10.1016/j.fsi.2024.109851. Online ahead of print.PMID: 39173980

Rapid and one-tube detection of human metapneumovirus using the RT-RPA and CRISPR/Cas12a.

Du Y, Liu X, Gao H, Liu X, Huang M, Chai Q, Xing Z, Zhang T, Ma D.J Virol Methods. 2024 Sep;329:115001. doi: 10.1016/j.jviromet.2024.115001. Epub 2024 Jul 20.PMID: 39038660

Dengue virus: pathogenesis and potential for small molecule inhibitors.

Chauhan N, Gaur KK, Asuru TR, Guchhait P.Biosci Rep. 2024 Aug 28;44(8):BSR20240134. doi: 10.1042/BSR20240134.PMID: 39051974

Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses.

Paciello I, Pierleoni G, Pantano E, Antonelli G, Pileri P, Maccari G, Cardamone D, Realini G, Perrone F, Neto MM, Pozzessere S, Fabbiani M, Panza F, Rancan I, Tumbarello M, Montagnani F, Medini D, Maes P, Temperton N, Simon-Loriere E, Schwartz O, Rappuoli R, Andreano E.Cell Rep. 2024 Aug 27;43(9):114645. doi: 10.1016/j.celrep.2024.114645. Online ahead of print.PMID: 39207904

Genomic analysis of two penicillin- and rifampin-resistant Corynebacterium rouxii strains isolated from cutaneous infections in dogs.

Araújo MRB, Prates FD, Viana MVC, Santos LS, Mattos-Guaraldi AL, Camargo CH, Sacchi CT, Campos KR, Vieira VV, Santos MBN, Bokermann S, Ramos JN, Azevedo V.Res Vet Sci. 2024 Aug 26;179:105396. doi: 10.1016/j.rvsc.2024.105396. Online ahead of print.PMID: 39213744

Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies.

Semenzato L, Le Vu S, Botton J, Bertrand M, Jabagi MJ, Drouin J, Cuenot F, Zores F, Dray-Spira R, Weill A, Zureik M.JAMA. 2024 Aug 26:e2416380. doi: 10.1001/jama.2024.16380. Online ahead of print.PMID: 39186694

Quantification of the time-varying epidemic growth rate and of the delays between symptom onset and presenting to healthcare for the mpox epidemic in the UK in 2022.

Hinch R, Panovska-Griffiths J, Ward T, Charlett A, Watkins N, Fraser C.Sci Rep. 2024 Aug 26;14(1):19755. doi: 10.1038/s41598-024-68154-8.PMID: 39187529

The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma.

Nakayama I, Shitara K.Expert Opin Biol Ther. 2024 Aug 28:1-13. doi: 10.1080/14712598.2024.2395921. Online ahead of print.PMID: 39171531

Management of the vaccination campaign in a population of frail older outpatients affected by cognitive or endocrinological conditions: a pilot study in Italy.

Veronese N, Ragusa FS, Titone PR, Vernuccio L, Catanese G, Randazzo MA, Palermo M, Di Bella G, Mansueto P, Dominguez LJ, Barbagallo M.Aging Clin Exp Res. 2024 Aug 30;36(1):179. doi: 10.1007/s40520-024-02824-5.PMID: 39212773

Lung-resident CD3-NK1.1+CD69+CD103+ Cells Play an Important Role in Bacillus Calmette-Guerin **Vaccine**-Induced Protective Immunity against Mycobacterium tuberculosis Infection.

Durojaye O, Vankayalapati A, Paidipally P, Mukherjee T, Vankayalapati R, Radhakrishnan RK.J Immunol. 2024 Sep 1;213(5):669-677. doi: 10.4049/jimmunol.2200728.PMID: 39007739

Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.

Shi Q, Wang Q, Shen Y, Chen S, Gan S, Lin T, Song F, Ma Y.Mol Immunol. 2024 Sep;173:10-19. doi: 10.1016/j.molimm.2024.07.001. Epub 2024 Jul 14.PMID: 39004021

Infectious Diseases Among People Experiencing Homelessness: A Systematic Review of the Literature in the United States and Canada, 2003-2022.

Waddell CJ, Saldana CS, Schoonveld MM, Meehan AA, Lin CK, Butler JC, Mosites E.Public Health Rep. 2024 Sep-Oct;139(5):532-548. doi: 10.1177/00333549241228525. Epub 2024 Feb 20.PMID: 38379269

The socioeconomic impacts of Rift Valley fever: A rapid review.

O'Neill L, Gubbins S, Reynolds C, Limon G, Giorgakoudi K.PLoS Negl Trop Dis. 2024 Aug 29;18(8):e0012347. doi: 10.1371/journal.pntd.0012347. eCollection 2024 Aug.PMID: 39207938

A SARS-CoV-2 peptide antigen purified from bacteria and displayed in a high-density repetitive manner on a virus-like particle could generate anti-SARS-CoV-2 neutralizing antibodies unlike free peptide.

Begum F, Chandra S, Mallik MH, Dey J, Tripathi PP, Ray U.Biochem Biophys Res Commun. 2024 Aug 22;739:150579. doi: 10.1016/j.bbrc.2024.150579. Online ahead of print.PMID: 39205338

A Missed Opportunity: Evaluating Immunization Status and Barriers in Hospitalized Children.

Lissinna B, Gilbert C, Isaac C, Mian Q, MacDonald SE, Forbes KL.Hosp Pediatr. 2024 Sep 1;14(9):714-721. doi: 10.1542/hpeds.2024-007728.PMID: 39099437

Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.

Gandhi M, Sharma B, Nair S, Vaidya ADB.Pharm Res. 2024 Aug 26. doi: 10.1007/s11095-024-03761-8. Online ahead of print.PMID: 39187686

Modulating Elasticity of Liposome for Enhanced Cancer Immunotherapy.

Yuan P, Yan X, Zong X, Li X, Yang C, Chen X, Li Y, Wen Y, Zhu T, Xue W, Dai J.ACS Nano. 2024 Aug 27;18(34):23797-23811. doi: 10.1021/acsnano.4c09094. Epub 2024 Aug 14.PMID: 39140567

Self-enhanced regulation of stable organic radicals with polypeptide nanoparticles for mild second near-infrared phototheranostics.

Xu Y, Teng C, Wang Y, Chen D, Yin D, Yan L.J Colloid Interface Sci. 2024 Sep;669:578-589. doi: 10.1016/j.jcis.2024.05.032. Epub 2024 May 7.PMID: 38729006

Barriers to Childhood Immunization in Rural and Remote Areas: A Qualitative Exploration From the Perspectives of Community Leaders in Sindh, Pakistan.

Sahitia S, Idris IB, Safian N, Ali RF, Shamsuddin K, Hod R.Qual Health Res. 2024 Aug 27:10497323241263279. doi: 10.1177/10497323241263279. Online ahead of print.PMID: 39189685

Molecular and phylogenetic analysis of transmissible gastroenteritis virus strain VET-16, isolated from piglets in Vietnam.

Moon SH, Park GN, Choe S, Song S, Le VP, Cho YS, An DJ.Arch Virol. 2024 Aug 21;169(9):183. doi: 10.1007/s00705-024-06101-8.PMID: 39164596

Oral immunization against foot-and-mouth disease virus using recombinant Saccharomyces cerevisiae with the improved expression of the codon-optimized VP1 fusion protein.

Le NMT, So KK, Kim DH.Vet Microbiol. 2024 Sep;296:110192. doi: 10.1016/j.vetmic.2024.110192. Epub 2024 Jul 18.PMID: 39032444

Near Real-Time Syndromic Surveillance of Emergency Department Triage Texts Using Natural Language Processing: Case Study in Febrile Convulsion Detection.

Khademi S, Palmer C, Javed M, Dimaguila GL, Clothier H, Buttery J, Black J.JMIR AI. 2024 Aug 30;3:e54449. doi: 10.2196/54449.PMID: 39213519

Factors affecting the antimicrobial changes during treatment for acute otitis media in Japan: A retrospective cohort study using classification and regression trees (CART) analysis.

Kono M, Murakami D, Sakatani H, Okuda K, Kinoshita T, Hijiya M, Iyo T, Shiga T, Morita Y, Itahashi K, Sasagawa Y, Iwama Y, Yamaguchi T, Hotomi M.J Infect Chemother. 2024 Sep;30(9):832-837. doi: 10.1016/j.jiac.2024.02.022. Epub 2024 Feb 27.PMID: 38417479

TLR3/TRIF and MAVS Signaling Is Essential in Regulating Mucosal T Cell Responses during Rotavirus Infection.

Zhang RR, Yang XY, Yang YL, Guo TK, Huang JS, Yang YS, Shi CW, Yang GL, Huang HB, Wang JZ, Jiang YL, Cao X, Wang N, Zeng Y, Yang WT, Wang CF.J Immunol. 2024 Aug 28:ji2300867. doi: 10.4049/jimmunol.2300867. Online ahead of print.PMID: 39194407

Virological characterization of Hepatitis B virus infection in Morocco: A ten-years study (2014 - 2023).

Madihi S, Charoute H, Boukaira S, Bouafi H, Baha W, Zyad A, Benani A.Diagn Microbiol Infect Dis. 2024 Aug 22;110(4):116502. doi: 10.1016/j.diagmicrobio.2024.116502. Online ahead of print.PMID: 39191154

From discovery to treatment: tracing the path of hepatitis E virus.

Letafati A, Taghiabadi Z, Roushanzamir M, Memarpour B, Seyedi S, Farahani AV, Norouzi M, Karamian S, Zebardast A, Mehrabinia M, Ardekani OS, Fallah T, Khazry F, Daneshvar SF, Norouzi M.Virol J. 2024 Aug 23;21(1):194. doi: 10.1186/s12985-024-02470-3.PMID: 39180020

Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment.

Wang Z, Miao F, Gu L, Zhang R, Ma Y, Li Y, Zheng J, Lin Z, Gao Y, Huang L, Shen Y, Wu T, Luo F, Li W.ACS Nano. 2024 Aug 22. doi: 10.1021/acsnano.4c05657. Online ahead of print.PMID: 39172516

A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology.

Lieberman JA, Chu DK, Ahmed T, Dribin TE, Abrams EM, Anagnostou A, Blumenthal KG, Boguniewicz M, Chase NM, Golden DBK, Hartog NL, Heimall JR, Ho T, Lawrence MG, Khan DA, Minniear TD, Mustafa SS, Oppenheimer JJ, Phillips EJ, Ramsey A, Rider NL, Schneider L, Shaker MS, Spergel JM, Stone CA Jr, Stukus DR, Wang J, Greenhawt MJ.Ann Allergy Asthma Immunol. 2024 Sep;133(3):286-294. doi: 10.1016/j.anai.2024.05.014. Epub 2024 Jun 5.PMID: 38848870

Vaccination of teenagers in France over a 10-year period (2012-2021).

Gaudelus J, Cohen R, Stahl JP, Denigot M, Gelin P, Gruber A, Mediouni L, Martinot A.Infect Dis Now. 2024 Sep;54(6):104952. doi: 10.1016/j.idnow.2024.104952. Epub 2024 Jun 29.PMID: 38950884

The Unique Immune Evasion Mechanisms of the Mpox Virus and Their Implication for Developing New Vaccines and Immunotherapies.

Fang D, Liu Y, Dou D, Su B.Virol Sin. 2024 Aug 22:S1995-820X(24)00135-4. doi: 10.1016/j.virs.2024.08.008. Online ahead of print.PMID: 39181538

Mycobacterium bovis BCG reverses deleterious effects of H. pylori components towards gastric barrier cells in vitro.

Gonciarz W, Płoszaj P, Chmiela M.Biomed Pharmacother. 2024 Sep;178:117193. doi: 10.1016/j.biopha.2024.117193. Epub 2024 Jul 26.PMID: 39067167

Epidemiologic, clinicopathologic, and diagnostic findings in pet rabbits with myxomatosis caused by the California MSW strain of myxoma virus: 11 cases (2022-2023).

Stern HS, Biswell E, Kiupel M, Ossiboff RJ, Brust K.J Am Vet Med Assoc. 2024 May 24;262(9):1-11. doi: 10.2460/javma.24.02.0139. Print 2024 Sep 1.PMID: 38788762

New-onset of rheumatic diseases following COVID-19 vaccination: the report of three cases and a literature review.

Matsuda M, Funakubo Asanuma Y, Emoto K, Sakai S, Okumura N, Yazawa H, Maruyama T, Tsuzuki Wada T, Yokota K, Araki Y, Akiyama Y, Mimura T.Immunol Med. 2024 Sep;47(3):205-216. doi: 10.1080/25785826.2024.2339542. Epub 2024 Apr 16.PMID: 38627989

Lichen planus after COVID-19 infection and vaccination.

Saleh W, Alharbi H, Yue S, Fernandes RP.Oral Dis. 2024 Sep;30(6):3925-3930. doi: 10.1111/odi.14834. Epub 2023 Dec 8.PMID: 38069546

Human Papillomavirus Vaccination Coverage Among Adolescent Girls Aged 13-17 Years - U.S.-Affiliated Pacific Islands, 2013-2023.

Tippins A, Mutamba G, Boyd EM, Coy KC, Kriss JL.MMWR Morb Mortal Wkly Rep. 2024 Aug 22;73(33):715-721. doi: 10.15585/mmwr.mm7333a2.PMID: 39173143

Comparative pathogenicity and histopathological analysis of Edwardsiella anguillarum intraperitoneal infection in milkfish (Chanos chanos), Nile tilapia (Oreochromis niloticus) and Asian seabass (Lates calcarifer).

Rahmawaty A, Cheng LW, Wang PC, Chen SC.J Fish Dis. 2024 Sep;47(9):e13982. doi: 10.1111/jfd.13982. Epub 2024 Jun 20.PMID: 38899543

Assessment of the antileishmanial activity of diallyl sulfide combined with meglumine antimoniate on Leishmania major: Molecular docking, in vitro, and animal model.

Zarrinkar F, Sharifi I, Salarkia E, Keyhani A, Babaei Z, Khamesipour A, Hakimi Parizi M, Molaakbari E, Sharifi F, Dabiri S, Bamorovat M.PLoS One. 2024 Aug 30;19(8):e0307537. doi: 10.1371/journal.pone.0307537. eCollection 2024.PMID: 39213335

Recent Advances in Immunotherapy for Breast Cancer: A Review.

Wen QE, Li L, Feng RQ, Li DH, Qiao C, Xu XS, Zhang YJ.Breast Cancer (Dove Med Press). 2024 Aug 27;16:497-516. doi: 10.2147/BCTT.S482504. eCollection 2024.PMID: 39220564

An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection.

Liu T, He Q, Yang X, Li Y, Yuan D, Lu Q, Tang T, Guan G, Zheng L, Zhang H, Xia C, Yin X, Wei G, Chen X, Lu F, Wang L.Gastroenterology. 2024 Sep;167(4):750-763.e10. doi: 10.1053/j.gastro.2024.03.038. Epub 2024 Apr 5.PMID: 38582270

Marine sponge microbe provides insights into evolution and virulence of the tubercle bacillus.

Pidot SJ, Klatt S, Ates LS, Frigui W, Sayes F, Majlessi L, Izumi H, Monk IR, Porter JL, Bennett-Wood V, Seemann T, Otter A, Taiaroa G, Cook GM, West N, Tobias NJ, Fuerst JA, Stutz MD, Pellegrini M, McConville M, Brosch R, Stinear TP.PLoS Pathog. 2024 Aug 29;20(8):e1012440. doi: 10.1371/journal.ppat.1012440. eCollection 2024 Aug.PMID: 39207937

Association of COVID-19 vaccination and anxiety symptoms: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort longitudinal study.

Virgili-Gervais G, Henry RS, Kwakkenbos L, Carrier ME, Patten S, Bartlett SJ, Mouthon L, Varga J, Benedetti A, Thombs BD; SPIN COVID-19 Patient Advisory Team; SPIN Investigators.J Psychosom Res. 2024 Sep;184:111852. doi: 10.1016/j.jpsychores.2024.111852. Epub 2024 Jun 23.PMID: 38936011

Role of Influenza Vaccination in Cardiovascular Disease: Systematic Review and Meta-Analysis.

Gupta R, Quy R, Lin M, Mahajan P, Malik A, Sood A, Sreenivasan J, Bandyopadhyay D, Goel A, Agrawal A, Vyas AV, Patel NC, Frishman WH, Aronow WS.Cardiol Rev. 2024 Sep-Oct 01;32(5):423-428. doi: 10.1097/CRD.0000000000000533. Epub 2023 May 9.PMID: 37158999

CD4⁺ T cells exhibit distinct transcriptional phenotypes in the lymph nodes and blood following mRNA vaccination in humans.

Borcherding N, Kim W, Quinn M, Han F, Zhou JQ, Sturtz AJ, Schmitz AJ, Lei T, Schattgen SA, Klebert MK, Suessen T, Middleton WD, Goss CW, Liu C, Crawford JC, Thomas PG, Teefey SA, Presti RM, O'Halloran JA, Turner JS, Ellebedy AH, Mudd PA.Nat Immunol. 2024 Sep;25(9):1731-1741. doi: 10.1038/s41590-024-01888-9. Epub 2024 Aug 20.PMID: 39164479

Influenza virus antibodies inhibit antigen-specific *de novo* B cell responses in mice.

Goodwin E, Gibbs JS, Yewdell JW, Eisenlohr LC, Hensley SE.J Virol. 2024 Aug 28:e0076624. doi: 10.1128/jvi.00766-24. Online ahead of print.PMID: 39194245

Respiratory Viral Infections from 2015 to 2022 in the HIVE Cohort of American Households: Incidence, illness characteristics, and seasonality.

Monto AS, Foster-Tucker JE, Callear AP, Leis AM, Godonou ET, Smith M, Truscon R, Johnson E, Thomas LJ, Thompson MS, Fry AM, Flannery B, Malosh RE, Petrie JG, Lauring AS, Martin ET.J Infect Dis. 2024 Aug 24:jiae423. doi: 10.1093/infdis/jiae423. Online ahead of print.PMID: 39179953

Current status of the small molecule anti-HIV drugs in the pipeline or recently approved.

Umumararungu T, Nyandwi JB, Katandula J, Twizeyimana E, Claude Tomani J, Gahamanyi N, Ishimwe N, Olawode EO, Habarurema G, Mpenda M, Uyisenga JP, Saeed SI.Bioorg Med Chem. 2024 Sep 1;111:117860. doi: 10.1016/j.bmc.2024.117860. Epub 2024 Jul 29.PMID: 39094527

Effects of the timing of maternal SARS-CoV-2 infection and vaccination status on placental transfer of antibodies to neonates: A cross-sectional study.

Zhang D, Liu S, Peng B, Shi X, Weng T, Fang D, Lu L, Meng X, Xiong H, Zhang X, Qu J, Zhong J, Wang P.Int J Infect Dis. 2024 Sep;146:107098. doi: 10.1016/j.ijid.2024.107098. Epub 2024 May 16.PMID: 38762044

The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.

Papp H, Tóth E, Bóvári-Biri J, Bánfai K, Juhász P, Mahdi M, Russo LC, Bajusz D, Sipos A, Petri L, Szalai TV, Kemény Á, Madai M, Kuczmog A, Batta G, Mózner O, Vaskó D, Hirsch E, Bohus P, Méhes G, Tőzsér J, Curtin NJ, Helyes Z, Tóth A, Hoch NC, Jakab F, Keserű GM, Pongrácz JE, Bai P.Br J Pharmacol. 2024 Aug 27. doi: 10.1111/bph.17305. Online ahead of print.PMID: 39191429

Evaluation of the prophylactic effect of egg yolk antibody (IgY) produced against the recombinant protein containing IpaD, IpaB, StxB, and VirG proteins from Shigella.

Felegary A, Nazarian S, Zafarmand-Samarin M, Sadeghi D, Fathi J, Samiei-Abianeh H.Mol Immunol. 2024 Sep;173:53-60. doi: 10.1016/j.molimm.2024.07.002. Epub 2024 Jul 24.PMID: 39053389

COVID-19 Vaccination Uptake, Infection Rates, and Seropositivity Among Youth Experiencing Homelessness in the United States.

Santa Maria DM, Padhye N, Ostrosky-Zeichner L, Grimes CZ, Nyamathi A, Lightfoot M, Quadri Y, Paul ME, Jones JT.Nurs Res. 2024 Sep-Oct 01;73(5):373-380. doi: 10.1097/NNR.0000000000000747. Epub 2024 May 10.PMID: 38809559

Phylodynamics of high pathogenicity avian influenza virus in Bangladesh identifying domestic ducks as the amplifying host reservoir.

Islam A, Wille M, Rahman MZ, Porter AF, Hosaain ME, Hassan MM, Shirin T, Epstein JH, Klaassen M.Emerg Microbes Infect. 2024 Aug 29:2399268. doi: 10.1080/22221751.2024.2399268. Online ahead of print.PMID: 39207215

Geographical and temporal dynamics of genetic diversity of *Plasmodium falciparum* merozoite surface proteins 1/2 in India.

Kojom Foko LP, Jakhan J, Narang G, Singh V.J Parasit Dis. 2024 Sep;48(3):610-623. doi: 10.1007/s12639-024-01698-8. Epub 2024 Jun 28.PMID: 39145372

Inhibition of dengue virus infection in vitro by fucoidan and polysaccharide extract from marine alga Sargassum spp.

Panwong S, Phinyo K, Duangjan K, Sattayawat P, Pekkoh J, Tragoolpua Y, Yenchitsomanus PT, Panya A.Int J Biol Macromol. 2024 Sep;276(Pt 1):133496. doi: 10.1016/j.ijbiomac.2024.133496. Epub 2024 Jul 8.PMID: 38986999

Proteomic characterization of Tenacibaculum dicentrarchi under iron limitation reveals an upregulation of proteins related to iron oxidation and reduction metabolism, iron uptake systems and gliding motility.

Avendaño-Herrera R, Echeverría-Bugueño M, Hernández M, Saldivia P, Irgang R.J Fish Dis. 2024 Sep;47(9):e13984. doi: 10.1111/jfd.13984. Epub 2024 Jun 29.PMID: 38943549

Influence of the Olfatín Project on the reduction of pain related to intranasal influenza vaccination, as part of a school influenza vaccination program.

Molina-Salas Y, Romera-Guirado FJ, García-Rubio A, Pérez-Martín JJ, Zornoza-Moreno M; for FLUSCHOOLVAC Team.J Pediatr Nurs. 2024 Aug 27;79:52-58. doi: 10.1016/j.pedn.2024.08.022. Online ahead of print.PMID: 39197260

Cohort profile: follow-up of a household cohort throughout five epidemic waves of SARS-CoV-2 in Rio de Janeiro, Brazil.

Silva MFBD, Guaraldo L, Santos HFP, Bastos LS, Pina-Costa A, Penetra SLS, Moraes ICV, Calvet GA, Fuller TL, Silva PCR, Siqueira MAMT, Brasil P.Cad Saude Publica. 2024 Aug 26;40(7):e00152023. doi: 10.1590/0102-311XEN152023. eCollection 2024.PMID: 39194089

Exogenous Increases in Basic Income Provisions Increase Preventive Health-Seeking Behavior: A Quasi-Experimental Study.

Motta M, Haglin K.Am J Prev Med. 2024 Aug 21:S0749-3797(24)00291-5. doi: 10.1016/j.amepre.2024.08.012. Online ahead of print.PMID: 39179181

Tartrolon D induces immunogenic cell death in melanoma.

Brito TL, Edson EA, Dias Florêncio KG, Machado-Neto JA, Garnique ADMB, Mesquita Luiz JP, Cunha FQ, Alves-Filho JC, Haygood M, Wilke DV.Chem Biol Interact. 2024 Sep 1;400:111177. doi: 10.1016/j.cbi.2024.111177. Epub 2024 Aug 2.PMID: 39097071

Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.

Loubet P, Lelievre JD, François A, Botelho-Nevers E, Chidiac C, Chirio D, Dubee V, Dussol B, Galtier F, Hessamfar M, Hodaj E, Jaffuel S, Lacombe K, Laine F, Lefebvre M, Maakaroun-Vermesse Z, Makinson A, Portefaix A, Pourcher V, Rey D, Zucman D, Longobardi J, Bertheau M, Tartour E, de Lamballerie X, Launay O, Wittkop L; ANRS0001s COV-POPART study group.Int J Infect Dis. 2024 Sep;146:107110. doi: 10.1016/j.ijid.2024.107110. Epub 2024 May 31.PMID: 38825164

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.

Sevendal ATK, Hurley S, Bartlett AW, Rawlinson W, Walker GJ.Rev Med Virol. 2024 Sep;34(5):e2576. doi: 10.1002/rmv.2576.PMID: 39209729

Descriptions of Scientific Evidence and Uncertainty of Unproven COVID-19 Therapies in US News: Content Analysis Study.

Watson S, Benning TJ, Marcon AR, Zhu X, Caulfield T, Sharp RR, Master Z.JMIR Infodemiology. 2024 Aug 29;4:e51328. doi: 10.2196/51328.PMID: 39207825

Effectiveness of COVID-19 Vaccination against Severe Symptoms and Death Among Geriatric Inpatients: A Retrospective Cohort Study in Macao.

Zhang XZ, Wong PHH, Lai KS, Yang B, Song M, Li J, Ung COL.Vaccines (Basel). 2024 Aug 21;12(8):933. doi: 10.3390/vaccines12080933.PMID: 39204056

Characterization and treatment protocol of injuries inflicted to humans by synurbic European wild boars (Sus scrofa).

Pujol O, Nuño M, Minguell J, Selga J, Tomás J, Rodríguez D, Martínez X, Mentaberre G, López-Olvera JR.Eur J Trauma Emerg Surg. 2024 Aug 27. doi: 10.1007/s00068-024-02654-0. Online ahead of print.PMID: 39190058

Determinants of undervaccination of routine childhood immunization in Argentina: A cross-sectional study.

Melchinger H, Winters M, Christie S, Arias N, Lirman L, Abeyesekera S, Thomson A, Omer SB.Vaccine. 2024 Aug 24;42(23):126235. doi: 10.1016/j.vaccine.2024.126235. Online ahead of print.PMID: 39182313

Trusted Sources of Information and COVID-19 Vaccination Among Black Adults in Chicago.

Hirschtick JL, Walsh JL, DiFranceisco W, Jacobs J, Hunt B, Valencia J, Quinn K.Am J Health Promot. 2024 Sep;38(7):942-953. doi: 10.1177/08901171241240529. Epub 2024 Mar 22.PMID: 38516840

Impact of cultural diversity on COVID-19 vaccination hesitancy in kidney transplant recipients.

Frederick R, Ierino F, Lopez R, Goodman D.Nephrology (Carlton). 2024 Sep;29(9):600-606. doi: 10.1111/nep.14351. Epub 2024 Jul 9.PMID: 38981586

Evaluating the Accuracy of ChatGPT in Common Patient Questions Regarding HPV+ Oropharyngeal Carcinoma.

Bellamkonda N, Farlow JL, Haring CT, Sim MW, Seim NB, Cannon RB, Monroe MM, Agrawal A, Rocco JW, McCrary HC.Ann Otol Rhinol Laryngol. 2024 Sep;133(9):814-819. doi: 10.1177/00034894241259137. Epub 2024 Jul 29.PMID: 39075853

COVID-19 vaccination before or during pregnancy results in high, sustained maternal neutralizing activity to SARS-CoV-2 wild-type and Delta/Omicron variants of concern, particularly following a booster dose or infection.

Mahyuddin AP, Swa HLF, Weng R, Zhang J, Dhanaraj JP, Sesurajan BP, Rauff M, Dashraath P, Kanneganti A, Lee R, Wang LF, Young BE, Tambyah PA, Lye DC, Chai LYA, Yee S, Choolani M, Mattar CNZ.Int J Infect Dis. 2024 Sep;146:107121. doi: 10.1016/j.ijid.2024.107121. Epub 2024 May 31.PMID: 38823622

Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity.

Moon TJ, Ta HM, Bhalotia A, Paulsen KE, Hutchinson DW, Arkema GM, Choi AS, Haynie MG, Ogunnaike L, Dever M, Wang LL, Karathanasis E.J Immunother Cancer. 2024 Aug 28;12(8):e008977. doi: 10.1136/jitc-2024-008977.PMID: 39209454

Hypoxia-associated markers in the prognosis of oral canine melanoma.

Gola C, Maniscalco L, Iussich S, Morello E, Olimpo M, Martignani E, Accornero P, Giacobino D, Mazzone E, Modesto P, Varello K, Aresu L, De Maria R.Vet Pathol. 2024 Sep;61(5):721-731. doi: 10.1177/03009858241244853. Epub 2024 Apr 13.PMID: 38613423

Host WD repeat-containing protein 5 inhibits protein kinase R-mediated integrated stress response during measles virus infection.

BenDavid E, Yang C, Zhou Y, Pfaller CK, Samuel CE, Ma D.J Virol. 2024 Aug 28:e0102024. doi: 10.1128/jvi.01020-24. Online ahead of print.PMID: 39194235

Financing pandemic prevention, preparedness and response: lessons learned and perspectives for future.

Ndembi N, Dereje N, Nonvignon J, Aragaw M, Raji T, Fallah MP, Abdulaziz M, Djoudalbaye B, Aluso A, Boum Ii Y, Mwaba G, Shisana O, Ngongo N, Kaseya J.Global Health. 2024 Aug 21;20(1):65. doi: 10.1186/s12992-024-01066-4.PMID: 39169389

Isolation, characterization, and immunomodulatory effects of extracellular vesicles isolated from fish pathogenic Aeromonas hydrophila.

Dias MKHM, Jayathilaka EHTT, De Zoysa M.Fish Shellfish Immunol. 2024 Sep;152:109787. doi: 10.1016/j.fsi.2024.109787. Epub 2024 Jul 22.PMID: 39047924

Diagnostic features of autoimmune hepatitis in SARS-CoV-2-vaccinated vs. unvaccinated individuals.

Kuwano A, Nagasawa S, Koga Y, Tanaka K, Yada M, Masumoto A, Motomura K.Exp Ther Med. 2024 Jun 26;28(3):337. doi: 10.3892/etm.2024.12626. eCollection 2024 Sep.PMID: 39006455

Associations between obesity, a composite risk score for probable long COVID, and sleep problems in SARS-CoV-2 vaccinated individuals.

Xue P, Merikanto I, Delale EA, Bjelajac A, Yordanova J, Chan RNY, Korman M, Mota-Rolim SA, Landtblom AM, Matsui K, Reis C, Penzel T, Inoue Y, Nadorff MR, Holzinger B, Morin CM, Espie CA, Plazzi G, De Gennaro L, Chung F, Bjorvatn B, Wing YK, Dauvilliers Y, Partinen M, Benedict C.Int J Obes (Lond). 2024 Sep;48(9):1300-1306. doi: 10.1038/s41366-024-01556-w. Epub 2024 Jun 7.PMID: 38849462

Factors Associated with HPV Vaccination Among Middle-Aged Adults in the United States.

Gallagher TJ, Chwa J, Lin ME, Kokot NC.Otolaryngol Head Neck Surg. 2024 Aug 27. doi: 10.1002/ohn.952. Online ahead of print.PMID: 39189152

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms.

Zhang C, Li T, Hou S, Tang J, Wen R, Wang C, Yuan S, Li Z, Zhao W.PLoS Pathog. 2024 Aug 23;20(8):e1012479. doi: 10.1371/journal.ppat.1012479. Online ahead of print.PMID: 39178325

CD4⁺ and CD8⁺ T-cell multi-epitope chimeric protein associated with an MPLA adjuvant induce protective efficacy and long-term immunological memory for the immunoprophylaxis of American Tegumentary Leishmaniasis.

Moura DM, Carvalho AMRS, Brito RCF, Roatt BM, Lage DP, Martins VT, Cruz LDR, Medeiros FAC, Batista SD, Pinheiro GRG, da Costa Rocha MO, Coelho EAF, Duarte MC, Mendes TAO, Menezes-Souza D.Vaccine. 2024 Aug 30;42(21):126178. doi: 10.1016/j.vaccine.2024.126178. Epub 2024 Aug 2.PMID: 39096765

Rotavirus genotype dynamics in Pakistan: G9 and G12 emerging as dominant strains in vaccinated children (2019).

Sadiq A, Khan J, Basit A, Sardar N, Ajmal MN.Acta Trop. 2024 Sep;257:107300. doi: 10.1016/j.actatropica.2024.107300. Epub 2024 Jun 22.PMID: 38909724

Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review.

Melgarejo Segura MT, Yáñez Castillo Y, Lozano Lorca M, Morales Martínez A, Arrabal Polo MÁ, Arrabal Martín M.Urol Oncol. 2024 Sep;42(9):251-265. doi: 10.1016/j.urolonc.2024.03.013. Epub 2024 Apr 25.PMID: 38670818

Anxiety and Depression Among Pediatric Emergency Nurses and Physicians During the Coronavirus Disease 2019 Pandemic.

Gupta NK, Lo C, Shi J, MacDowell D, Malone J, Stanley R, Shihabuddin B.J Emerg Nurs. 2024 Sep;50(5):644-650.e1. doi: 10.1016/j.jen.2023.12.013. Epub 2024 Feb 13.PMID: 38349292

Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Policy Statement.

Committee on Infectious Diseases.Pediatrics. 2024 Aug 26:e2024068507. doi: 10.1542/peds.2024-068507. Online ahead of print.PMID: 39183669

Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.

Besbassi H, Elias G, Meysman P, Jansens H, Laukens K, Damme PV, Hens N, Beutels P, Ogunjimi B.Vaccine. 2024 Aug 30;42(21):126148. doi: 10.1016/j.vaccine.2024.07.049. Epub 2024 Jul 30.PMID: 39084154

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium.Int J Infect Dis. 2024 Sep;146:107161. doi: 10.1016/j.ijid.2024.107161. Epub 2024 Jul 9.PMID: 38992789

Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.

Sunar Yayla EN, Gezgin Yıldırım D, Adıgüzel Dündar H, Adrovic A, Akbörü EG, Aktay Ayaz N, Aliyev E, Avar Aydın PÖ, Aydın F, Baba Ö, Bağlan E, Bora Makay B, Bozkaya Yücel B, Çakan M, Çelikel E, Demir F, Demir S, Demirkan FG, Ekici Tekin Z, Esmeray Şenol P, Guliyeva V, Güngörer V, İşgüder R, Kalyoncu M, Karadağ ŞG, Kısaoğlu H, Kışla Ekinci RM, Kızıldağ Z, Kurt T, Özdel S, Özdemir Çiçek S, Öztürk K, Polat MC, Sezer M, Sönmez HE, Sözeri B, Şener S, Taşkın SN, Türkuçar S, Ünsal E, Yıldız Ç, Bakkaloğlu SA.Eur J Pediatr. 2024 Sep;183(9):3959-3968. doi: 10.1007/s00431-024-05654-9. Epub 2024 Jun 26.PMID: 38926187

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation.

Wan EYF, Wang B, Lee AL, Zhou J, Chui CSL, Lai FTT, Li X, Wong CKH, Hung IFN, Lau CS, Chan EWY, Wong ICK.Int J Infect Dis. 2024 Sep;146:107149. doi: 10.1016/j.ijid.2024.107149. Epub 2024 Jun 21.PMID: 38909928

Infectious risk profile and strategies for prevention and control of outbreaks in refugee, asylum seekers and migrant populations in EU/EEA countries: a systematic narrative review of evidence.

Bianchi FP, Fiacchini D, Frisicale EM, Gili R, Greco S, Guicciardi S, Riccò M, Zichichi S, Zotti N, Tafuri S.Ann Ig. 2024 Sep-Oct;36(5):549-568. doi: 10.7416/ai.2024.2610. Epub 2024 Mar 28.PMID: 38436078

Epidemiology Characteristics and Potential Cervical Cancer Screening Value of Vulvar Human Papillomavirus in Chinese Women: A Multicenter Cross-Sectional Study.

Li X, Xie H, Fu Y, Zhang X, Dong X, Ji Y, Lu W, Wang X.Arch Pathol Lab Med. 2024 Sep 1;148(9):1035-1040. doi: 10.5858/arpa.2023-0255-OA.PMID: 38059501

Long-term safety and effectiveness of mRNA-1273 **vaccine** in adults: COVE trial open-label and booster phases.

Baden LR, El Sahly HM, Essink B, Follmann D, Hachigian G, Strout C, Overcash JS, Doblecki-Lewis S, Whitaker JA, Anderson EJ, Neuzil K, Corey L, Priddy F, Tomassini JE, Brown M, Girard B, Stolman D, Urdaneta V, Wang X, Deng W, Zhou H, Dixit A, Das R, Miller JM; COVE Trial Consortium.Nat Commun. 2024 Aug 29;15(1):7469. doi: 10.1038/s41467-024-50376-z.PMID: 39209823

Examining the effects of voluntary avoidance behaviour and policy-mediated behaviour change on the dynamics of SARS-CoV-2: A mathematical model.

Brankston G, Fisman DN, Poljak Z, Tuite AR, Greer AL.Infect Dis Model. 2024 Apr 10;9(3):701-712. doi: 10.1016/j.idm.2024.04.001. eCollection 2024 Sep.PMID: 38646062

Association between Bacillus Calmette-Guérin (BCG) vaccination and inflammatory bowel disease: A two-stage sampling design within the Quebec Birth Cohort on Immunity and Health (CO·MMUNITY).

Fantodji C, Jantchou P, Benedetti A, Rousseau MC.Prev Med. 2024 Sep;186:108071. doi: 10.1016/j.ypmed.2024.108071. Epub 2024 Jul 17.PMID: 39029744

Telemedicine Utilization Among Residents With Alzheimer Disease and Related Dementia: Association With Nursing Home Characteristics.

Qin Q, Yang M, Veazie P, Temkin-Greener H, Conwell Y, Cai S.J Am Med Dir Assoc. 2024 Sep;25(9):105152. doi: 10.1016/j.jamda.2024.105152. Epub 2024 Jul 14.PMID: 39013475

A Comprehensive Analysis of COVID-19 Misinformation, Public Health Impacts, and Communication Strategies: Scoping Review.

Kisa S, Kisa A.J Med Internet Res. 2024 Aug 21;26:e56931. doi: 10.2196/56931.PMID: 39167790

Protected biofactors and antioxidants reduce the negative consequences of virus and cold challenge by modulating immunometabolism via changes in the interleukin-6 receptor signaling cascade in the liver.

Perry F, Johnson CN, Lahaye L, Santin E, Korver DR, Kogut MH, Arsenault RJ.Poult Sci. 2024 Sep;103(9):104044. doi: 10.1016/j.psj.2024.104044. Epub 2024 Jun 28.PMID: 39043025

Human papillomavirus prevalence among Australian men aged 18-35 years in 2015-2018 according to vaccination status and sexual preference.

Balgovind P, Aung E, Shilling H, Murray GL, Molano M, Garland SM, Fairley CK, Chen MY, Hocking JS, Ooi C, McNulty A, McCloskey J, McNamee K, Bateson D, Owen L, Tabrizi SN, Machalek DA.J Infect Dis. 2024 Aug 30:jiae412. doi: 10.1093/infdis/jiae412. Online ahead of print.PMID: 39213380

Racial inequalities in child vaccination and barriers to vaccination in Brazil among live births in 2017 and 2018: an analysis of a retrospective cohort of the first two years of life.

Boing AF, Boing AC, França AP, Moraes JC; ICV 2020 Group; Silva AID, Ramos AN Jr, França AP, Oliveira ANM, Boing AF, Domingues CMAS, Oliveira CS, Maciel ELN, Guibu IA, Mirabal IRB, Barbosa JC, Lima JC, Moraes JC, Luhm KR, Caetano KAA, Lima LHO, Antunes MBC, Teixeira MDG, Teixeira MDC, Borges

MFSO, Queiroz RCS, Gurgel RQ, Barata RB, Azevedo RNC, Oliveira SMDVL, Teles SA, Gama SGND, Mengue SS, Simões TC, Nascimento V, Araújo WN.Epidemiol Serv Saude. 2024 Aug 23;33(spe2):e20231216. doi: 10.1590/S2237-96222024v33e20231216.especial2.en. eCollection 2024.PMID: 39194084 English, Portuguese.

Evaluation of human antibodies from vaccinated volunteers for protection against *Yersinia pestis* infection.

Zhang L, Zheng B, Lu J, Wu H, Wu H, Zhang Q, Jiao L, Pan H, Zhou J.Microbiol Spectr. 2024 Aug 27:e0105424. doi: 10.1128/spectrum.01054-24. Online ahead of print.PMID: 39189763

Female patients with hepatitis B may exhibit a reduced risk of breast cancer: A review of NHANES data.

Han M, Zhao R, Lin S, Feng J, Yang S, Zhu W, Chen Y.Medicine (Baltimore). 2024 Aug 23;103(34):e39373. doi: 10.1097/MD.0000000000039373.PMID: 39183392

Early warning COVID-19 outbreak in long-term care facilities using wastewater surveillance: correlation, prediction, and interaction with clinical and serological statuses.

Pang X, Lee BE, Gao T, Rosychuk RJ, Immaraj L, Qiu JY, Wen J, Zelyas N, Howden K, Wallace J, Risling E, Little LA, Kim J, Wood H, Robinson A, Parkins M, Hubert CRJ, Frankowski K, Hrudey SE, Sikora C.Lancet Microbe. 2024 Aug 22:100894. doi: 10.1016/S2666-5247(24)00126-5. Online ahead of print.PMID: 39182502

Mycobacterium vaccae attenuates airway inflammation by inhibiting autophagy and activating PI3K/Akt signaling pathway in OVA-induced allergic airway inflammation mouse model.

Xiao H, Tang AZ, Xu ML, Chen HL, Wang F, Li CQ.Mol Immunol. 2024 Sep;173:30-39. doi: 10.1016/j.molimm.2024.07.006. Epub 2024 Jul 16.PMID: 39018745

Characteristics of Immunogenicity against SARS-CoV-2 in a Community-Based Model of Care during the Fourth Wave of COVID-19 Outbreak in Ho Chi Minh City.

Trinh THK, Tran TD, Pham DL, Nguyen VN, Vu QTT, Pham TD, Nguyen PH, Le MK, Truong DDK, Hoang VA, Huynh N, Ngo DQ, Vuong LN.Yonsei Med J. 2024 Sep;65(9):501-510. doi: 10.3349/ymj.2023.0567.PMID: 39193758

Influenza vaccination and COVID-19 infection risk and disease severity: A systematic review and multilevel meta-analysis of prospective studies.

Del Riccio M, Caini S, Bonaccorsi G, Lorini C, Paget J, van der Velden K, Cosma C.Am J Infect Control. 2024 Sep;52(9):1091-1098. doi: 10.1016/j.ajic.2024.05.009. Epub 2024 May 18.PMID: 38768817

Epidemiological trends in viral meningitis in England: Prospective national surveillance, 2013-2023.

Kadambari S, Abdullahi F, Celma C, Ladhani S.J Infect. 2024 Sep;89(3):106223. doi: 10.1016/j.jinf.2024.106223. Epub 2024 Jul 8.PMID: 38986749

Development and Bayesian validation of a competitive inhibition ELISA for detection of antibodies against Brucella abortus in cattle.

Novoa MB, Aguirre N, Valentini B, Signorini M, Aznar N, Vanzini V, Torioni-de-Echaide S.Acta Trop. 2024 Sep;257:107319. doi: 10.1016/j.actatropica.2024.107319. Epub 2024 Jul 5.PMID: 38972562

Influenza Vaccination in Adults in the United States with COPD before and after the COVID-19 Pandemic (2017-2022): A Multi-Year Cross-Sectional Study.

Wold M, Oancea SC.Vaccines (Basel). 2024 Aug 21;12(8):931. doi: 10.3390/vaccines12080931.PMID: 39204054

Efficacy and safety of therapeutic vaccines for the treatment of chronic hepatitis B: A systematic review and meta-analysis of randomized controlled trials update.

Geta M, Mengistu G, Yizengaw E, Manyzewal T, Hailu A, Woldeamanuel Y.Medicine (Baltimore). 2024 Aug 30;103(35):e39344. doi: 10.1097/MD.0000000000039344.PMID: 39213251

Antiviral effect of the viroporin inhibitors against Taiwan isolates of infectious bronchitis virus (IBV).

Sitinjak MC, Chen JK, Liu FL, Hou MH, Lin SM, Liu HJ, Wang CY.Virus Res. 2024 Aug 27;349:199458. doi: 10.1016/j.virusres.2024.199458. Online ahead of print.PMID: 39187047

Asthma as a risk factor and allergic rhinitis as a protective factor for COVID-19 severity: a case-control study.

Lira Tenório MD, Dos Santos Menezes Siqueira GV, Costa Caldas G, Pacheco de Almeida R, Ribeiro de Jesus A, Martins-Filho PR.Eur Arch Otorhinolaryngol. 2024 Aug 24. doi: 10.1007/s00405-024-08893-6. Online ahead of print.PMID: 39180537

COVID-19 IgG seropositivity and its determinants in occupational groups of varying infection risks in two Andean cities of Ecuador before mass vaccination.

Leon-Rojas JE, Arias-Erazo F, Jiménez-Arias P, Recalde-Navarrete R, Guevara A, Coloma J, Martin M, Chis Ster I, Cooper P, Romero-Sandoval N; Seroprevalence ECU-Group.PLoS One. 2024 Aug 29;19(8):e0309466. doi: 10.1371/journal.pone.0309466. eCollection 2024.PMID: 39208200

Genetic and epigenetic analyses of IFN-γ gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-γ among COVID-19 vaccinated Bangladeshi adults.

Tahsin A, Bhattacharjee P, Al Saba A, Yasmin T, Nabi AHMN.Vaccine. 2024 Aug 30;42(21):126157. doi: 10.1016/j.vaccine.2024.126157. Epub 2024 Jul 30.PMID: 39079811

Going (Anti)Viral: Improving HIV and HCV Screening and HPV Vaccination in Primary Care.

McGaffey A, Castelli G, Friedlander MP, Proddutur S, Simpkins C, Middleton DB, Spencer KO, Taormina JM, Gerlach A, Nowalk MP.Jt Comm J Qual Patient Saf. 2024 Sep;50(9):645-654. doi: 10.1016/j.jcjq.2024.06.002. Epub 2024 Jun 8.PMID: 38981779

Improving large language models for clinical named entity recognition via prompt engineering.

Hu Y, Chen Q, Du J, Peng X, Keloth VK, Zuo X, Zhou Y, Li Z, Jiang X, Lu Z, Roberts K, Xu H.J Am Med Inform Assoc. 2024 Sep 1;31(9):1812-1820. doi: 10.1093/jamia/ocad259.PMID: 38281112

Enhancing quality of life with 3-year course of sublingual immunotherapy for house dust mite-induced allergic rhinitis: An observational prospective study in real-life settings.

Zhang Y, Li J, Long Y, Ling Z.Am J Otolaryngol. 2024 Sep-Oct;45(5):104418. doi: 10.1016/j.amjoto.2024.104418. Epub 2024 Jul 21.PMID: 39067091

Dual nature of type I interferon responses and feedback regulations by SOCS1 dictate malaria mortality.

Lu J, Hu Z, Jiang H, Wen Z, Li H, Li J, Zeng K, Xie Y, Chen H, Su XZ, Cai C, Yu X.J Adv Res. 2024 Aug 22:S2090-1232(24)00370-9. doi: 10.1016/j.jare.2024.08.027. Online ahead of print.PMID: 39181199

Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study.

Szanyi J, Price DJ, Carville KS, Batty M, Yallop S, Nicholson S, Karapanagiotidis T, Rowe S, Sullivan S, Menon V, West D, Manoharan L, Copsey E, Majumdar SS, Sutton B, Williamson DA, McVernon J.Commun Dis Intell (2018). 2024 Aug 21;48. doi: 10.33321/cdi.2024.48.28.PMID: 39165016

Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients.

Sharifi P, Rezaeimanesh N, Moradi A, Moghadasi AN.eNeurologicalSci. 2024 Jun 12;36:100511. doi: 10.1016/j.ensci.2024.100511. eCollection 2024 Sep.PMID: 38989276

Hepatitis B vaccination coverage and associated factors among nurses working at health centers in Addis Ababa, Ethiopia: a cross-sectional study.

Bayissa L, Gela D, Boka A, Ararsa T.BMC Nurs. 2024 Aug 28;23(1):600. doi: 10.1186/s12912-024-02224-0.PMID: 39198790

Respiratory syncytial virus infection among children younger than 2 years admitted to a paediatric intensive care unit with extended severe acute respiratory infection in ten Gavi-eligible countries: the RSV GOLD-ICU Network study.

RSV GOLD—ICU Network collaborators.Lancet Glob Health. 2024 Aug 28:S2214-109X(24)00269-9. doi: 10.1016/S2214-109X(24)00269-9. Online ahead of print.PMID: 39216503

Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.

Kar D, Taylor KS, Joy M, Venkatesan S, Meeraus W, Taylor S, Anand SN, Ferreira F, Jamie G, Fan X, de Lusignan S.J Med Internet Res. 2024 Aug 26;26:e56042. doi: 10.2196/56042.PMID: 39186368

COVID-19 vaccination and ocular adverse events: a self-controlled case series study from the entire South Korean population.

Hwang S, Kang SW, Choi J, Park KA, Lim DH, Shin JY, Kang D, Cho J, Kim SJ.Am J Ophthalmol. 2024 Aug 21:S0002-9394(24)00376-3. doi: 10.1016/j.ajo.2024.08.015. Online ahead of print.PMID: 39179130

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

Wongnak P, Schilling WHK, Jittamala P, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Singh S, Kouhathong J, Pagornrat W, Khanthagan P, Hanboonkunupakarn B, Poovorawan K, Mayxay M, Chotivanich K, Imwong M, Pukrittayakamee S, Ashley EA, Dondorp AM, Day NPJ, Teixeira MM, Piyaphanee W, Phumratanaprapin W, White NJ, Watson JA; PLATCOV Collaborative Group.Lancet Infect Dis. 2024 Sep;24(9):953-963. doi: 10.1016/S1473-3099(24)00183-X. Epub 2024 Apr 24.PMID: 38677300

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([13.08.2024 TO 20.08.2024]) *as the publication date 65 records.*

1.4419136CORONAVIRUS-IMPFSTOFF

EP - 28.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 21823190Solicitante BIONTECH SEInventor/a SAHIN UGUR

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

2.4419081MRNA-IMPFSTOFFZUSAMMENSETZUNG

EP - 28.08.2024

Clasificación Internacional A61K 9/127Nº de solicitud 22803430Solicitante SAIL BIOMEDICINES INCInventor/a MOSAHEB MUNIR

Disclosed herein are nucleic acid vaccine compositions including one or more polynucleotides encoding one or more antigenic polypeptide, formulated within a lipid reconstructed plant messenger packs (LPMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a nucleic acid vaccine, comprising reconstituting a film comprising purified PMP lipids in the presence of an ionizable lipid to produce a LPMP comprising the ionizable lipid, and loading into the LPMPs with one or more polynucleotides encoding one or more antigenic polypeptides.

3.20240285746PROTECTIVE VACCINE ANTIGEN AGAINST STREPTOCOCCAL INFECTION

US - 29.08.2024

Clasificación Internacional A61K 39/09Nº de solicitud 18564537Solicitante The Regents of the University of CaliforniaInventor/a David J. Gonzalez

Group A *Streptococcus* (GAS) is associated with an estimated half-million deaths per year and 21 severe autoimmune sequalae. Despite the ubiquity of GAS infection, no vaccine currently exists. Provided herein is a *Streptococcus* S protein or an equivalent thereof used as a vaccine, along with the related compositions and methods.

4.4415748SELBSTANGEORDNETE MULTIEPITOP-NANOPARTIKELIMPFSTOFFPLATTFORM (MSN-IMPFSTOFFPLATTFORM) UND VERWENDUNGEN DAVON

EP - 21.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 22880508Solicitante TRANSLATIONAL HEALTH SCIENCE AND TECH INSTITUTEInventor/a SAMAL SWEETY

The present invention is drawn to a next generation nano vaccine platform by using structure- based design to utilize the conserved or less variable or highly immunogenic domains or epitopes and displaying it in a nano cage and produces it in as nanoparticle protein in prokaryotic expression system. The present invention is illustrated in detail by a vaccine design and construct for SARS CoV-2, SARS-CoV-2 variants, betacorona viruses, Monkey pox virus and Dengue virus.

5.WO/2024/168828VACCINE ADJUVANT, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 22.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud PCT/CN2023/076832Solicitante THE SPIRIT JINYU BIOLOGICAL PHARMACEUTICAL CO., LTDInventor/a LI, Xiaoyan

The present invention relates to the technical field of veterinary vaccine adjuvants, and in particular to a vaccine adjuvant, a preparation method therefor, and a use thereof. The vaccine adjuvant comprises the following components in parts by mass: 25-60 parts of a liposome and 20-50 parts of pine pollen, wherein the liposome has an excellent ability of carrying drugs, and the pine pollen is used as a natural immunopotentiator. By using the liposome in combination with the pine pollen, the speed and strength of the specific immune response of the pine pollen can be significantly enhanced, and a non-specific defense mechanism can be accurately identified and started, such that resistibility is improved, and the disease resistance is improved. In addition, the vaccine adjuvant provided by the present invention has good water solubility, small particle size, good uniformity and high storage stability. A veterinary vaccine further prepared according to the present invention has the advantages of high stability, high safety, long standing without delamination, and easy injection, and can induce long and efficient immune response of a body.

6.WO/2024/177429DNA TEMPLATE AND MRNA VACCINE MANUFACTURED USING SAME

WO - 29.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud PCT/KR2024/002384Solicitante UNIVERSITY OF SEOUL INDUSTRY COOPERATION FOUNDATION.Inventor/a LEE, Jong Bum

The present invention relates to an mRNA vaccine based on an mRNA multimer, and more specifically, to an mRNA vaccine that is capable of reliably delivering high-density mRNA due to comprising an mRNA multimer in which a DNA template including an IRES and an antigen encoding sequence is rotary-transcribed.

7.20240277830CORONAVIRUS VACCINE

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 17276788Solicitante CureVac SEInventor/a Susanne RAUCH

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-COV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

8.WO/2024/173621DENGUE VIRUS MRNA VACCINE AND METHOD AGAINST DENGUE VIRUS INFECTION USING THE SAME

WO - 22.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/015894Solicitante ACADEMIA SINICAInventor/a WU, Han-Chung

The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response.

9.WO/2024/171316INACTIVATED VACCINE PREPARATION AND INFECTION PREVENTION METHOD

WO - 22.08.2024

Clasificación Internacional A61K 39/09Nº de solicitud PCT/JP2023/005050Solicitante KYORITSU SEIYAKU CORPORATIONInventor/a UCHIYAMA Ai

[Problem] To isolate and identify novel Lactococcus garvieae and provide an effective prevention means for a disease having said bacteria as a pathogenic bacteria. [Solution] Provided is an inactivated vaccine preparation and the like for fish streptococcosis having Lactococcus garvieae as a pathogenic bacteria, the preparation containing inactivated bacterial cells of Lactococcus garvieae that produce a negative result for agglutination by an anti-type I serum and an anti-type II serum in a viable-cell state. It is possible that said vaccine preparation can effectively prevent the occurrence, transmission, and spread of a novel streptococcosis that cannot be prevented with conventional inactivated vaccines for Lactococcus garvieae.

10.4420733VERFAHREN ZUR ERHÖHUNG DER WIRKSAMKEIT EINES IMPFSTOFFS DURCH VERABREICHUNG EINES IL-4-ANTAGONISTEN

EP - 28.08.2024

Clasificación Internacional A61P 37/04Nº de solicitud 24174931Solicitante REGENERON PHARMAInventor/a PURCELL NGAMBO LISA

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

11.WO/2024/170516RABBIT HEMORRHAGIC DISEASE VIRUS VACCINE AND USES THEREOF

WO - 22.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2024/053521Solicitante HIPRA SCIENTIFIC, S.L.U.Inventor/a NADAL FULLA, Guillem

The present invention relates to an immunogenic or vaccine composition which provides protection against rabbit hemorrhagic disease (RHD) caused by rabbit hemorrhagic disease virus of variant strain 1 (RHDV-1) and of variant strain 2 (RHDV-2) and uses thereof.

12.4419135MULTIVALENTER IMPFSTOFF GEGEN ACINETOBACTER BAUMANNII MIT MANGEL AN LIPOPOLYSACCHARID (LPS)

EP - 28.08.2024

Clasificación Internacional A61K 39/108Nº de solicitud 22809352Solicitante VAXDYN S LInventor/a INFANTE VIÑOLO JUAN JOSÉ

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases caused by K. pneumoniae, P. aeruginosa, E. coli, and/or A. pleuropneumoniae. and optionally A. baumannii.

13.20240277837DEIMMUNIZED FLAGELLIN AND VACCINE COMPOSITION COMPRISING SAME

US - 22.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18568069Solicitante INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITYInventor/a Joon Haeng RHEE

The present invention relates to: deimmunized flagellin that does not induce the production of flagellin-specific antibodies; and use thereof. In particular, the present invention relates to a flagellin variant in which a major epitope that forms an antibody against flagellin is deleted, the flagellin variant being characterized by, when used as a vaccine adjuvant, not producing antibodies against flagellin while maintaining an excellent immune enhancer effect.

14.WO/2024/170728VACCINE COMPOSITION COMPRISING A SYSTEM FOR DELIVERING AN INACTIVATED WHOLE BACTERIUM VIA CATIONIC POLYSACCHARIDE NANOPARTICLES WITHOUT ANY ADJUVANT

WO - 22.08.2024

Clasificación Internacional A61K 9/51Nº de solicitud PCT/EP2024/053960Solicitante VAXINANOInventor/a BETBEDER, Didier

The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.

15.20240285655METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION

US - 29.08.2024

Clasificación Internacional A61K 31/00Nº de solicitud 18586450Solicitante PKZ, LLCInventor/a J. Phillip Kennedy

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

16.WO/2024/176194METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION

WO - 29.08.2024

Clasificación Internacional A61K 31/05Nº de solicitud PCT/IB2024/051784Solicitante PKZ, LLCInventor/a KENNEDY, J. Phillip

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

17.20240277754IMMUNO-ONCOLOGY THERAPEUTIC COMPOSITION USING ADJUVANT INCLUDING LIPOPEPTIDES AND POLY (I:C)

US - 22.08.2024

Clasificación Internacional A61K 31/713Nº de solicitud 18563350Solicitante CHA VACCINE RESEARCH INSTITUTE CO., LTDInventor/a Jung Sun Yum

An immuno-oncology therapeutic composition containing, as an active ingredient, an adjuvant including lipopeptides and poly (I:C) provided in one aspect of the present invention can induce a large therapeutic effect on a variety of carcinomas, and can be effectively used for anticancer therapy by significantly enhancing anticancer effects through combined administration with conventional anticancer drugs, such as chemical anticancer drugs, anticancer vaccines, and immune checkpoint inhibitors, having different mechanisms.

18.WO/2024/173143VACCINES INCORPORATING HIV TH/CTL EPITOPE PEPTIDES TO PREVENT AND TREAT PATIENTS WITH HIV INFECTION AND AIDS

WO - 22.08.2024

Clasificación Internacional C07K 14/16Nº de solicitud PCT/US2024/015005Solicitante CYW INVESTMENT CO., LTDInventor/a WANG, Chang-Yi

An HIV Th/CTL vaccine composition is provided. The HIV Th/CTL vaccine composition includes a Th/CTL peptide. A method for treating HIV infection and AIDS in a subject is also provided. The method includes administering a pharmaceutically effective amount of the HIV Th/CTL vaccine composition to the subject. An

HIV vaccine composition, a Global HIV T vaccine composition, a method for preventing and treating HIV infection in a subject are also provided.

19.WO/2024/174012IMMUNOGENIC COMPOSITION, USE THEREOF AND PROCESS OF OBTAINING A COMBINED IMMUNOGENIC COMPOSITION AGAINST COVID-19 AND SEASONAL INFLUENZA

WO - 29.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud PCT/BR2024/050022Solicitante INSTITUTO BUTANTANInventor/a AKAMATSU, Milena Apetito

The present invention relates to an immunogenic composition that comprises (i) antigens of the inactivated Newcastle virus (NDV) expressing a stabilized form of the spike antigen (HXP-S) of SARS-CoV-2 (NDV-HXP-S); and (ii) antigens of the trivalent vaccine for seasonal influenza, the composition optionally also comprising an adjuvant. Furthermore, the present invention relates to the use of said immunogenic composition for producing a combined vaccine against COVID-19 and seasonal influenza. Additionally, the present invention relates to a method for obtaining said combined vaccine that comprises the following steps: (a) producing the virus and NDV-HXP-S antigen on an industrial scale using the same factory as that used for producing a monovalent seasonal influenza vaccine; (b) producing the monovalent seasonal influenza vaccine; and (c) combining the antigen compositions of steps "a" and "b" with an acceptable pharmaceutical vehicle to create the combined vaccine.

20.WO/2024/176229ANTI-POX VIRUSES ANTIBODIES

WO - 29.08.2024

Clasificación Internacional A61K 39/42Nº de solicitud PCT/IL2024/050198Solicitante STATE OF ISRAEL, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCHInventor/a MAZOR, Ohad

The invention provides monoclonal antibodies which bind and neutralize pox viruses. The invention also provides pharmaceutical compositions comprising the antibodies, and combinations thereof, and their use in methods of prophylaxis, treatment, or amelioration of infections caused by pox viruses, and for reducing side effects of vaccinia-based vaccines.

21.12073483SYSTEMS AND METHODS FOR MULTIDIMENSIONAL ACCESS SYSTEM FOR DISTRIBUTED SITES

US - 27.08.2024

Clasificación Internacional G06Q 50/26Nº de solicitud 18323081Solicitante Morgan Stanley Services Group Inc.Inventor/a Ankit Pandya

Systems and methods for remote badging and/or computer access, automatic individual verification, automatic vaccine verification and/or automatically remotely determining an individual's physical presence at a site are provided. The systems and methods include automatic vaccine proof verification.

22.4419139NEOADJUVANTE VERWENDUNG VON PFLANZENVIRUS ODER VIRUSÄHNLICHEN PARTIKELN ZUR KREBSBEHANDLUNG

EP - 28.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 22884755Solicitante DARTMOUTH COLLEGEInventor/a FIERING STEVEN

A neoadjuvant for use in treating cancer includes an *in situ* vaccine and optionally an immune check point therapeutic. The *in situ* vaccine includes at least one of cowpea mosaic virus or cowpea mosaic virus-like particles.

23.4415753MANIPULATION VON ANTIGENEN ZUR BINDUNG AN UND AUSRICHTUNG AUF ADJUVANTIEN FÜR ERWEITERTE HUMORALE REAKTIONEN UND IMMUNFOKUSSIERUNG

EP - 21.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 22881883Solicitante CZ BIOHUB SF LLCInventor/a XU DUO

New vaccine compositions comprising a modified antigen bound to the surface of an adjuvant or carrier by electrostatic interactions are disclosed. The antigen of the vaccine composition is presented in a defined orientation on an adjuvant surface such that epitope accessibility is altered and an immune response is redirected toward specific epitopes. In some embodiments the vaccine composition comprises one or more recombinant antigen polypeptides adsorbed to an alum particle. In some embodiments, the recombinant antigen polypeptide comprises a Region of Repetitive Carboxylic Groups (RRC) or a Region of Repetitive Lysyl/Guanidino Groups (RRL).

24.20240277828MULTIVALENT INFLUENZA VACCINES COMPRISING RECOMBINANT HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME

US - 22.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18653422Solicitante SANOFI PASTEUR INCInventor/a Timothy ALEFANTIS

Disclosed herein are multivalent vaccine or immunogenic compositions comprising one or more recombinant influenza virus hemagglutinin (HA), one or more recombinant influenza virus neuraminidase (NA), and an optional adjuvant. Also disclosed are methods of using the vaccine or immunogenic composition.

25.20240277835VACCINE

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18417379Solicitante ASTRAZENECA ABInventor/a Joseph Richard FRANCICA

The present disclosure relates to methods of inducing a pan-sarbecoronavirus variant immune response for the treatment and prevention of coronavirus infections.

26.20240277836SELF-AMPLIFYING RNA-BASED VLP VACCINES

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18567611Solicitante CHIMERON BIO CORPORATIONInventor/a Jolly Mazumdar Chendrimada

The present disclosure provides compositions comprising an sa-RNA VLP vaccine (e.g. the VLP vaccine) that is capable of delivering a self-amplifying RNA to a target cell in a patient, and subsequently elicit an immune

response in the patient, which immune response is sufficient to prevent or significantly decrease the duration of an infection by an infectious agent, such as SARS-CoV-2.

27.WO/2024/173214SIALOKININ IMMUNOGEN AND METHODS FOR USING SAME

WO - 22.08.2024

Clasificación Internacional A61K 39/385Nº de solicitud PCT/US2024/015340Solicitante UNM RAINFOREST INNOVATIONSInventor/a CHACKERIAN, Bryce

An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic *Aedes* spp. sialokinin peptide that includes amino acids of SEQ ID NO:1 linked to the immunogenic carrier. The immunogen can be formulated into a pharmaceutical composition such as vaccine. The composition or vaccine may be used to treat a subject having, or at risk of having a mosquito-borne condition.

28.4417694GENKONSTRUKT ZUR EXPRESSION VON MRNA

EP - 21.08.2024

Clasificación Internacional C12N 15/63Nº de solicitud 22881396Solicitante GENOMICTREE INCInventor/a AN SUNGWHAN

The present invention relates to a gene construct for expressing an mRNA, and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct. More specifically, the present invention relates to a gene construct including a coronavirus (SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2)-derived 5' untranslated region (UTR) and/or 3' untranslated region (UTR), and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct.

29.20240285750HYBRID MULTIVALENT INFLUENZA VACCINES COMPRISING HEMAGGLUTININ AND NEURAMINIDASE AND METHODS OF USING THE SAME

US - 29.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18653458Solicitante SANOFIInventor/a Timothy ALEFANTIS

Disclosed herein are hybrid multivalent vaccine or immunogenic compositions comprising (i) one or more influenza virus proteins selected from one or more influenza virus hemagglutinin (HA) proteins, one or more influenza virus neuraminidase (NA) proteins, or a combination thereof; and (ii) one or more ribonucleic acid molecules encoding one or more influenza virus proteins selected from one or more influenza virus HA proteins, one or more influenza virus NA proteins, or a combination thereof. Also disclosed are methods of using the vaccine or immunogenic compositions.

30.4417974CD33 ALS BIOMARKER DER HIV-KONTROLLE

EP - 21.08.2024

Clasificación Internacional G01N 33/569Nº de solicitud 23382150Solicitante FUNDACIO PRIVADA INST DE RECERCA DE LA SIDA CAIXAInventor/a RUIZ RIOL MARTA

The present invention relates to the use of CD33 as a biomarker of the response to a T-cell vaccine in a HIV-1 infected subject and to a method for the prognosis of the response of a HIV-1 infected subject to a T-

cell vaccine comprising analyzing the CD33 levels in a sample from said subject, as well as of the use of an inhibitor or CD33 for the treatment and/or prevention of HIV-1 infection.

31.20240277824BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS

US - 22.08.2024

Clasificación Internacional A61K 39/112Nº de solicitud 18402174Solicitante GLAXOSMITHKLINE BIOLOGICALS SAInventor/a Fabiana FERNANDEZ

The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

32.20240287620METHOD OF TAGGING FISH AND OTHER ANIMALS

US - 29.08.2024

Clasificación Internacional C12Q 1/6888Nº de solicitud 18569829Solicitante SALMOTRACE ASInventor/a Dag HAUGSE

The present invention relates to a method of tagging a non-human animal, particularly fish, said method comprising administering to said animal a tag nucleic acid molecule, wherein the tag nucleic acid molecule:

-
  - (i) comprises an ID sequence which is unique to the tag, which is non-coding and/or cannot be transcribed, and which may be distinguished from the ID sequences of other tag molecules, and
  - (ii) is detectable in or on said animal, or in a body tissue or fluid sample from said animal.

The tag may be used to identify the animal, for example in the context of tracking and tracing the animal. The tag may be administered to the animal in conjunction with a vaccine component, which may be provided as part of the tag nucleic acid molecule, or separately. Also provided herein are methods of tagging and vaccinating non-human animals, and combination products comprising a vaccine composition and a tag nucleic acid molecule, as well as apparatus for administering the tag nucleic acid molecule together with a vaccine.

33.WO/2024/174031CONSERVED EPITOPES IN CORONAVIRUSES AND VACCINES AND ANTIBODIES THERETO

WO - 29.08.2024

Clasificación Internacional C07K 14/165Nº de solicitud PCT/CA2024/050214Solicitante THE UNIVERSITY OF BRITISH COLUMBIAInventor/a PLOTKIN, Steven

A vaccine immunogen comprising a S2 conserved epitope located in the S2 domain of the coronavirus spike protein is disclosed. Some embodiments pertain to a vaccine immunogen comprising a scaffolded protein. The scaffolded protein comprises the S2 conserved epitope and one or more non-naturally occurring regions.

The one or more non-naturally occurring regions may be designed to patch two or more contiguous chains or structures of the S2 conserved epitope. Antibodies that selectively bind to the S2 conserved epitope and/or scaffolded protein, and methods of producing scaffolded proteins comprising the S2 conserved epitope are also disclosed.

34.4416274PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR ABGABE VON VIRALEN ANTIGENEN UND ZUGEHÖRIGE VERFAHREN

EP - 21.08.2024

Clasificación Internacional C12N 7/00Nº de solicitud 22803413Solicitante BIONTECH SEInventor/a ROONEY MICHAEL STEVEN

The present disclosure provides pharmaceutical compositions for delivery of viral antigens (e.g., a viral vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

35.WO/2024/169991COMPOSITIONS AND METHODS OF GAMMA-DELTA T CELL EXTRACELLULAR VESICLE-BASED TUMOR VACCINES

WO - 22.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2024/077451Solicitante THE UNIVERSITY OF HONG KONGInventor/a TU, Wenwei

It has been discovered that γδ-T-extracellular vesicles (EV) have immune adjuvant effects that promote DCs maturation, mediated by the IFN-γ associated with the γδ-T-EVs. Cell-free compositions including extracellular vesicles (EVs) derived from γδ-T cells (γδ-T-EVs) and methods of use thereof are provided. The γδ-T-EVs can associated with or encapsulate tumor-associated antigens (TAAs) or peptide pools to form a γδ-T-EV vaccine composition. γδ-T-EVs compositions can be used as adjuvants in cancer immunotherapy or the γδ-T-EV vaccine compositions are to induce tumor-specific T-cell responses and direct killing of tumor cells in subjects in need thereof.

36.12070493DOUBLE AUXOTROPHIC MYCOBACTERIUM AND USES THEREOF

US - 27.08.2024

Clasificación Internacional A61K 39/04Nº de solicitud 18307998Solicitante Albert Einstein College of MedicineInventor/a William R. Jacobs, Jr.

Described herein are methods of determining the efficacy of a candidate tuberculosis vaccine and methods of determining the efficacy of a candidate small organic molecule tuberculosis treatment by administering the candidate tuberculosis vaccine or the small organic molecule tuberculosis treatment to an animal which has been infected with an auxotrophic *Mycobacterium*. The auxotrophic *Mycobacterium* has a mycobacterial genome in which (i) argB gene, or a gene encoding a mycobacterial ArgB enzyme, has been fully or partially deleted and (ii) metA gene, or a gene encoding a mycobacterial MetA enzyme, has been fully or partially deleted, wherein the *Mycobacterium* is sterilized in the absence of arginine and methionine). The methods include quantifying the amount of auxotrophic *Mycobacterium* to determine the efficacy.

37.20240285739MULTIEPITOPE VACCINE CASSETTES

US - 29.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18458062Solicitante Gritstone bio, Inc.Inventor/a Karin Jooss

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of KRAS neoepitope-encoding sequences and/or lacking immunodominant epitopes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

38.WO/2024/174690BRUCELLOSIS CELL IMMUNE PROTEIN AND USE THEREOF

WO - 29.08.2024

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2023/139476Solicitante TECON BIOPHARMACEUTICAL CO., LTDInventor/a HE, Sun

Provided are a Brucellosis cell immune protein and the use thereof. In the present invention, firstly, a Brucella protein with relatively high immunogenicity is screened by means of antibody spectrum technology; then, the protein gene sequence of Brucella and the T cell epitope and antigen gene sequence of Brucella are subjected to fusion and expression by using molecular biology technology, so as to improve the ability for producing an immune response which is induced by an antigen; next, the antigen is expressed in vitro and then subjected to multi-stage purification, and the obtained purified protein is used as a stimulant; and finally, anti-coagulated blood from an immunized animal is collected, the stimulant is added thereto, the mixture is incubated for 24 hours at 37°C , the resulting product is centrifuged to collect a supernatant, and the level of IL-17 in the supernatant is detected by means of an ELISA method. By means of preparing the Brucellosis cell immune protein into a reagent for detecting the level of IL-17, and then detecting IL-17 by means of an ELISA method, the level of protection for animals after immunization with a Brucella vaccine can be effectively evaluated; and the present invention involves simple operation and is accurate, and the problem of it not being possible to rapidly evaluate the level of vaccine protection after immunization with the Brucella vaccine is solved.

39.WO/2024/177525AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS

WO - 29.08.2024

Clasificación Internacional Nº de solicitud PCT/PL2024/050015Solicitante INSTYTUT IMMUNOLOGII I TERAPII PANInventor/a RAZIM, Agnieszka

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

40.20240285742UNIVERSAL MRNA ANTIMALARIAL VACCINE

US - 29.08.2024

Clasificación Internacional A61K 39/015Nº de solicitud 18398119Solicitante Sarfaraz K. NiaziInventor/a Sarfaraz K. Niazi

An mRNA composition for malaria prevention and treatment comprising a coding mRNA capable of expressing proteins and peptides of malaria pathogens, coming from linear epitopes and protein structure of antigens.

41.WO/2024/175040RSV MRNA VACCINES

WO - 29.08.2024

Clasificación Internacional C07K 14/135Nº de solicitud PCT/CN2024/077962Solicitante EVEREST MEDICINES (CHINA) CO., LTD.Inventor/a LUO, Yuan

It relates to a recombinant RSV F protein, nucleic acids encoding the recombinant RSV F protein, a vaccine comprising an RNA polynucleotide that comprises at least one open reading frame (ORF) encoding the recombinant RSV F protein, and pharmaceutical composition thereof. It also provides a method of preventing RSV infection or eliciting an immune response against RSV in the subject.

42.20240277834NUCLEIC ACID MOLECULES

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18417362Solicitante ASTRAZENECA ABInventor/a Albert George THOM

The present disclosure relates to a nucleic acid molecule comprising 5'-UTR and/or 3'-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as a vaccine in the treatment and prevention of infectious diseases, including those caused by a coronavirus, compositions comprising said nucleic acid molecules and methods of treating or preventing infectious diseases.

43.WO/2024/173808MICROBIOME-DERIVED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS

WO - 22.08.2024

Clasificación Internacional A23L 33/135Nº de solicitud PCT/US2024/016173Solicitante DUKE UNIVERSITYInventor/a SURANA, Neeraj

Described herein are microbiome-derived compositions and methods of treating and/or preventing of a viral infection, inhibiting of the progression of a viral infection, increasing and/or prolonging of the time of acquisition of a viral infection, minimizing and/or reducing the risk of an HIV infection and/or a CMV infection, and improving and/or enhancing of vaccine efficacy, or any combination thereof.

44.20240287470CETYLTRIMETHYLAMMONIUM BROMIDE (CTAB) AS A LYSIS AND FLOCCULATION REAGENT IN GENE THERAPY DOWNSTREAM PROCESSES

US - 29.08.2024

Clasificación Internacional C12N 7/00Nº de solicitud 18586896Solicitante Pfizer Inc.Inventor/a Hannah Kim BARE

The present disclosure describes improved methods for use in purifying biological products made by host cells. In some embodiments, the improved methods comprise one or more steps of lysing host cells to release the biological product and precipitating host cell DNA, using a detergent such as cetyltrimethylammonium

bromide (CTAB). In some embodiments, the biological product is a vaccine, or a viral vector for gene therapy, such as an AAV vector or a lentiviral vector.

45.WO/2024/169040PANAX GINSENG HETEROPOLYSACCHARIDE, SEPARATION METHOD THEREFOR AND USE THEREOF

WO - 22.08.2024

Clasificación Internacional C08B 37/00Nº de solicitud PCT/CN2023/089771Solicitante SHENYANG PHARMACEUTICAL UNIVERSITYInventor/a YIN, Jun

The present application discloses a heteropolysaccharide, comprising galacturonic acid, arabinose, galactose, glucose, rhamnose, xylose, and mannose. Specifically, the present application relates to a Panax ginseng heteropolysaccharide (GAPS-FL), which is a novel polysaccharide substance separated from Panax ginseng roots, can nonspecifically change or enhance the immune response reaction of multiple types of vaccines including influenza vaccines, can enhance humoral immunity of influenza vaccine immune mice, and can also enhance cellular immunity thereof.

46.WO/2024/174011LIPOSOME, METHOD FOR PREPARING A LIPOSOME, INTRANASAL COMPOSITION COMPRISING A LIPOSOME, METHOD FOR PREPARING AN INTRANASAL COMPOSITION, KIT AND USE OF THE COMPOSITION

WO - 29.08.2024

Clasificación Internacional A61K 9/127Nº de solicitud PCT/BR2023/050062Solicitante ROSSI BERGMANN, BartiraInventor/a ROSSI BERGMANN, Bartira

This invention relates to liposomes having mucus-penetrating action and rates of incorporation of a retinoid, for example retinoic acid (RA), greater than those obtained in solid lipid nanoparticles (0.1%), thus increasing the uptake thereof via the nasal mucosa, and to the method for preparing a liposome. The present invention also relates to an intranasal composition, for example a vaccine, comprising said liposome, which is more effective than existing vaccines, the method for preparing same and the use thereof for preventing illnesses.

47.20240279286CORE AMINO ACID SEQUENCE GROUP CAPABLE OF TARGET RECOGNIZING ANTI-NOVEL CORONAVIRUS NEUTRALIZING ANTIBODIES N-IGY-PABS AND USE THEREOF

US - 22.08.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18636457Solicitante SINO-SWED TONGKANG BIO-TECH (SHENZHEN) LIMITEDInventor/a Ailian HEI

Specifically disclosed are a core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs and a use thereof. The core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs includes 15 types of the amino acid sequences positioned in an S-ECD region and 5 types of the amino acid sequences positioned in a non-structural protein (NSP) region, and can be applied to a detection of the novel coronavirus, a design of therapeutic targets and a design of vaccine targets.

48.4421174ADJUVANS ENTHALTEND EIN GLYCOARCHAEOL UND EIN IMMUNSTIMULANS

EP - 28.08.2024

Clasificación Internacional C12N 15/11Nº de solicitud 24183967Solicitante NAT RES COUNCIL CANADAInventor/a

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and/or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

49.20240285738NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS

US - 29.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18647775Solicitante Immatics Biotechnologies GmbHInventor/a Andrea MAHR

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

50.20240277833NON-VIRAL DNA VECTORS FOR VACCINE DELIVERY

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18289622Solicitante Generation Bio Co.Inventor/a Phillip Samayoa

The application describes methods and compositions comprising ceDNA vectors useful for the expression of antigens and immunogenic peptides in a cell, tissue or subject, and methods of treatment and/or prevention of various infectious diseases, autoimmune disorders and cancers.

51.4416304NUKLEINSÄUREARRAYS ZUR MRNA-CHARAKTERISIERUNG

EP - 21.08.2024

Clasificación Internacional C12Q 1/6841Nº de solicitud 22881991Solicitante INDEVR INCInventor/a ROWLEN KATHY L

Provided herein are methods and related systems, including assays and kits, for characterization of one or more polynucleotides, including mRNA polynucleotides or other nucleic acid targets. Capture agents are provided on a substrate that are specific to a target region of mRNA in a vaccine or therapeutic sample, wherein the nucleic acid capture agents specifically bind to the target region. Contacting the capture agents with a sample containing relevant mRNA sequences forms a capture agent-target hybridized complex that can be labeled with a variety of detection label agents to generate a measurable signal that may be used for

identity, quantification, integrity and/or stability measurements of mRNA in mRNA-based vaccines and therapeutics.

52.WO/2024/173855HEMOLYSIN ANTIGENS AND VACCINE EMBODIMENTS FOR BACTERIAL INFECTION

WO - 22.08.2024

Clasificación Internacional A61K 39/02Nº de solicitud PCT/US2024/016249Solicitante BAYLOR COLLEGE OF MEDICINEInventor/a XING, Yikun

Embodiments of the disclosure include methods of treating, preventing, reducing the risk of, delaying the onset of, and/or reducing the severity of an infection (including pathogenic) in an individual infected with a bacteria from the Gammaproteobacteria Class. In specific embodiments, the methods comprise the step of administering to the individual an effective amount of an immunogenic composition comprising a non-acylated/inactive form alphahemolysin (HlyA) and/or a non-acylated/inactive form, or functional fragment(s) of either. In specific embodiments, the individual is also provided a composition comprising SinH or a functional fragment thereof.

53.WO/2024/174496VARICELLA-ZOSTER VIRUS VACCINE AND PREPARATION METHOD THEREFOR

WO - 29.08.2024

Clasificación Internacional C07K 19/00Nº de solicitud PCT/CN2023/117634Solicitante GUANGZHOU QIANYANG BIO-TECHNOLOGY PHARMACEUTICAL CO., LTD.Inventor/a ZHANG, Hui

Provided in the present invention are varicella-zoster virus nanoparticles, a preparation method therefor, and the use thereof. The varicella-zoster virus nanoparticles of the present invention comprise a component 1 and a component 2, which are linked by means of a self-assembly system, wherein the component 1 is varicella-zoster virus glycoprotein E, the component 2 is Helicobacter pylori ferritin, and the self-assembly system is a GvoTagOpti/SdCatcher system. The varicella-zoster virus nanoparticles in the present invention involve a simple preparation method, have high safety, and can induce mice to generate a specific antibody targeting an antigen.

54.WO/2024/173724P36 AND P52 AS PROTECTIVE MALARIA VACCINE ANTIGENS

WO - 22.08.2024

Clasificación Internacional A61K 39/015Nº de solicitud PCT/US2024/016044Solicitante UNIVERSITY OF WASHINGTONInventor/a MURPHY, Sean C.

An immunostimulating composition comprising up to three *Plasmodium* proteins (or antigenic fragments thereof) or nucleic acids encoding said *Plasmodium* proteins, wherein the *Plasmodium* proteins are selected from *Plasmodium* circumsporozoite protein ("CSP"), and/or *Plasmodium* P52 ("P52"), and/or *Plasmodium* P36 ("P36").

55.4417212TRANSPLANTATIONSTOLERANZINDUKTION MIT CARBODIIMIDBEHANDELTEM TOLERIERENDEM IMPFSTOFF

EP - 21.08.2024

Clasificación Internacional A61K 35/39Nº de solicitud 24172142Solicitante UNIV MINNESOTAInventor/a HERING BERNHARD J

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines/regimen or preparatory regimens.

56.4420675EPITOPMODIFIKATION

EP - 28.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 22860493Solicitante NANTONG YICHEN BIOPHARMA CO LTDInventor/a WANG FENG

The present invention relates to epitope modification based on a chemical cross-linking reactive group and the use thereof in changing the immunogenicity of an antigen and increasing animal immune response to a target epitope of an antigen. The present invention relates to the administration of a mutant antigen incorporated by a group with chemical cross-slinking activity on the target epitope of a wild-type antigen or derivative thereof to an animal, wherein the antibody reaction in the animal is directed and enriched to the target epitope of the mutant antigen. Provided are a method for selecting antibodies against a target epitope of an antigen and the antibodies obtained thereby; further provided is the use of the method in the preparation of a vaccine for preventing and treating diseases.

57.WO/2024/177672ADJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

WO - 29.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud PCT/US2023/063067Solicitante D4 LABS, LLCInventor/a WRIGHT, David, Craig

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non- phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-CoV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

58.20240277832DJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

US - 22.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18172966Solicitante D4 Labs, LLCInventor/a David Craig Wright

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from:

(i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes;

(ii) a modified spike protein sequence of a coronavirus;

(iii) a protein sequence from a coronavirus; and

(iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections.

Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

59.20240287544MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

US - 29.08.2024

Clasificación Internacional C12N 15/86Nº de solicitud 18433149Solicitante CYANVAC LLCInventor/a Biao HE

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

60.WO/2024/174022RECOMBINANT VACCINE PROTEINS FOR THE PREVENTION OF AVIAN NECROTIC ENTERITIS

WO - 29.08.2024

Clasificación Internacional C07K 14/33Nº de solicitud PCT/CA2024/050201Solicitante UNIVERSITÉ DE MONTRÉALInventor/a GAUCHER, Marie-lou

Recombinant antigenic proteins unique to pathogenic strains of *Clostridium perfringens* which causes avian necrotic enteritis (NE) are provided. The recombinant proteins were identified using a comparative and subtractive reverse vaccinology approach. The recombinant proteins raise antibodies recognized by both recombinant and native forms of the protein in the pathogenic strain of C. perfringens and are predicted to be surface-exposed.

61.20240279308TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

US - 22.08.2024

Clasificación Internacional C07K 14/725Nº de solicitud 18581947Solicitante IMMATICS BIOTECHNOLOGIES GMBHInventor/a Dominik MAURER

Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tmor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

62.WO/2024/178371MULTICISTRONIC VACCINE AND METHODS FOR PRODUCING AND USING THE SAME

WO - 29.08.2024

Clasificación Internacional C12N 15/861Nº de solicitud PCT/US2024/017139Solicitante OCUGEN, INC.Inventor/a UPADHYAY, Arun Kumar

The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.

63.WO/2024/172784A NOVEL VACCINE FOR PROPHYLAXIS OF BOVINE VIRAL DIARRHEA VIRUS INFECTION

WO - 22.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/TR2023/050618Solicitante BURSA ULUDAĞ ÜNİVERSİTESİInventor/a YEŞİLBAĞ, Kadir

The present invention provides a pharmaceutical composition that elicits a homologous immune response against Bovine viral diarrhea virus (BVDV) infection. Said pharmaceutical composition; BVDV-11 strain includes components selected from a group consisting of BVDV-1 f strain, BVDV-2b strain.

64.3416685METHODS FOR ENHANCING EFFICACY OF A VACCINE BY ADMINISTERING AN IL-4R ANTAGONIST

PL - 26.08.2024

Clasificación Internacional A61K 39/395Nº de solicitud 17708398SolicitanteInventor/a LISA PURCELL NGAMBO

65.20240277826PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

US - 22.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 18003036Solicitante UNTHREADT B.V.Inventor/a Nisar Ahmed KHAN

The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b. identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a vaccine comprising one or more agents interacting with at least one region of at least 4 consecutive amino acids present in the SARS-CoV-2 proteome, not conserved between the SARS-CoV-2 proteome and the human proteome. Finally, the invention can provide a molecular and cellular explanation for the deviant infectivity, clinical behaviour, and pathology of emerging SARS-CoV-2 variants over time, to design vaccines to specifically prevent these complications, and to select peptides as therapeutic modality to treat these clinical manifestations and complications.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

CUBA